{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "60050127",
   "metadata": {},
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup\n",
    "import requests\n",
    "#comment"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "36858d11",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<!doctype html><html lang=\"en\" prefix=\"og: https://ogp.me/ns#\" style=\"--headerFullHeight: 90px; --headerHeight: 90px;\"><head><meta charset=\"utf-8\"><title data-static-tag-from=\"prerender\">BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript | Seeking Alpha</title><link rel=\"preconnect\" href=\"https://static.seekingalpha.com\"><link rel=\"preconnect\" href=\"https://static1.seekingalpha.com\"><link rel=\"preconnect\" href=\"https://static2.seekingalpha.com\"><link rel=\"preconnect\" href=\"https://static3.seekingalpha.com\"><link rel=\"preconnect\" href=\"https://www.googletagmanager.com\" crossorigin=\"anonymous\"><link rel=\"preconnect\" href=\"https://www.google-analytics.com\" crossorigin=\"anonymous\"><meta name=\"viewport\" content=\"width=device-width,initial-scale=1,viewport-fit=cover\"><meta content=\"ie=edge\" http-equiv=\"X-UA-Compatible\"><meta name=\"application-name\" content=\"SeekingAlpha\"><meta name=\"HandheldFriendly\" content=\"true\"><meta name=\"apple-mobile-web-app-capable\" content=\"yes\"><meta name=\"apple-mobile-web-app-title\" content=\"SeekingAlpha\"><meta name=\"apple-mobile-web-app-status-bar-style\" content=\"black\"><meta name=\"format-detection\" content=\"telephone=yes\"><meta name=\"theme-color\" content=\"#333333\"><meta property=\"fb:app_id\" content=\"159723149420031\"><meta property=\"fb:pages\" content=\"224867310939090\"><meta content=\"SeekingAlpha\" property=\"al:ios:app_name\"><meta content=\"552799694\" property=\"al:ios:app_store_id\"><meta content=\"SeekingAlpha\" property=\"al:android:app_name\"><meta content=\"com.seekingalpha.webwrapper\" property=\"al:android:package\"><meta name=\"google-site-verification\" content=\"8arRaWMkVniCnxJWf9hbm-0PYkb_LhjaXAk7rGd97iw\"><meta name=\"msvalidate.01\" content=\"0FEA0055AC330065CFA87CA3045E9860\"><meta property=\"og:locale\" content=\"en_US\"><meta property=\"og:site_name\" content=\"SeekingAlpha\"><link rel=\"mask-icon\" href=\"/samw/static/images/favicon.svg\" color=\"#ff7200\"><link rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon.png\"><link sizes=\"57x57\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-57x57.png\"><link sizes=\"60x60\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-60x60.png\"><link sizes=\"72x72\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-72x72.png\"><link sizes=\"76x76\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-76x76.png\"><link sizes=\"114x114\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-114x114.png\"><link sizes=\"120x120\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-120x120.png\"><link sizes=\"144x144\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-144x144.png\"><link sizes=\"152x152\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-152x152.png\"><link sizes=\"180x180\" rel=\"apple-touch-icon\" href=\"/samw/static/images/apple-touch-icon-180x180.png\"><link sizes=\"16x16\" rel=\"icon\" type=\"image/png\" href=\"/samw/static/images/favicon-16x16.png\"><link sizes=\"32x32\" rel=\"icon\" type=\"image/png\" href=\"/samw/static/images/favicon-32x32.png\"><link sizes=\"32x32\" rel=\"icon\" type=\"image/png\" href=\"/samw/static/images/favicon-96x96.png\"><link sizes=\"192x192\" rel=\"icon\" type=\"image/png\" href=\"/samw/static/images/favicon-192x192.png\"><link href=\"/samw/favicon.ico\" rel=\"icon\"><style data-href=\"/samw/static/styles/app.a5187a0e.css\">@-webkit-keyframes hxB{to{transform:rotate(1turn)}}@keyframes hxB{to{transform:rotate(1turn)}}.hxA{-webkit-animation:hxB 1s linear infinite;animation:hxB 1s linear infinite;color:var(--sa-spinner-color-1);color:var(--sa-spinner-color,var(--sa-spinner-color-1));height:1em;width:1em}@media screen and (prefers-reduced-motion:reduce){.hxA{-webkit-animation:none;animation:none}}.bmA{padding:0}.bmB{margin:0}.bmC{padding-top:0}.bmD{padding-top:2px}.bmE{padding-top:4px}.bmF{padding-top:6px}.bmG{padding-top:8px}.bmH{padding-top:10px}.bmI{padding-top:12px}.bmJ{padding-top:14px}.bmK{padding-top:16px}.bmL{padding-top:18px}.bmM{padding-top:20px}.bmN{padding-top:24px}.bmO{padding-top:28px}.bmP{padding-top:30px}.bmQ{padding-top:32px}.bmR{padding-top:36px}.bmS{padding-top:40px}.bmT{padding-top:48px}.bmU{padding-top:64px}.bmV{padding-top:72px}.bmW{padding-left:0}.bmX{padding-left:2px}.bmY{padding-left:4px}.bmZ{padding-left:6px}.bm0{padding-left:8px}.bm1{padding-left:10px}.bm2{padding-left:12px}.bm3{padding-left:14px}.bm4{padding-left:16px}.bm5{padding-left:18px}.bm6{padding-left:20px}.bm7{padding-left:24px}.bm8{padding-left:28px}.bm9{padding-left:30px}.bmBA{padding-left:32px}.bmBB{padding-left:36px}.bmBC{padding-left:40px}.bmBD{padding-left:48px}.bmBE{padding-left:50px}.bmBF{padding-left:64px}.bmBG{padding-left:72px}.bmBH{padding-right:0}.bmBI{padding-right:2px}.bmBJ{padding-right:4px}.bmBK{padding-right:6px}.bmBL{padding-right:8px}.bmBM{padding-right:10px}.bmBN{padding-right:12px}.bmBO{padding-right:14px}.bmBP{padding-right:16px}.bmBQ{padding-right:18px}.bmBR{padding-right:20px}.bmBS{padding-right:24px}.bmBT{padding-right:28px}.bmBU{padding-right:30px}.bmBV{padding-right:32px}.bmBW{padding-right:36px}.bmBX{padding-right:40px}.bmBY{padding-right:48px}.bmBZ{padding-right:64px}.bmB0{padding-right:72px}.bmB1{padding-bottom:0}.bmB2{padding-bottom:2px}.bmB3{padding-bottom:4px}.bmB4{padding-bottom:6px}.bmB5{padding-bottom:8px}.bmB6{padding-bottom:10px}.bmB7{padding-bottom:12px}.bmB8{padding-bottom:14px}.bmB9{padding-bottom:16px}.bmCA{padding-bottom:18px}.bmCB{padding-bottom:20px}.bmCC{padding-bottom:24px}.bmCD{padding-bottom:28px}.bmCE{padding-bottom:30px}.bmCF{padding-bottom:32px}.bmCG{padding-bottom:36px}.bmCH{padding-bottom:40px}.bmCI{padding-bottom:48px}.bmCJ{padding-bottom:64px}.bmCK{padding-bottom:72px}.bmCL,.bmCM{margin-top:0}.bmCN{margin-top:2px}.bmCO{margin-top:-2px}.bmCP{margin-top:4px}.bmCQ{margin-top:-4px}.bmCR{margin-top:6px}.bmCS{margin-top:-6px}.bmCT{margin-top:8px}.bmCU{margin-top:-8px}.bmCV{margin-top:10px}.bmCW{margin-top:-10px}.bmCX{margin-top:12px}.bmCY{margin-top:-12px}.bmCZ{margin-top:14px}.bmC0{margin-top:-14px}.bmC1{margin-top:16px}.bmC2{margin-top:-16px}.bmC3{margin-top:18px}.bmC4{margin-top:-18px}.bmC5{margin-top:20px}.bmC6{margin-top:-20px}.bmC7{margin-top:24px}.bmC8{margin-top:-24px}.bmC9{margin-top:28px}.bmDA{margin-top:-28px}.bmDB{margin-top:30px}.bmDC{margin-top:-30px}.bmDD{margin-top:32px}.bmDE{margin-top:-32px}.bmDF{margin-top:36px}.bmDG{margin-top:-36px}.bmDH{margin-top:40px}.bmDI{margin-top:-40px}.bmDJ{margin-top:48px}.bmDK{margin-top:-48px}.bmDL{margin-top:64px}.bmDM{margin-top:-64px}.bmDN{margin-top:72px}.bmDO{margin-top:-72px}.bmDP{margin-left:auto}.bmDQ,.bmDR{margin-left:0}.bmDS{margin-left:2px}.bmDT{margin-left:-2px}.bmDU{margin-left:4px}.bmDV{margin-left:-4px}.bmDW{margin-left:6px}.bmDX{margin-left:-6px}.bmDY{margin-left:8px}.bmDZ{margin-left:-8px}.bmD0{margin-left:10px}.bmD1{margin-left:-10px}.bmD2{margin-left:12px}.bmD3{margin-left:-12px}.bmD4{margin-left:14px}.bmD5{margin-left:-14px}.bmD6{margin-left:16px}.bmD7{margin-left:-16px}.bmD8{margin-left:18px}.bmD9{margin-left:-18px}.bmEA{margin-left:20px}.bmEB{margin-left:-20px}.bmEC{margin-left:24px}.bmED{margin-left:-24px}.bmEE{margin-left:28px}.bmEF{margin-left:-28px}.bmEG{margin-left:30px}.bmEH{margin-left:-30px}.bmEI{margin-left:32px}.bmEJ{margin-left:-32px}.bmEK{margin-left:36px}.bmEL{margin-left:-36px}.bmEM{margin-left:40px}.bmEN{margin-left:-40px}.bmEO{margin-left:48px}.bmEP{margin-left:-48px}.bmEQ{margin-left:64px}.bmER{margin-left:-64px}.bmES{margin-left:72px}.bmET{margin-left:-72px}.bmEU{margin-right:auto}.bmEV,.bmEW{margin-right:0}.bmEX{margin-right:2px}.bmEY{margin-right:-2px}.bmEZ{margin-right:4px}.bmE0{margin-right:-4px}.bmE1{margin-right:6px}.bmE2{margin-right:-6px}.bmE3{margin-right:8px}.bmE4{margin-right:-8px}.bmE5{margin-right:10px}.bmE6{margin-right:-10px}.bmE7{margin-right:12px}.bmE8{margin-right:-12px}.bmE9{margin-right:14px}.bmFA{margin-right:-14px}.bmFB{margin-right:16px}.bmFC{margin-right:-16px}.bmFD{margin-right:18px}.bmFE{margin-right:-18px}.bmFF{margin-right:20px}.bmFG{margin-right:-20px}.bmFH{margin-right:24px}.bmFI{margin-right:-24px}.bmFJ{margin-right:28px}.bmFK{margin-right:-28px}.bmFL{margin-right:30px}.bmFM{margin-right:-30px}.bmFN{margin-right:32px}.bmFO{margin-right:-32px}.bmFP{margin-right:36px}.bmFQ{margin-right:-36px}.bmFR{margin-right:40px}.bmFS{margin-right:-40px}.bmFT{margin-right:48px}.bmFU{margin-right:-48px}.bmFV{margin-right:64px}.bmFW{margin-right:-64px}.bmFX{margin-right:72px}.bmFY{margin-right:-72px}.bmFZ{margin-bottom:auto}.bmF0,.bmF1{margin-bottom:0}.bmF2{margin-bottom:2px}.bmF3{margin-bottom:-2px}.bmF4{margin-bottom:4px}.bmF5{margin-bottom:-4px}.bmF6{margin-bottom:6px}.bmF7{margin-bottom:-6px}.bmF8{margin-bottom:8px}.bmF9{margin-bottom:-8px}.bmGA{margin-bottom:10px}.bmGB{margin-bottom:-10px}.bmGC{margin-bottom:12px}.bmGD{margin-bottom:-12px}.bmGE{margin-bottom:14px}.bmGF{margin-bottom:-14px}.bmGG{margin-bottom:16px}.bmGH{margin-bottom:-16px}.bmGI{margin-bottom:18px}.bmGJ{margin-bottom:-18px}.bmGK{margin-bottom:20px}.bmGL{margin-bottom:-20px}.bmGM{margin-bottom:24px}.bmGN{margin-bottom:-24px}.bmGO{margin-bottom:28px}.bmGP{margin-bottom:-28px}.bmGQ{margin-bottom:30px}.bmGR{margin-bottom:-30px}.bmGS{margin-bottom:32px}.bmGT{margin-bottom:-32px}.bmGU{margin-bottom:36px}.bmGV{margin-bottom:-36px}.bmGW{margin-bottom:40px}.bmGX{margin-bottom:-40px}.bmGY{margin-bottom:48px}.bmGZ{margin-bottom:-48px}.bmG0{margin-bottom:64px}.bmG1{margin-bottom:-64px}.bmG2{margin-bottom:72px}.bmG3{margin-bottom:-72px}.bmG4{margin-top:auto}.blA{display:flex}.blB{display:inline-flex}.blC{align-items:center}.blD{align-items:flex-start}.blE{align-items:flex-end}.blF{align-items:baseline}.blG{align-items:stretch}.blH{justify-content:center}.blI{justify-content:flex-end}.blJ{justify-content:flex-start}.blK{justify-content:space-between}.blL{justify-content:space-around}.blM{flex-flow:row wrap}.blN{flex-flow:column wrap}.blO{flex-flow:row}.blP{flex-flow:row-reverse}.blQ{flex-flow:row nowrap}.blR{flex-flow:column}.blS{flex-flow:column-reverse}.blT{flex-flow:column nowrap}.blU{flex-grow:1}.blV{flex-grow:9999}.blW{flex-shrink:0}.dcA{--modal-padding:36px;max-width:420px;width:calc(100vw - var(--modal-padding))}@media(min-width:768px){.dcA{flex-grow:0;height:160px;max-width:none;width:408px}}.dcB{font-size:2.5rem}.cjA{position:relative;text-align:center}@media(min-width:768px){.cjA{padding:14px 54px 52px}}@media(min-width:768px){.cjB{margin-bottom:20px}}@media(min-width:768px){.cjC{margin-bottom:20px}}@media(min-width:768px){.cjD{margin-bottom:32px}}.cjE+.cjE{margin-top:12px}@media(min-width:768px){.cjE+.cjE{margin-top:16px}}.cjF{font-size:14px;font-weight:600;min-height:44px}@media(min-width:768px){.cjF{min-height:36px}}.cjG{justify-content:center}.cjJ{background-color:var(--black-5)}@media(min-width:768px){.cjJ{padding:36px}}[data-color-scheme=dark] .cjJ{background-color:var(--black-95)}.cjK{border:0;color:var(--sa-link-color);font-weight:500;vertical-align:initial}@media(min-width:768px){.cjL{left:54px;margin-bottom:0;position:absolute;right:54px}}p+.chA{margin-top:12px}p+.chB{margin-top:18px}p+.chC{margin-top:20px}p+.chD{margin-top:24px}.ciA{font-weight:400}.ciB{font-weight:500}.ciC{font-weight:600}.ciD{font-weight:700}.ciE{font-weight:900}.ciF{font-style:italic}.ciG{font-size:.625rem}.ciH{font-size:.6875rem}.ciI{font-size:.75rem}.ciJ{font-size:.875rem}.ciK{font-size:1rem}.ciL{font-size:1.125rem}.ciM{font-size:1.25rem}.ciN{font-size:1.375rem}.ciO{font-size:1.5rem}.ciP{font-size:1.75rem}.ciQ{font-size:2rem}.ciR,.ciS{font-size:2.25rem}.ciT{font-size:3rem}.ciU{font-size:3.125rem}.ciV{line-height:.75rem}.ciW{line-height:.8125rem}.ciX{line-height:.875rem}.ciY{line-height:1rem}.ciZ{line-height:1.1875rem}.ci0{line-height:1.25rem}.ci1{line-height:1.375rem}.ci2{line-height:1.5rem}.ci3{line-height:1.625rem}.ci4{line-height:1.75rem}.ci5{line-height:1.8125rem}.ci6{line-height:1.875rem}.ci7{line-height:2rem}.ci8{line-height:2.125rem}.ci9{line-height:2.25rem}.ciBA{line-height:2.375rem}.ciBB,.ciBC,.ciBD{line-height:2.6875rem}.ciBE{line-height:3.625rem}.ciBF{line-height:3.75rem}@media(min-width:768px){.ciBG{font-size:.625rem}}@media(min-width:1024px){.ciBH{font-size:.625rem}}@media(min-width:1200px){.ciBI{font-size:.625rem}}@media(min-width:768px){.ciBJ{font-size:.6875rem}}@media(min-width:1024px){.ciBK{font-size:.6875rem}}@media(min-width:1200px){.ciBL{font-size:.6875rem}}@media(min-width:768px){.ciBM{font-size:.75rem}}@media(min-width:1024px){.ciBN{font-size:.75rem}}@media(min-width:1200px){.ciBO{font-size:.75rem}}@media(min-width:768px){.ciBP{font-size:.875rem}}@media(min-width:1024px){.ciBQ{font-size:.875rem}}@media(min-width:1200px){.ciBR{font-size:.875rem}}@media(min-width:768px){.ciBS{font-size:1rem}}@media(min-width:1024px){.ciBT{font-size:1rem}}@media(min-width:1200px){.ciBU{font-size:1rem}}@media(min-width:768px){.ciBV{font-size:1.125rem}}@media(min-width:1024px){.ciBW{font-size:1.125rem}}@media(min-width:1200px){.ciBX{font-size:1.125rem}}@media(min-width:768px){.ciBY{font-size:1.25rem}}@media(min-width:1024px){.ciBZ{font-size:1.25rem}}@media(min-width:1200px){.ciB0{font-size:1.25rem}}@media(min-width:768px){.ciB1{font-size:1.375rem}}@media(min-width:1024px){.ciB2{font-size:1.375rem}}@media(min-width:1200px){.ciB3{font-size:1.375rem}}@media(min-width:768px){.ciB4{font-size:1.5rem}}@media(min-width:1024px){.ciB5{font-size:1.5rem}}@media(min-width:1200px){.ciB6{font-size:1.5rem}}@media(min-width:768px){.ciB7{font-size:1.75rem}}@media(min-width:1024px){.ciB8{font-size:1.75rem}}@media(min-width:1200px){.ciB9{font-size:1.75rem}}@media(min-width:768px){.ciCA{font-size:2rem}}@media(min-width:1024px){.ciCB{font-size:2rem}}@media(min-width:1200px){.ciCC{font-size:2rem}}@media(min-width:768px){.ciCD{font-size:2.25rem}}@media(min-width:1024px){.ciCE{font-size:2.25rem}}@media(min-width:1200px){.ciCF{font-size:2.25rem}}@media(min-width:768px){.ciCG{font-size:3rem}}@media(min-width:1024px){.ciCH{font-size:3rem}}@media(min-width:1200px){.ciCI{font-size:3rem}}@media(min-width:768px){.ciCJ{font-size:3.125rem}}@media(min-width:1024px){.ciCK{font-size:3.125rem}}@media(min-width:1200px){.ciCL{font-size:3.125rem}}@media(min-width:768px){.ciCM{line-height:.75rem}}@media(min-width:1024px){.ciCN{line-height:.75rem}}@media(min-width:1200px){.ciCO{line-height:.75rem}}@media(min-width:768px){.ciCP{line-height:.8125rem}}@media(min-width:1024px){.ciCQ{line-height:.8125rem}}@media(min-width:1200px){.ciCR{line-height:.8125rem}}@media(min-width:768px){.ciCS{line-height:.875rem}}@media(min-width:1024px){.ciCT{line-height:.875rem}}@media(min-width:1200px){.ciCU{line-height:.875rem}}@media(min-width:768px){.ciCV{line-height:1rem}}@media(min-width:1024px){.ciCW{line-height:1rem}}@media(min-width:1200px){.ciCX{line-height:1rem}}@media(min-width:768px){.ciCY{line-height:1.1875rem}}@media(min-width:1024px){.ciCZ{line-height:1.1875rem}}@media(min-width:1200px){.ciC0{line-height:1.1875rem}}@media(min-width:768px){.ciC1{line-height:1.25rem}}@media(min-width:1024px){.ciC2{line-height:1.25rem}}@media(min-width:1200px){.ciC3{line-height:1.25rem}}@media(min-width:768px){.ciC4{line-height:1.375rem}}@media(min-width:1024px){.ciC5{line-height:1.375rem}}@media(min-width:1200px){.ciC6{line-height:1.375rem}}@media(min-width:768px){.ciC7{line-height:1.5rem}}@media(min-width:1024px){.ciC8{line-height:1.5rem}}@media(min-width:1200px){.ciC9{line-height:1.5rem}}@media(min-width:768px){.ciDA{line-height:1.625rem}}@media(min-width:1024px){.ciDB{line-height:1.625rem}}@media(min-width:1200px){.ciDC{line-height:1.625rem}}@media(min-width:768px){.ciDD{line-height:1.75rem}}@media(min-width:1024px){.ciDE{line-height:1.75rem}}@media(min-width:1200px){.ciDF{line-height:1.75rem}}@media(min-width:768px){.ciDG{line-height:1.8125rem}}@media(min-width:1024px){.ciDH{line-height:1.8125rem}}@media(min-width:1200px){.ciDI{line-height:1.8125rem}}@media(min-width:768px){.ciDJ{line-height:1.875rem}}@media(min-width:1024px){.ciDK{line-height:1.875rem}}@media(min-width:1200px){.ciDL{line-height:1.875rem}}@media(min-width:768px){.ciDM{line-height:2rem}}@media(min-width:1024px){.ciDN{line-height:2rem}}@media(min-width:1200px){.ciDO{line-height:2rem}}@media(min-width:768px){.ciDP{line-height:2.125rem}}@media(min-width:1024px){.ciDQ{line-height:2.125rem}}@media(min-width:1200px){.ciDR{line-height:2.125rem}}@media(min-width:768px){.ciDS{line-height:2.25rem}}@media(min-width:1024px){.ciDT{line-height:2.25rem}}@media(min-width:1200px){.ciDU{line-height:2.25rem}}@media(min-width:768px){.ciDV{line-height:2.375rem}}@media(min-width:1024px){.ciDW{line-height:2.375rem}}@media(min-width:1200px){.ciDX{line-height:2.375rem}}@media(min-width:768px){.ciDY{line-height:2.6875rem}}@media(min-width:1024px){.ciDZ{line-height:2.6875rem}}@media(min-width:1200px){.ciD0{line-height:2.6875rem}}@media(min-width:768px){.ciD1{line-height:3.625rem}}@media(min-width:1024px){.ciD2{line-height:3.625rem}}@media(min-width:1200px){.ciD3{line-height:3.625rem}}@media(min-width:768px){.ciD4{line-height:3.75rem}}@media(min-width:1024px){.ciD5{line-height:3.75rem}}@media(min-width:1200px){.ciD6{line-height:3.75rem}}@media(min-width:768px){.ciD7{font-weight:400}}@media(min-width:1024px){.ciD8{font-weight:400}}@media(min-width:1200px){.ciD9{font-weight:400}}@media(min-width:768px){.ciEA{font-weight:500}}@media(min-width:1024px){.ciEB{font-weight:500}}@media(min-width:1200px){.ciEC{font-weight:500}}@media(min-width:768px){.ciED{font-weight:600}}@media(min-width:1024px){.ciEE{font-weight:600}}@media(min-width:1200px){.ciEF{font-weight:600}}@media(min-width:768px){.ciEG{font-weight:700}}@media(min-width:1024px){.ciEH{font-weight:700}}@media(min-width:1200px){.ciEI{font-weight:700}}@media(min-width:768px){.ciEJ{font-weight:900}}@media(min-width:1024px){.ciEK{font-weight:900}}@media(min-width:1200px){.ciEL{font-weight:900}}@media(min-width:768px){.ciEM{font-style:italic}}@media(min-width:1024px){.ciEN{font-style:italic}}@media(min-width:1200px){.ciEO{font-style:italic}}.xA{color:var(--sa-text-color-1);text-align:center}@media(min-width:768px){.xA{width:590px}}.xD{max-width:420px}.xE{word-break:break-all}.xH{text-align:center}@media(min-width:768px){.xI{margin-top:36px}}.eA{background-color:var(--red-100);border-radius:50%;bottom:20px;height:30px;position:fixed;right:20px;width:30px;z-index:1070}.bpA{display:none}.bpB{display:inline}.bpC{display:block}.bpD{display:inline-block}.fA{align-items:center;background:var(--black-100-alpha-80);justify-content:center;left:0;position:fixed;top:0;z-index:1060}.fA,.fB{height:100%;width:100%}.fB{--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background:var(--white-100);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.fB{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.fB:before{content:\" \";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.fB:before{height:0;height:var(--env-safe-area-inset-top,0)}}@media(min-width:768px){.fB{height:500px;width:400px}}.px-captcha-visible{display:flex}.iA{bottom:-56px;height:56px;left:0;opacity:0;position:fixed;right:0;z-index:1070}.iB{background-color:var(--black-100);border:1px solid var(--black-10);border-radius:28px;color:var(--white-100);font-size:.875rem;font-weight:700;min-width:252px;text-align:center}@media(min-width:1024px){.iB{min-width:172px}}[data-color-scheme=dark] .iB{background-color:var(--black-10);border-color:var(--black-10);color:var(--black-100)}.iC{background:var(--red-100-alpha-75)}.iD{background:var(--teal-100-alpha-75)}@-webkit-keyframes iF{0%{bottom:-56px;opacity:0}10%{bottom:26px;opacity:1}90%{bottom:26px;opacity:1}to{bottom:-56px;opacity:0}}@keyframes iF{0%{bottom:-56px;opacity:0}10%{bottom:26px;opacity:1}90%{bottom:26px;opacity:1}to{bottom:-56px;opacity:0}}.iE{-webkit-animation-name:iF;animation-name:iF;-webkit-animation-timing-function:linear;animation-timing-function:linear}@media screen and (prefers-reduced-motion:reduce){.iE{-webkit-animation:none;animation:none}}.aA{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-bottom:0}@supports(padding:max(0px)){.aA{padding-bottom:0;padding-bottom:var(--env-safe-area-inset-bottom,0)}}.crA{border-radius:50%;line-height:1}.crA:hover{background-color:var(--black-5)}[data-color-scheme=dark] .crA:hover{background-color:var(--black-90)}.crB{height:1.125rem;width:1.125rem}.crC{fill:var(--white-100)}.crC:hover{background-color:var(--black-50)}.crD{fill:var(--black-100)}.crE{fill:currentColor}.crF{fill:var(--black-35)}[data-color-scheme=dark] .crF{fill:var(--black-10)}.crF:hover{fill:var(--black-50)}[data-color-scheme=dark] .crF:hover{fill:var(--black-10)}.cuA{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);max-width:1264px;padding-left:0;padding-right:0;width:100%}@supports(padding:max(0px)){.cuA{padding-left:0;padding-left:var(--env-safe-area-inset-left,0);padding-right:0;padding-right:var(--env-safe-area-inset-right,0)}}.cuB{max-width:100%;width:100%}.cuC{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.cuC{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}@media(min-width:576px){.cuD{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.cuD{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}}@media(min-width:768px){.cuE{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.cuE{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}}@media(min-width:1024px){.cuF{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.cuF{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}}@media(min-width:1200px){.cuG{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.cuG{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}}.beA{min-height:30px;position:relative}.beC{margin:0;padding-top:0;position:absolute;right:0;top:50%;transform:translateY(-50%)}.beC:active,.beC:focus,.beC:hover{background-color:var(--black-100-alpha-10)}.beC:active,.beC:focus{background-color:transparent}.cvA{text-decoration:underline}.bzA{border:0;width:100%}.bzA,.bzA:focus,.bzA:hover,.bzA:visited{color:currentColor}.bzA:before{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0}.cgA{text-align:left}.cgB{text-align:center}.cgC{text-align:right}.bcA{position:relative}@media(min-width:576px){.bcA{max-width:100%;text-align:center}}@media(min-width:768px){.bcB{margin-bottom:4px;margin-top:4px}}.bcC{border:0}.bcC,.bcC:focus,.bcC:hover,.bcC:visited{color:currentColor}.bcD{height:26px}@media(min-width:576px){.bcD{height:30px}}@media(min-width:768px){.bcD{height:22px}}.bcE{height:23px}@media(min-width:576px){.bcE{height:32px;margin-bottom:0}}@media(min-width:768px){.bcE{height:22px}}.lA{background:#d92846;color:var(--white-100)}.lB{padding-right:0;padding-top:0}@media(min-width:1024px){.lB{padding-bottom:0}}.bwA{border:0}.bwA,.bwA:focus,.bwA:hover,.bwA:visited{color:currentColor}.bwA:before{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0}.bdA{position:relative}@media(min-width:576px){.bdA{max-width:100%;text-align:center}}@media(min-width:768px){.bdB{margin-bottom:6px;margin-top:6px}}[data-color-scheme=dark] .bdB{color:var(--black-80)}.bdC{border:0}.bdC,.bdC:focus,.bdC:hover,.bdC:visited{color:currentColor}.bdD{height:20px}.bdE{height:18px}.mA{background:#fc0;color:var(--sa-text-color-1)}.mB{padding-right:0;padding-top:0}@media(min-width:1024px){.mB{padding-bottom:0}}.bxA{border:0}.bxA,.bxA:focus,.bxA:hover,.bxA:visited{color:currentColor}.bxA:before{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0}.bbA{min-height:30px;position:relative}@media(min-width:768px){.bbA{text-align:center}}.bbC{min-width:23px}.nA{background-color:#fc0;color:var(--black-100)}.nB{padding-right:0;padding-top:0}@media(min-width:1024px){.nB{padding-bottom:0}}.pA{background:linear-gradient(90deg,#15316c,#0b2d73 56%,#1c5387);color:var(--white-100)}@media(min-width:768px){.pA{text-align:center}}.pB{padding-right:0;padding-top:0}@media(min-width:768px){.pB{display:flex;justify-content:center}}@media(min-width:1024px){.pB{padding-bottom:0}}.pC{background:linear-gradient(90deg,#15316c,#173982);-webkit-clip-path:polygon(0 0,calc(100% - 8px) 0,100% 50%,calc(100% - 8px) 100%,0 100%);clip-path:polygon(0 0,calc(100% - 8px) 0,100% 50%,calc(100% - 8px) 100%,0 100%);min-width:102px}@media(min-width:768px){.pC{padding-right:20px}}.pD{display:inline-block;max-width:240px}@media(min-width:768px){.pD{align-items:center;display:flex;max-width:none;padding-bottom:0;padding-left:32px;padding-top:0}}.pE{color:#ffe352}.pF{height:21px}.bfA,.bfA:focus,.bfA:hover,.bfA:visited{color:#ffe352}.bfA:after{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0}.byA{border:0;white-space:pre}.byA,.byA:focus,.byA:hover,.byA:visited{color:currentColor}.byA:before{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0}.baA{position:relative}@media(min-width:768px){.baA{text-align:center}}.oA{-webkit-animation:oB 3s ease infinite;animation:oB 3s ease infinite;background:linear-gradient(90deg,#ff7044,#ff8e6c,#ffab35,#ffbb5c,#ff7044);background-size:200% 200%;color:var(--black-100)}@media screen and (prefers-reduced-motion:reduce){.oA{-webkit-animation:none;animation:none}}.oC{padding-right:0;padding-top:0}@media(min-width:1024px){.oC{padding-bottom:0}}@-webkit-keyframes oB{to{background-position:0 50%}50%{background-position:50% 100%}0%{background-position:100% 0}}@keyframes oB{to{background-position:0 50%}50%{background-position:50% 100%}0%{background-position:100% 0}}.bjA{width:130px}.bjB{max-height:30px;max-width:130px}.bjB,[data-color-scheme=dark] .bjB{background:0 0}.rB{padding-top:0}@media(min-width:1024px){.rB{height:30px;padding-bottom:0;padding-top:0}}.rC{width:768px}@media(min-width:1024px){.rC .rB{height:auto}}.rD{width:375px}@media(min-width:1024px){.rD .rB{height:auto}}.rE{background-color:var(--backgroundColor)}@media(min-width:576px){.rE{text-align:center}}.rF{color:var(--closeColor)}.rF:focus,.rF:hover,[data-color-scheme=dark] .rF:focus,[data-color-scheme=dark] .rF:hover{background-color:transparent}.rG{flex:1}@media(min-width:1024px){.rG{margin-left:18px;margin-right:18px}}.rG p{color:var(--black-100);margin-bottom:0}.rG a,.rG a:focus,.rG a:hover,.rG a:visited{color:currentColor;text-decoration:inherit}.rG a:before{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0}.buA{overflow:visible}@media(min-width:768px){.buA{overflow:hidden}}.buA :before{height:0}@media(min-width:768px){.buB{align-items:center;background-color:transparent;box-shadow:none;display:flex;height:100%;max-width:100%}}.fkA,.fkA:visited{--sa-btn-color:var(--sa-link-color)}.fkA,.fkB{--sa-spinner-color:currentColor;--sa-btn-border-color:transparent;--sa-btn-border-r:var(--sa-border-r-4);--sa-btn-icon-size:24px;align-items:center;background-clip:padding-box;border:1px solid;cursor:pointer;display:inline-flex;justify-content:center;position:relative;text-decoration:none;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;-webkit-user-select:none;-moz-user-select:none;user-select:none;white-space:nowrap;word-break:break-word}.fkA,.fkA:visited,.fkB,.fkB:visited{background-color:var(--sa-btn-bg-color);border-color:var(--sa-btn-border-color);border-radius:var(--sa-btn-border-r);box-shadow:var(--sa-btn-shadow);color:var(--sa-btn-color)}@media screen and (prefers-reduced-motion:reduce){.fkA,.fkB{transition:none}}.fkA svg,.fkB svg{transition:fill .15s ease-in-out}@media screen and (prefers-reduced-motion:reduce){.fkA svg,.fkB svg{transition:none}}.fkA:hover,.fkB:hover{text-decoration:none}.fkA:focus,.fkB:focus{--sa-btn-shadow:none}.fkA.fkC,.fkA:disabled,.fkB.fkC,.fkB:disabled{--sa-btn-shadow:none;cursor:default;opacity:.6;pointer-events:none}[data-color-scheme=dark] .fkA.fkC,[data-color-scheme=dark] .fkA:disabled,[data-color-scheme=dark] .fkB.fkC,[data-color-scheme=dark] .fkB:disabled{opacity:.2}.fkD{height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}.fkD svg{fill:currentColor;fill:var(--sa-btn-icon-color,currentColor);color:inherit;color:var(--sa-btn-icon-color,inherit);display:block;height:100%;width:100%}.fkE .fkD{margin:0}.fkE.fkF{padding:4px}.fkE.fkG{padding:6px}.fkE.fkH,.fkE.fkI{padding:5px}.fkE.fkI{min-width:44px}.fkE.fkJ{padding:10px}.fkK{clip:rect(0,0,0,0);border:0!important;height:1px!important;overflow:hidden;padding:0!important;position:absolute!important;white-space:nowrap;width:1px!important}.fkH{--sa-btn-icon-size:24px;min-height:36px}.fkF{min-height:24px}.fkF,.fkG{--sa-btn-icon-size:14px}.fkG{min-height:28px}.fkI{min-height:44px}.fkI,.fkJ{--sa-btn-icon-size:24px}.fkJ{min-height:54px}.fkL{width:100%}.fkM{white-space:normal}.fkN{pointer-events:none;position:relative}.fkO{opacity:0}.fkP{left:50%;position:absolute;top:50%;transform:translate(-50%,-50%)}.fkQ{color:var(--sa-btn-color);color:var(--sa-btn-spinner-color,var(--sa-btn-color));height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}@-webkit-keyframes fkR{0%{transform:rotate(0)}to{transform:rotate(1turn)}}@keyframes fkR{0%{transform:rotate(0)}to{transform:rotate(1turn)}}.ceA,.ceA:visited{--sa-btn-bg-color:var(--black-100);--sa-btn-color:var(--white-100);--sa-btn-border-color:var(--black-100)}@media(hover:hover)and (pointer:fine){.ceA:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-70);--sa-btn-border-color:var(--black-70)}}.ceA:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-70);--sa-btn-border-color:var(--black-70)}.ceA.ceB,.ceA:disabled{background-color:var(--black-20);border-color:var(--black-20);cursor:default}[data-color-scheme=dark] .ceA.ceB,[data-color-scheme=dark] .ceA:disabled{opacity:.2}[data-color-scheme=dark] .ceA,[data-color-scheme=dark] .ceA:visited{--sa-btn-bg-color:var(--black-10);--sa-btn-color:var(--black-100);--sa-btn-border-color:var(--black-10)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .ceA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-30);--sa-btn-border-color:var(--black-70)}}[data-color-scheme=dark] .ceA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-10)}[data-color-scheme=dark] .ceA.ceB,[data-color-scheme=dark] .ceA:disabled{background-color:var(--black-30);border-color:var(--black-30);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .ceA.ceB,[data-color-scheme=dark] [data-color-scheme=dark] .ceA:disabled{opacity:.2}.ceC,.ceC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--black-100);--sa-btn-border-color:var(--black-100)}@media(hover:hover)and (pointer:fine){.ceC:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-100);--sa-btn-border-color:var(--black-100)}}.ceC:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-100);--sa-btn-border-color:var(--black-100)}.ceC.ceB,.ceC:disabled{background-color:transparent;border-color:var(--black-100);cursor:default}[data-color-scheme=dark] .ceC.ceB,[data-color-scheme=dark] .ceC:disabled{opacity:.2}[data-color-scheme=dark] .ceC,[data-color-scheme=dark] .ceC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--white-100);--sa-btn-border-color:var(--white-100)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .ceC:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-30);--sa-btn-border-color:var(--black-30)}}[data-color-scheme=dark] .ceC:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-300);--sa-btn-border-color:var(--black-30)}[data-color-scheme=dark] .ceC.ceB,[data-color-scheme=dark] .ceC:disabled{background-color:transparent;border-color:var(--white-100);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .ceC.ceB,[data-color-scheme=dark] [data-color-scheme=dark] .ceC:disabled{opacity:.2}.ccA{color:var(--sa-link-color);display:inline}@media(min-width:768px){.bgA{align-items:center;display:flex;flex-flow:row}}@media(min-width:768px){.bgB{padding-bottom:0;padding-right:18px}}.bgC{fill:currentColor}@media(min-width:768px){.bgC{height:24px;margin-right:8px;width:32px}}@media(min-width:768px){.bgD{margin-bottom:0;margin-right:8px}}.bgE{color:currentColor}@media(min-width:768px){.bgE{margin-left:auto;padding-right:0!important}}.tA{background-color:var(--sa-negative-color);color:var(--sa-invert-default-color)}.tB{padding-top:12px}@media(min-width:768px){.tB{padding-bottom:1px;padding-top:1px}}.biA{color:var(--black-100)}@media(min-width:768px){.biA{text-decoration:underline}}.biA:focus,.biA:hover,.biA:visited{color:var(--black-100)}.biA:after{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0}.vA{background:#fae319;color:var(--black-100)}@media(min-width:768px){.vA{background:#f59d12;text-align:center}}.vB{padding-left:0}@media(min-width:768px){.vB{padding-right:18px}}.vC,.vD{height:100%}.vD{padding-right:0;padding-top:0}@media(min-width:1024px){.vD{padding-bottom:0}}.vE{margin:0}@media(min-width:768px){.vE{padding-right:0;position:relative}}.vF{overflow:hidden;padding-left:85px;position:relative;width:100%}@media(min-width:768px){.vF{padding:7px 38px;width:auto}}.vG{left:0}.vG,.vH{height:100%;position:absolute;top:0}.vH{background-color:#fae319;left:5%;right:5%}.vI{height:100%;left:3%;position:absolute;top:0}@media(min-width:1024px){.vI{left:5%}}.vI svg,.vJ{height:100%}.vJ{position:absolute;right:3%;top:0}@media(min-width:1024px){.vJ{right:5%}}.vJ svg{height:100%}.bhA,.bhA:focus,.bhA:hover,.bhA:visited{color:#002b69}.bhA:after{bottom:0;content:\"\";left:0;position:absolute;right:0;top:0;z-index:1}.uA{background:#51afc4;color:var(--white-100)}@media(min-width:768px){.uA{text-align:center}}.uB{padding-left:5px;padding-right:0}@media(min-width:768px){.uB{padding-right:18px}}.uC{padding-right:0;padding-top:0}@media(min-width:1024px){.uC{padding-bottom:0}}@media(min-width:768px){.uD{padding:0}}.uE{display:inline-block;max-height:60px;max-width:100%;overflow:hidden;position:relative;width:100%}@media(min-width:768px){.uE{padding:7px 80px;width:auto}}.uF{bottom:0;left:0;position:absolute;top:0;transform:translateX(100%)}@media(min-width:1024px){.uF{left:35px;transform:none}}.uF svg{height:100%}.uG{bottom:0;position:absolute;right:0;top:0;transform:translateX(-100%)}@media(min-width:1024px){.uG{right:35px;transform:none}}.uG svg{height:100%}.uH{z-index:1}.feA,.feA:visited{--sa-btn-bg-color:var(--black-35);--sa-btn-color:var(--white-100);--sa-btn-border-color:var(--black-35)}@media(hover:hover)and (pointer:fine){.feA:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-50);--sa-btn-border-color:var(--black-50)}}.feA:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-50);--sa-btn-border-color:var(--black-50)}.feA.feB,.feA:disabled{background-color:var(--black-35);border-color:var(--black-35);cursor:default}[data-color-scheme=dark] .feA.feB,[data-color-scheme=dark] .feA:disabled{opacity:.2}[data-color-scheme=dark] .feA,[data-color-scheme=dark] .feA:visited{--sa-btn-bg-color:var(--black-30);--sa-btn-color:var(--black-100);--sa-btn-border-color:var(--black-30)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .feA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-10)}}[data-color-scheme=dark] .feA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-50)}[data-color-scheme=dark] .feA.feB,[data-color-scheme=dark] .feA:disabled{background-color:var(--black-30);border-color:var(--black-30);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .feA.feB,[data-color-scheme=dark] [data-color-scheme=dark] .feA:disabled{opacity:.2}.feC,.feC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--black-35);--sa-btn-border-color:var(--black-35)}@media(hover:hover)and (pointer:fine){.feC:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-50);--sa-btn-border-color:var(--black-50)}}.feC:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-50);--sa-btn-border-color:var(--black-50)}.feC.feB,.feC:disabled{background-color:transparent;border-color:var(--black-35);cursor:default}[data-color-scheme=dark] .feC.feB,[data-color-scheme=dark] .feC:disabled{opacity:.2}.eiA{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px;width:100%}@supports(padding:max(0px)){.eiA{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.bsA{color:var(--sa-text-color-2);font-size:.875rem;line-height:1.75}.kiA{list-style:none;margin:0;padding-left:0}.kiC,.kiC:focus,.kiC:hover,.kiC:visited{color:var(--white-100);text-decoration:none}.kiC:focus,.kiC:hover{text-decoration:underline}.ecA{background-image:url(/samw/static/images/stock-exchange.6370cf82.jpg);background-size:cover}.ecB{background-image:linear-gradient(180deg,transparent,rgba(0,0,0,.1) 0,rgba(0,0,0,.11) 0,#000 55%)}.ecC{color:var(--white-100);padding-top:170px}.ecD{font-size:3rem;line-height:1}.ecE{font-size:.875rem}.ecF{color:var(--sa-text-color-3);font-weight:400}.ecG{height:0;visibility:hidden;width:0}.enA,.enA:visited{--sa-btn-bg-color:var(--red-100);--sa-btn-color:var(--white-100);--sa-btn-border-color:var(--red-100)}@media(hover:hover)and (pointer:fine){.enA:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--orange-100);--sa-btn-border-color:var(--orange-100)}}.enA:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--orange-100);--sa-btn-border-color:var(--orange-100)}.enA.enB,.enA:disabled{background-color:var(--black-20);border-color:var(--black-20);cursor:default}[data-color-scheme=dark] .enA.enB,[data-color-scheme=dark] .enA:disabled{opacity:.2}[data-color-scheme=dark] .enA,[data-color-scheme=dark] .enA:visited{--sa-btn-bg-color:var(--red-80);--sa-btn-color:var(--black-100);--sa-btn-border-color:var(--red-80)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .enA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--orange-100);--sa-btn-border-color:var(--orange-100)}}[data-color-scheme=dark] .enA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--orange-100);--sa-btn-border-color:var(--orange-100)}[data-color-scheme=dark] .enA.enB,[data-color-scheme=dark] .enA:disabled{background-color:var(--black-30);border-color:var(--black-30);color:var(--black-100);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .enA.enB,[data-color-scheme=dark] [data-color-scheme=dark] .enA:disabled{opacity:.2}.enC,.enC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--red-100);--sa-btn-border-color:var(--red-100)}@media(hover:hover)and (pointer:fine){.enC:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--red-100);--sa-btn-border-color:var(--red-100)}}.enC:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--red-100);--sa-btn-border-color:var(--red-100)}.enC.enB,.enC:disabled{background-color:transparent;border-color:var(--red-100);cursor:default}[data-color-scheme=dark] .enC.enB,[data-color-scheme=dark] .enC:disabled{opacity:.2}.bqA{background-color:var(--sa-modal-container-bg-color);position:relative;text-align:center;width:320px}@media(min-width:576px){.bqA{padding:32px 36px;width:544px}}@media(min-width:768px){.bqA{width:736px}}@media(min-width:1024px){.bqA{width:800px}}.bqC{white-space:break-spaces}@media(min-width:576px){.bqE{padding:32px 0}}.bqF{border-radius:.25rem;height:44px;width:100%}@media(min-width:576px){.bqF{height:35px;width:160px}}.brA{color:var(--white-100);text-align:center;width:320px}.brD{fill:currentColor;-webkit-animation:brE 1.4s linear infinite;animation:brE 1.4s linear infinite;height:62px;width:62px}@media screen and (prefers-reduced-motion:reduce){.brD{-webkit-animation:none;animation:none}}@-webkit-keyframes brE{to{transform:rotate(1turn)}}@keyframes brE{to{transform:rotate(1turn)}}.qA{height:100vh;left:0;min-width:100%;position:fixed;top:0;z-index:1051}.qB{position:relative;z-index:1052}.qB,.qC{height:100%;width:100%}.qC{background:var(--black-100);left:0;opacity:.6;position:fixed;top:0;z-index:1040}.qD{overflow:hidden}.scrollLocked .cfA{padding-right:var(--scrollbar-width)}.cardsLayout,[data-color-scheme=dark] .cardsLayout{background-color:var(--sa-body-bg-color)}.bodyNavOpened .wA{background:var(--black-100);height:100%;left:0;opacity:.6;position:fixed;top:0;width:100%;z-index:1040}.wC a:focus,.wC a:hover{text-decoration:none}.wD{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);min-height:100vh;position:relative;width:100%;z-index:1}.wD:after{content:\" \";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.wD:after{height:0;height:var(--env-safe-area-inset-bottom,0)}}@media print{.wD *{font-family:sans-serif!important}}.wE{padding-top:var(--headerFullHeight)}.wF{padding-bottom:80px}@media(min-width:768px){.wG .wB{display:flex}}.wG .tp-backdrop,.wG .tp-modal{display:none!important}.wG.tp-modal-open{height:auto}.bvA{color:var(--sa-text-color-1);min-height:2.125rem}@media(min-width:768px){.bvA{min-height:1.875rem}}.bvA:active,.bvA:focus,.bvA:hover{color:var(--black-80)}[data-color-scheme=dark] .bvA:active,[data-color-scheme=dark] .bvA:focus,[data-color-scheme=dark] .bvA:hover{color:var(--black-20)}.cbA{position:relative;z-index:1}@media(min-width:768px){.cbA{padding-bottom:16px}}.cbB{color:var(--sa-modal-title-color)}.cbC{--sa-modal-title-color:var(--black-35)}[data-color-scheme=dark] .cbC{--sa-modal-title-color:var(--black-30)}.cbD{--sa-modal-title-color:var(--orange-60)}.kA{background:var(--black-100);height:100%;opacity:.6;position:fixed;position:absolute;width:100%;z-index:auto}.kA,.kB{left:0;top:0}.kB{-webkit-overflow-scrolling:touch;bottom:0;overflow-y:auto;position:fixed;right:0;z-index:1050}.kC{min-height:0;position:relative;width:100%}@media(min-width:768px){.kC{align-items:center;padding:18px 0}}.kD{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background-color:var(--sa-modal-container-bg-color);box-shadow:0 4px 8px 0 rgba(0,0,0,.25);pointer-events:auto;position:relative;width:100%}@media(min-width:768px){.kD{max-width:500px}}.kD:before{content:\" \";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.kD:before{height:0;height:var(--env-safe-area-inset-top,0)}}@media(min-width:768px){.kE{padding-bottom:32px;padding-left:36px;padding-right:36px}}.kF .kD{max-width:100%;width:auto}@media(min-width:768px){.kG .kC{overflow:hidden;padding:36px}.kG .kD{max-height:100%;overflow:auto}}.kH{display:none}.zA{background:var(--black-100-alpha-50);height:100%;min-height:100vh;position:fixed;top:0;width:100%;z-index:1050}[data-color-scheme=dark] .zA{background:var(--white-100-alpha-50)}.zB{background:var(--sa-card-bg-color);border-radius:10px;box-sizing:border-box;position:relative;width:330px}.zD,.zE{text-align:center}.zE{word-wrap:break-word;font-size:.875rem}.zF{border-top:1px solid var(--sa-section-separator-thin-color);bottom:0;color:var(--sa-link-color);font-weight:400}.zG{width:100%}.zH{left:0}.zH,.zI{width:50%}.zI{border-left:1px solid var(--sa-section-separator-thin-color);right:0}.esA:active,.esA:focus,.esA:hover{text-decoration:underline}.coA{background:var(--white-100);border-bottom:1px solid var(--black-50);color:var(--sa-text-color-3);font-size:.875rem;line-height:1.125rem;padding:15px 0;position:fixed;top:var(--headerHeight);width:100%;z-index:1}.coC{height:10px;width:10px}.coD{align-self:center;height:20px;width:20px}[data-color-scheme=dark] .coD{fill:var(--black-50)}.coE{max-width:960px}.bnA{opacity:0;pointer-events:none}.bnA,.bnA:focus,.bnA:hover,.bnA:visited{color:inherit;text-decoration:none}.bnA:focus,.bnA:hover{text-decoration:underline}.bnA:focus{opacity:1;pointer-events:auto}.dtA{bottom:0;box-shadow:0 -4px 8px rgba(0,0,0,.25);left:0;position:fixed;right:0;z-index:1020}.dtB{visibility:hidden}.bkA{z-index:1}.bkA,.bkB{bottom:0;position:fixed;width:100%}.bkB{z-index:2}.bkC{bottom:80px}.icA{overflow:hidden;text-overflow:ellipsis}.ekA{background-color:var(--orange-60);outline:1px solid var(--orange-60)}.ekB{height:44px}@media(min-width:1024px){.ekB{height:30px}}.ekC{font-size:.875rem;font-weight:700;white-space:nowrap}.ekC,.ekC:focus,.ekC:hover,.ekC:visited{color:var(--white-100);text-decoration:none}.ekC:focus,.ekC:hover{text-decoration:underline}.ekD{height:25px;opacity:.7;position:relative;width:25px}.ekD:focus,.ekD:hover{cursor:pointer;opacity:1}.ekD:after,.ekD:before{background-color:var(--white-100);content:\" \";height:25px;left:12.5px;position:absolute;top:0;width:1px}.ekD:before{transform:rotate(45deg)}.ekD:after{transform:rotate(-45deg)}@media print{.fuA{display:none!important}}.emA{--sa-header-bg-color:var(--black-70);--sa-header-color:var(--white-100);--sa-header-top-nav-index:1;--sa-header-bottom-nav-index:2;left:0;pointer-events:none;position:fixed;top:0;transition:transform .3s;-webkit-user-select:none;-moz-user-select:none;user-select:none;width:100%;z-index:1030}[data-color-scheme=dark] .emA{--sa-header-bg-color:var(--black-90);--sa-header-color:var(--black-10)}@media screen and (prefers-reduced-motion:reduce){.emA{transition:none}}.emB>*{pointer-events:auto}.emB>:first-child{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom)}.emB>:first-child:before{content:\" \";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.emB>:first-child:before{height:0;height:var(--env-safe-area-inset-top,0)}}.emC{position:absolute;top:var(--header-top-position)}.keA{background-color:var(--black-100);font-size:.875rem;height:1.875rem;line-height:1rem}.keA,.keB{height:1.875rem}.keC{color:var(--black-10)}.xmB{border:1px solid var(--black-10);flex-grow:1;min-width:10rem;position:relative}@media(min-width:768px){.xmB{flex-grow:0}}.xmC{border:0}.xmD{border-bottom-left-radius:4px;border-bottom-right-radius:4px;min-width:100%}@media(min-width:768px){.xmD{position:absolute;z-index:1020}}.xmD:after{border:1px solid var(--black-10);border-bottom-left-radius:4px;border-bottom-right-radius:4px;bottom:0;box-shadow:0 4px 8px rgba(0,0,0,.25);content:\"\";left:-1px;pointer-events:none;position:absolute;right:-1px;top:0}.xmE{flex-shrink:0}.xmE,.xmF{color:var(--black-35)}.xmF{background-color:var(--black-5);border-radius:inherit;line-height:1rem;position:relative;width:100%}.xmG:after{border-color:var(--black-35) transparent transparent transparent;border-style:solid;border-width:.75rem .375rem 0;content:\"\";height:0;position:absolute;right:16px;top:50%;transform:translateY(-50%);width:0}@media(min-width:768px){.xmG:after{border-color:var(--black-35) transparent transparent transparent;border-style:solid;border-width:.5rem .25rem 0;height:0;right:7px;width:0}}.xmH{border-bottom-left-radius:0;border-bottom-right-radius:0;border-left-color:transparent;border-right-color:transparent;border-top-color:transparent;box-shadow:0 4px 8px rgba(0,0,0,.25)}.xmH:after{transform:translateY(-50%) rotate(180deg)}.xmI .xmH{box-shadow:none}.xmJ{min-width:7.5rem}@media(min-width:768px){.xmJ{min-width:5.5rem}}.xmJ,.xmK{border-radius:4px}.xmJ .xmF,.xmK .xmF{border-width:1px;padding:5px 24px 5px 8px}.xmL{border-radius:8px}.xmL .xmF{color:var(--black-35);font-size:.875rem;font-weight:400;line-height:1rem;padding:14px 26px 14px 18px}.xmL .xmF:after{right:18px}.xmM{align-items:center;flex-direction:row}.xmM .xmE{margin-bottom:0;margin-right:8px}.xmN{flex-direction:column}.xmN .xmE{margin-bottom:4px;margin-right:8px}body .xmO{display:none}.bbxA{background:var(--black-100);background:rgba(0,0,0,.5);height:100%;opacity:.6;opacity:1;top:0;z-index:1050}.bbxA,.bbxB{left:0;position:fixed;width:100%}.bbxB{background-color:var(--white-100);bottom:0;max-height:100%;overflow:hidden}.ttA{min-width:auto}.ttA,.ttB{border:none}.ttB{background:0 0;overflow:visible;width:auto}.ttB:after{display:none}.ttB:focus{background:0 0}.ttC{box-shadow:none}.ttD{--sa-header-sub-menu-bg:var(--white-100);--sa-header-sub-menu-border-color:var(--black-10);--sa-header-sub-menu-color:var(--black-100);background-color:var(--sa-header-sub-menu-bg);border-radius:0;box-shadow:0 0 5px 2px rgba(0,0,0,.13);right:0;top:1.25rem;white-space:nowrap}[data-color-scheme=dark] .ttD{--sa-header-sub-menu-bg:var(--black-80);--sa-header-sub-menu-color:var(--black-10);--sa-header-sub-menu-border-color:var(--black-30)}.ttD:after{display:none}.xkA{fill:var(--black-35);height:8px;width:8px}.xkB{transform:rotate(180deg)}.jmA{height:6px}.jmB{height:4px}.jmC{height:1px}.jmD{height:18px}.jmE{margin-left:-50vw;margin-right:-50vw}.jmF{background-color:var(--black-100)}[data-color-scheme=dark] .jmF{background-color:var(--black-10)}.jmG{background-color:var(--black-5)}[data-color-scheme=dark] .jmG{background-color:var(--black-80)}.jmH{background-color:var(--sa-section-separator-color)}[data-color-scheme=dark] .jmH{background-color:var(--black-80)}.jmI{background-color:var(--black-50)}[data-color-scheme=dark] .jmI{background-color:var(--black-80)}.jmJ{background-color:var(--black-35)}[data-color-scheme=dark] .jmJ{background-color:var(--black-50)}.jmK{background-color:var(--black-20)}[data-color-scheme=dark] .jmK{background-color:var(--black-50)}.jmL{background-color:var(--sa-body-bg-color)}.bemA{cursor:pointer}.bbuA{display:block;word-break:break-word}.bbuA,.bbuA:focus,.bbuA:hover,.bbuA:visited{color:var(--black-10);text-decoration:none}.bbuA:focus,.bbuA:hover{text-decoration:underline}.tqA{background-color:var(--black-10);height:1px}[data-color-scheme=dark] .tqA{background-color:var(--black-50)}.jqA{list-style:none}.jqB{font-size:.875rem;font-weight:400}.jqB:not(:last-child){margin-bottom:16px}.xoA{min-width:0}.gaA{width:100%}.gaB{width:auto}.qeA{background-color:var(--sa-header-sub-menu-bg);font-size:.875rem;font-weight:700;line-height:1rem}.qeA,.qeA:focus,.qeA:hover,.qeA:visited{color:var(--sa-header-sub-menu-color);text-decoration:none}.qeA:focus,.qeA:hover{text-decoration:underline}.qeA:visited{color:var(--sa-header-sub-menu-color)}.qeA:focus,.qeA:hover{--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--white-100);text-decoration:none}[data-color-scheme=dark] .qeA:focus,[data-color-scheme=dark] .qeA:hover{--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--black-100)}.qeA:focus svg,.qeA:hover svg{fill:currentColor}.qeB:not(:last-child){margin-bottom:0}.jtD{z-index:1019}.smB{height:16px;width:16px}.xcA{height:12px;width:14px}.bhqA{background-color:var(--yellow-85);border-radius:0;border-style:none}.bhqA,.bhqA:focus,.bhqA:hover,.bhqA:visited{color:var(--black-100);text-decoration:none}.bhqA:focus,.bhqA:hover{text-decoration:underline}.bhqB{background-color:var(--yellow-85);border-radius:5px;max-width:130px;text-align:center}.bhqB,.bhqB:focus,.bhqB:hover,.bhqB:visited{color:var(--black-100);text-decoration:none}.bhqB:focus,.bhqB:hover{text-decoration:underline}.bhqC,.bhqC:focus,.bhqC:hover,.bhqC:visited{color:var(--yellow-85);text-decoration:none}.bhqC:focus,.bhqC:hover{text-decoration:underline}.bhqD{background-color:var(--yellow-85);border-radius:0;border-style:none;bottom:-26px;display:block;height:28px;line-height:28px;text-align:center;width:100%}.bhqD,.bhqD:focus,.bhqD:hover,.bhqD:visited{color:var(--black-100);text-decoration:none}.bhqD:focus,.bhqD:hover{text-decoration:underline}.beqA{margin-right:5px;text-align:center;width:12px}@media(min-width:1024px){.beqA{height:18px;margin-right:10px;width:18px}}.beqB{fill:currentColor;height:16px;width:16px}.wqA{height:12px;width:12px}@media(min-width:1024px){.wqA{height:18px;width:18px}}.wqB{height:14px;width:18px}.wqC{height:18px;width:16px}.xlA{max-height:386px;overflow-x:hidden;overflow-y:auto;overscroll-behavior:contain}.bigA:not(:last-child){margin-right:40px}.bnqA{font-size:.875rem;height:100%;line-height:1rem;opacity:.7;z-index:1}.bnqA,.bnqA:focus,.bnqA:hover,.bnqA:visited{color:var(--sa-header-color);text-decoration:none}.bnqA:active,.bnqA:focus,.bnqA:hover{opacity:.8}.bnqB,.bnqB:active,.bnqB:focus,.bnqB:hover{opacity:1}.bihA{font-size:.875rem;height:100%;line-height:1rem;opacity:.7}.bihA:active,.bihA:focus,.bihA:hover{opacity:.8}.bbzA,.bihB{height:100%}@media(min-width:1024px){.bbzA{padding-left:5px;padding-right:5px}}@media(min-width:1200px){.bbzA{padding-left:9px;padding-right:9px}}.bbzB{left:0;right:auto}.bbzC{height:100%}@media(min-width:1024px){.bbzC{height:auto}}.bbzD{height:40px;position:relative;white-space:nowrap}.bbzD:first-child .bbzA{padding-left:0}@media(hover:hover)and (pointer:fine)and (min-width:1024px){.bbzD{cursor:pointer;transition:opacity .2s ease-in-out}.bbzD:focus,.bbzD:hover{opacity:1!important}}@media screen and (hover:hover)and (pointer:fine)and (min-width:1024px)and (prefers-reduced-motion:reduce){.bbzD{transition:none}}@media(hover:hover)and (pointer:fine)and (min-width:1024px){.bbzD:not(:last-child){margin-right:1px}}.tuA{list-style:none;margin:0;overflow-y:hidden;padding-left:0}@media(min-width:1024px){.tuA{overflow-y:visible;padding-bottom:0}}@media(hover:hover)and (pointer:fine)and (min-width:1024px){.tuA:focus>li,.tuA:hover>li{opacity:.5}}.kyA{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);color:var(--white-100);padding-left:16px;padding-right:16px}@supports(padding:max(0px)){.kyA{padding-left:max(16px,0);padding-left:max(16px,var(--env-safe-area-inset-left,0));padding-right:max(16px,0);padding-right:max(16px,var(--env-safe-area-inset-right,0))}}@media(min-width:1024px){.kyB{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);display:flex;padding-left:18px;padding-right:18px;position:relative;z-index:var(--sa-header-bottom-nav-index)}@supports(padding:max(0px)){.kyB{padding-left:max(18px,0);padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,0);padding-right:max(18px,var(--env-safe-area-inset-right,0))}}}.kyC{height:40px;overflow:hidden;-webkit-user-select:none;-moz-user-select:none;user-select:none;width:auto}@media(min-width:1024px){.kyC{overflow:visible}}.kyD{position:relative}.kyD:after,.kyD:before{content:\"\";display:block;height:100%;opacity:0;pointer-events:none;position:absolute;transition:opacity .2s linear;width:60px;z-index:1}@media screen and (prefers-reduced-motion:reduce){.kyD:after,.kyD:before{transition:none}}.kyD:before{background-image:linear-gradient(to right,rgba(var(--black-70),1),rgba(var(--black-70),.001));left:0}.kyD:after{background-image:linear-gradient(to left,rgba(var(--black-70),1),rgba(var(--black-70),.001));right:0;top:0}.kyD.kyE:before,.kyD.kyF:after{opacity:1}.juA{background-color:var(--sa-header-bg-color);outline:1px solid var(--sa-header-bg-color)}.juB{color:var(--sa-header-color);height:50px;position:relative}.juC>:not(:last-child){margin-right:18px}.jsA,.jsA:focus,.jsA:hover,.jsA:visited{color:inherit;text-decoration:none}.jsB{height:26px;width:142px}@media(min-width:375px){.jsB{height:30px;width:150px}}.jsC{font-size:.75rem}.jsD{fill:var(--orange-60);color:var(--white-100)}.jsE{fill:var(--teal-50)}.jsF{fill:var(--yellow-85)}.jsG{width:35px}.jsH{height:26px}@media(min-width:375px){.jsH{height:30px}}.jsI{color:var(--white-100)}.jsJ{color:var(--sa-text-color-1)}.jsK{clip:rect(0,0,0,0);border:0!important;height:1px!important;overflow:hidden;padding:0!important;position:absolute!important;white-space:nowrap;width:1px!important}.jvA,.jvB{height:100%}.jvC{height:20px;position:relative}.jvC,.jvD{width:18px}.jvD{background-color:var(--white-100);height:2px;position:absolute;top:calc(50% - 1px);transition:top .1s ease,width .1s ease,bottom .1s ease,transform .1s cubic-bezier(.165,.84,.44,1)}@media screen and (prefers-reduced-motion:reduce){.jvD{transition:none}}.jvD:before{background-color:var(--white-100);content:\"\";display:block;height:2px;position:absolute;top:-5px;transition:transform .15s ease;width:18px}.jvD.jvE{transition:width .1s ease .1s;width:0}@media screen and (prefers-reduced-motion:reduce){.jvD.jvE{transition:none}}.jvD.jvE:before{top:1.5px;transform:translate3d(-4px,-6px,0) rotate(-45deg) scaleX(.7);width:20px}.jvD.jvE:after{bottom:1.5px;transform:translate3d(-4px,6px,0) rotate(45deg) scaleX(.7);width:20px}.jvD:after{background-color:var(--white-100);bottom:-5px;content:\"\";display:block;height:2px;position:absolute;width:18px}.noB{fill:currentColor;height:.75rem;position:relative;top:.0625rem;width:.875rem}.noC{color:var(--sa-negative-color)}.noD{color:var(--sa-text-color-3)}.lzA{-moz-appearance:textfield;background-clip:padding-box;background-color:var(--sa-input-background-color);border:1px solid var(--sa-input-border-color);border-radius:var(--sa-input-border-radius);color:var(--sa-input-color);display:inline-block;height:var(--sa-input-height);padding:var(--sa-input-padding);text-overflow:ellipsis}.lzA::-webkit-calendar-picker-indicator,.lzA::-webkit-clear-button,.lzA::-webkit-inner-spin-button{-webkit-appearance:none;appearance:none;display:none}.lzA:-webkit-autofill{-webkit-text-fill-color:var(--sa-input-color);box-shadow:0 0 0 1000px var(--sa-input-background-color) inset}.lzA::-ms-clear{display:none}.lzA:invalid{box-shadow:none}.lzA:disabled,.lzA[readonly]{opacity:1}.lzB,.lzC{height:var(--sa-input-button-size);position:absolute;right:var(--sa-input-button-right-offset);top:50%;transform:translateY(-50%);width:var(--sa-input-button-size)}.lzC{color:var(--sa-input-button-color);font-size:0}.lzC:disabled{color:var(--sa-input-button-disabled-color);pointer-events:none}.lzC:focus,.lzC:hover{color:var(--sa-input-button-hover-color)}.lzC svg{fill:currentColor;flex-grow:1}.lzB{fill:var(--sa-input-button-color);pointer-events:none}.geA.geB,.geA.geB:focus{--sa-input-border-color:var(--sa-negative-color)}.geC{position:relative}.geC:focus-within .geA{--sa-input-border-color:var(--black-35)}[data-color-scheme=dark] .geC:focus-within .geA{--sa-input-border-color:var(--black-10)}.geC:focus-within .geA.geB{--sa-input-border-color:var(--sa-negative-color)}.geC:focus-within .geA.geB:focus{--sa-input-border-color:var(--sa-negative-color)}.geD{--sa-input-border-color:var(--black-10);--sa-input-color:var(--black-100);--sa-input-background-color:var(--white-100)}.geD:focus{--sa-input-border-color:var(--black-35)}.geD::placeholder,.geD[readonly]{--sa-input-bg-color:var(--black-5);color:var(--black-10)}.geD:disabled{--sa-input-background-color:var(--black-5);--sa-input-border-color:var(--black-10);--sa-input-color:var(--black-10)}.geD~*{--sa-input-button-color:var(--black-35);--sa-input-button-disabled-color:var(--black-10);--sa-input-button-hover-color:var(--black-50)}[data-color-scheme=dark] .geD{--sa-input-border-color:var(--black-30);--sa-input-color:var(--black-10);--sa-input-background-color:var(--black-98)}[data-color-scheme=dark] .geD:focus{--sa-input-border-color:var(--black-10)}[data-color-scheme=dark] .geD::placeholder,[data-color-scheme=dark] .geD[readonly]{--sa-input-bg-color:var(--black-98);color:var(--black-80)}[data-color-scheme=dark] .geD:disabled{--sa-input-background-color:var(--black-98);--sa-input-border-color:var(--black-80);--sa-input-color:var(--black-80)}[data-color-scheme=dark] .geD~*{--sa-input-button-color:var(--black-30);--sa-input-button-disabled-color:var(--black-10);--sa-input-button-hover-color:var(--black-10)}.geE{--sa-input-height:var(--input-size-xs);--sa-input-padding:4px 8px;--sa-input-border-radius:var(--sa-border-r-4);--sa-input-button-size:1.25rem;--sa-input-button-right-offset:0.75rem}.geF{--sa-input-height:var(--input-size-sm);--sa-input-padding:8px 12px;--sa-input-border-radius:var(--sa-border-r-4);--sa-input-button-size:1.25rem;--sa-input-button-right-offset:0.75rem}.geG{--sa-input-height:var(--input-size-md);--sa-input-padding:8px 12px;--sa-input-border-radius:var(--sa-border-r-4);--sa-input-button-size:1.5rem;--sa-input-button-right-offset:0.375rem}.geH{--sa-input-height:var(--input-size-lg);--sa-input-padding:8px 12px;--sa-input-border-radius:var(--sa-border-r-8);--sa-input-button-size:2rem;--sa-input-button-right-offset:0.375rem}@media(min-width:1024px){.geN{margin-bottom:8px}}.geO{clip:rect(0,0,0,0);border:0!important;height:1px!important;overflow:hidden;padding:0!important;position:absolute!important;white-space:nowrap;width:1px!important}.mpA{color:var(--black-35)}[data-color-scheme=dark] .mpA{color:var(--black-30)}.ksA{--sa-input-height:var(--input-size-sm);--sa-input-padding:8px 12px;--sa-input-border-radius:var(--sa-border-r-4);--sa-input-button-size:1.25rem;--sa-input-button-right-offset:0.75rem}.ksB{--sa-input-height:var(--input-size-md);--sa-input-padding:8px 12px;--sa-input-border-radius:var(--sa-border-r-4);--sa-input-button-size:1.5rem;--sa-input-button-right-offset:0.375rem}.ksC{--sa-input-height:var(--input-size-lg);--sa-input-padding:8px 12px;--sa-input-border-radius:var(--sa-border-r-8);--sa-input-button-size:2rem;--sa-input-button-right-offset:0.375rem}.ksE{--sa-input-padding:8px calc(var(--sa-input-button-size) + var(--sa-input-button-right-offset)) 8px 12px}.ksH .ksD{margin-bottom:8px}.ksI .ksD{margin-bottom:0;margin-right:8px}.bbkA{border-bottom-left-radius:0;border-bottom-right-radius:0}[data-color-scheme=dark] .bbkB::placeholder,[data-color-scheme=dark] .bbkB[readonly]{color:var(--black-30)}.suA{margin-left:60px;position:relative;vertical-align:middle;width:300px}.kpA,.kpA:visited{--sa-btn-bg-color:var(--black-10);--sa-btn-color:var(--black-50);--sa-btn-border-color:var(--black-10)}@media(hover:hover)and (pointer:fine){.kpA:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-70);--sa-btn-border-color:var(--black-70)}}.kpA:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-70);--sa-btn-border-color:var(--black-70)}.kpA.kpB,.kpA:disabled{background-color:var(--black-10);border-color:var(--black-10);color:var(--black-20);cursor:default}[data-color-scheme=dark] .kpA.kpB,[data-color-scheme=dark] .kpA:disabled{opacity:.2}[data-color-scheme=dark] .kpA,[data-color-scheme=dark] .kpA:visited{--sa-btn-bg-color:var(--black-90);--sa-btn-color:var(--black-10);--sa-btn-border-color:var(--black-90)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .kpA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-30);--sa-btn-border-color:var(--black-30)}}[data-color-scheme=dark] .kpA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-30);--sa-btn-border-color:var(--black-30)}[data-color-scheme=dark] .kpA.kpB,[data-color-scheme=dark] .kpA:disabled{background-color:var(--black-30);border-color:var(--black-30);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .kpA.kpB,[data-color-scheme=dark] [data-color-scheme=dark] .kpA:disabled{opacity:.2}.kpC,.kpC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--black-50);--sa-btn-border-color:var(--black-10)}@media(hover:hover)and (pointer:fine){.kpC:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-70);--sa-btn-border-color:var(--black-70)}}.kpC:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--black-70);--sa-btn-border-color:var(--black-70)}.kpC.kpB,.kpC:disabled{background-color:transparent;border-color:var(--black-10);color:var(--black-95);cursor:default}[data-color-scheme=dark] .kpC.kpB,[data-color-scheme=dark] .kpC:disabled{opacity:.2}[data-color-scheme=dark] .kpC,[data-color-scheme=dark] .kpC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--black-30);--sa-btn-border-color:var(--black-80)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .kpC:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-30);--sa-btn-border-color:var(--black-30)}}[data-color-scheme=dark] .kpC:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-30);--sa-btn-border-color:var(--black-30)}[data-color-scheme=dark] .kpC.kpB,[data-color-scheme=dark] .kpC:disabled{background-color:transparent;border-color:var(--black-80);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .kpC.kpB,[data-color-scheme=dark] [data-color-scheme=dark] .kpC:disabled{opacity:.2}.jyA{font-size:12px;line-height:14px;padding:7px 8px}.jyA,.jyA:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--black-10);--sa-btn-border-color:var(--black-10)}@media(hover:hover)and (pointer:fine){.jyA:hover{--sa-btn-color:var(--black-50);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-70)}}.jyA:active{--sa-btn-color:var(--black-50);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-10)}.jyA.jyB,.jyA:disabled{background-color:transparent;border-color:var(--black-10);cursor:default}[data-color-scheme=dark] .jyA.jyB,[data-color-scheme=dark] .jyA:disabled{opacity:.2}.jnA{font-size:12px;line-height:14px;padding:7px 8px}.jnA,.jnA:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--black-10);--sa-btn-border-color:var(--black-10)}@media(hover:hover)and (pointer:fine){.jnA:hover{--sa-btn-color:var(--black-50);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-70)}}.jnA:active{--sa-btn-color:var(--black-50);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-10)}.jnA.jnB,.jnA:disabled{background-color:transparent;border-color:var(--black-10);cursor:default}[data-color-scheme=dark] .jnA.jnB,[data-color-scheme=dark] .jnA:disabled{opacity:.2}[data-color-scheme=dark] .jnA,[data-color-scheme=dark] .jnA:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--black-10);--sa-btn-border-color:var(--black-30)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .jnA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-10)}}[data-color-scheme=dark] .jnA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--black-10);--sa-btn-border-color:var(--black-10)}[data-color-scheme=dark] .jnA.jnB,[data-color-scheme=dark] .jnA:disabled{background-color:transparent;border-color:var(--black-30);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .jnA.jnB,[data-color-scheme=dark] [data-color-scheme=dark] .jnA:disabled{opacity:.2}.bbnA,.bbnA:visited{--sa-btn-bg-color:var(--yellow-85);--sa-btn-color:var(--white-100);--sa-btn-border-color:var(--yellow-85)}@media(hover:hover)and (pointer:fine){.bbnA:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--yellow-100);--sa-btn-border-color:var(--yellow-100)}}.bbnA:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--yellow-100);--sa-btn-border-color:var(--yellow-100)}.bbnA.bbnB,.bbnA:disabled{background-color:var(--yellow-85);border-color:var(--yellow-85);cursor:default}[data-color-scheme=dark] .bbnA.bbnB,[data-color-scheme=dark] .bbnA:disabled{opacity:.2}[data-color-scheme=dark] .bbnA,[data-color-scheme=dark] .bbnA:visited{--sa-btn-bg-color:var(--yellow-85);--sa-btn-color:var(--black-100);--sa-btn-border-color:var(--yellow-85)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .bbnA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--yellow-100);--sa-btn-border-color:var(--yellow-100)}}[data-color-scheme=dark] .bbnA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--yellow-100);--sa-btn-border-color:var(--yellow-100)}[data-color-scheme=dark] .bbnA.bbnB,[data-color-scheme=dark] .bbnA:disabled{background-color:var(--black-30);border-color:var(--black-30);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .bbnA.bbnB,[data-color-scheme=dark] [data-color-scheme=dark] .bbnA:disabled{opacity:.2}.tfA{font-size:12px;font-weight:700;line-height:14px;min-height:30px}.qsA,.qsA:visited{--sa-btn-bg-color:var(--blue-75);--sa-btn-color:var(--white-100);--sa-btn-border-color:var(--blue-75)}@media(hover:hover)and (pointer:fine){.qsA:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--blue-80);--sa-btn-border-color:var(--blue-80)}}.qsA:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--blue-80);--sa-btn-border-color:var(--blue-80)}.qsA.qsB,.qsA:disabled{background-color:var(--blue-75);border-color:var(--blue-75);cursor:default}[data-color-scheme=dark] .qsA.qsB,[data-color-scheme=dark] .qsA:disabled{opacity:.2}[data-color-scheme=dark] .qsA,[data-color-scheme=dark] .qsA:visited{--sa-btn-bg-color:var(--blue-75);--sa-btn-color:var(--black-100);--sa-btn-border-color:var(--blue-75)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .qsA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--blue-80);--sa-btn-border-color:var(--blue-80)}}[data-color-scheme=dark] .qsA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--blue-80);--sa-btn-border-color:var(--blue-80)}[data-color-scheme=dark] .qsA.qsB,[data-color-scheme=dark] .qsA:disabled{background-color:var(--black-30);border-color:var(--black-30);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .qsA.qsB,[data-color-scheme=dark] [data-color-scheme=dark] .qsA:disabled{opacity:.2}.qsC,.qsC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--blue-75);--sa-btn-border-color:var(--blue-75)}@media(hover:hover)and (pointer:fine){.qsC:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--blue-75);--sa-btn-border-color:var(--blue-80)}}.qsC:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--blue-75);--sa-btn-border-color:var(--blue-75)}.qsC.qsB,.qsC:disabled{background-color:transparent;border-color:var(--blue-75);cursor:default}[data-color-scheme=dark] .qsC.qsB,[data-color-scheme=dark] .qsC:disabled{opacity:.2}.jlA{font-size:12px;font-weight:700;line-height:14px;min-height:30px}.krA,.krA:visited{--sa-btn-bg-color:var(--orange-60);--sa-btn-color:var(--white-100);--sa-btn-border-color:var(--orange-60)}@media(hover:hover)and (pointer:fine){.krA:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--orange-70);--sa-btn-border-color:var(--orange-70)}}.krA:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--orange-70);--sa-btn-border-color:var(--orange-70)}.krA.krB,.krA:disabled{background-color:var(--orange-60);border-color:var(--orange-60);cursor:default}[data-color-scheme=dark] .krA.krB,[data-color-scheme=dark] .krA:disabled{opacity:.2}[data-color-scheme=dark] .krA,[data-color-scheme=dark] .krA:visited{--sa-btn-bg-color:var(--orange-60);--sa-btn-color:var(--black-100);--sa-btn-border-color:var(--orange-60)}@media(hover:hover)and (pointer:fine){[data-color-scheme=dark] .krA:hover{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--orange-70);--sa-btn-border-color:var(--orange-70)}}[data-color-scheme=dark] .krA:active{--sa-btn-color:var(--black-100);--sa-btn-bg-color:var(--orange-70);--sa-btn-border-color:var(--orange-70)}[data-color-scheme=dark] .krA.krB,[data-color-scheme=dark] .krA:disabled{background-color:var(--black-30);border-color:var(--black-30);cursor:default}[data-color-scheme=dark] [data-color-scheme=dark] .krA.krB,[data-color-scheme=dark] [data-color-scheme=dark] .krA:disabled{opacity:.2}.krC,.krC:visited{--sa-btn-bg-color:transparent;--sa-btn-color:var(--orange-60);--sa-btn-border-color:var(--orange-60)}@media(hover:hover)and (pointer:fine){.krC:hover{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--orange-70);--sa-btn-border-color:var(--orange-70)}}.krC:active{--sa-btn-color:var(--white-100);--sa-btn-bg-color:var(--orange-70);--sa-btn-border-color:var(--orange-70)}.krC.krB,.krC:disabled{background-color:transparent;border-color:var(--orange-60);cursor:default}[data-color-scheme=dark] .krC.krB,[data-color-scheme=dark] .krC:disabled{opacity:.2}.tgA{font-size:12px;line-height:14px;min-height:30px}.tcA,.tgA{font-weight:700}.tcA{background-color:var(--orange-60);border:2px solid var(--black-70);border-radius:4px;color:var(--black-100);min-width:1.25rem;position:absolute;right:0;top:0;transform:translateX(50%) translateY(-25%)}.jwA{overflow:visible}.jwB{max-height:24px}.jwC{color:var(--white-100);cursor:pointer;position:relative}[data-color-scheme=dark] .jwC{color:var(--black-10)}@media(min-width:1024px){.jwC{color:var(--black-35)}[data-color-scheme=dark] .jwC{color:var(--black-30)}}.tsA{position:relative}.tsB{height:30px;position:absolute;width:30px}.tsC{fill:var(--white-100)}[data-color-scheme=dark] .tsC{fill:var(--black-10)}.tsA,.tsC{height:24px;width:24px}.qxA,.qxB{border-radius:50%}.qxB{background-color:var(--white-96);color:var(--white-96);height:100%;overflow:hidden;width:100%}[data-color-scheme=dark] .qxB{background-color:var(--black-30);color:var(--black-100)}.qxC{border:1px solid var(--black-35)}[data-color-scheme=dark] .qxC{border-color:var(--black-30)}.qxD{height:20px;width:20px}.qxE{height:30px;width:30px}.qxF{height:36px;width:36px}.qxG{height:44px;width:44px}.qxH{height:48px;width:48px}.qxI{height:54px;width:54px}.qxJ{height:60px;width:60px}.qxK{height:72px;width:72px}.qxL{height:80px;width:80px}.qxM{height:100px;width:100px}.qxN{height:120px;width:120px}.qxO{height:170px;width:170px}.qxP{height:240px;width:240px}.qxQ{background-color:var(--black-20);color:var(--white-100);cursor:default;text-transform:uppercase}.qxR{--sa-userpic-marker-size:8px;--sa-userpic-border-cutout-size:2px;position:relative}.qxR:after{background-color:var(--blue-75);border:var(--sa-userpic-border-cutout-size) solid var(--sa-userpic-border-color,var(--sa-body-bg-color));border-radius:50%;content:\"\";height:calc(var(--sa-userpic-marker-size) + var(--sa-userpic-border-cutout-size)*2);position:absolute;right:-2px;top:-2px;width:calc(var(--sa-userpic-marker-size) + var(--sa-userpic-border-cutout-size)*2)}.jzA{position:relative}.jzB{fill:var(--white-100);height:25px;width:31px}[data-color-scheme=dark] .jzB{fill:var(--black-10)}@media(min-width:1024px){.jzB{fill:var(--sa-text-color-2)}[data-color-scheme=dark] .jzB{fill:var(--black-30)}}.jzC{clip:rect(0,0,0,0);border:0!important;height:1px!important;overflow:hidden;padding:0!important;position:absolute!important;white-space:nowrap;width:1px!important}.kaA{position:relative}.kaB{z-index:var(--sa-header-top-nav-index)}@media(min-width:1024px){.kaB{--sa-header-top-nav-index:3}}.sfA{color:var(--sa-text-color-2);display:block}.sfB{height:20px;margin-left:auto;margin-right:auto;width:20px}.sfB svg{fill:currentColor;height:100%;width:100%}.sfB svg,.sfC{display:block}.sfD{color:var(--sa-text-color-1)}.sfD .sfB{color:var(--blue-75)}.nyA{background-color:var(--black-4);border-top:1px solid var(--sa-section-separator-thin-color);min-height:80px}[data-color-scheme=dark] .nyA{background-color:var(--black-70)}.nyB{list-style:none;margin:0;padding-left:0}.nyC{min-width:60px}@media(min-width:576px){.nyC{min-width:78px}}.nyC:last-child{margin-right:0;min-width:60px}.dzA{position:relative}.dzB{background-color:var(--sa-header-bg-color)}.dzC{transition:transform .3s}@media screen and (prefers-reduced-motion:reduce){.dzC{transition:none}}.dzD{transform:translateY(-40px)}.dzE{transform:translateY(calc(var(--headerFullHeight)*-1))}@media(min-width:1024px){.dzF{position:absolute;width:100%}}.jA{top:53px}@media(orientation:landscape){.jA{top:23px}}@media(min-width:768px){.jB{min-height:18px}}@media(min-width:1024px){.jB{min-height:40px}}.gA{top:24px}.jxA{list-style:none;margin:0;padding-left:0}.jxB:after{align-self:stretch;background-color:var(--black-50);content:\"\";display:block;margin-left:18px;margin-right:18px;width:1px}.jxB:last-child:after{display:none}.ihA{background-color:var(--black-70);color:var(--white-100);flex-direction:column;left:0;top:0;z-index:1020}.ihB{height:50px;width:100%}.ihD{background-color:var(--black-50);height:60%;width:1px}.ihE{fill:var(--orange-60);height:18px;width:20px}.marketplaceLayout .elA{display:flex}.elE{white-space:nowrap}.elE,.elE:focus,.elE:hover,.elE:visited{color:var(--white-100);text-decoration:none}.elE:focus,.elE:hover{text-decoration:underline}.elF{fill:var(--blue-75)}.hA{top:14px}.eqA{color:var(--black-35);line-height:1.75}.eqB{font-weight:700}@media(min-width:768px){.sA{display:flex;flex-flow:row}}@media(min-width:768px){.sB{flex-grow:0}}.bA{max-height:100%}@media(orientation:landscape){.bA{max-height:668px}}@media(min-width:768px){.bA{max-height:none}}.bB.bC{padding:0;width:100%}@media(min-width:768px){.bB.bC{height:668px;max-width:375px}}@media(min-width:1024px){.bB.bC{height:656px;max-width:700px}}.dA{left:0;max-width:1264px;position:fixed;right:0;top:50px;width:100%;z-index:1050}</style><style data-href=\"/samw/static/styles/prerender.4ff2fea0.css\">:root{--twitter-color:#38a1f3;--reddit-color:#ff5700;--facebook-color:#3b5998;--linkedIn-color:#0077b5;--email-color:#999;--sa-sticky-top:calc(var(--headerHeight, 0px) + var(--stripBarHeight, 0px));--black-98-grad:linear-gradient(90deg,var(--black-98-alpha-0) 0%,var(--black-98) 100%);--black-95-grad:linear-gradient(90deg,var(--black-95-alpha-0) 0%,var(--black-95) 100%);--black-90-grad:linear-gradient(90deg,var(--black-90) 0%,var(--black-100-95) 100%);--black-80-grad:linear-gradient(90deg,var(--black-80) 0%,var(--black-95) 100%);--black-70-grad:linear-gradient(90deg,var(--black-70-alpha-0) 0%,var(--black-70) 100%);--black-60-grad:linear-gradient(180deg,var(--black-60-alpha-50) 0%,var(--black-60) 100%);--black-40-grad:linear-gradient(180deg,var(--black-40-alpha-50) 0%,var(--black-40) 100%);--black-10-grad:linear-gradient(90deg,var(--black-10) 0%,var(--white-100) 100%);--black-5-grad:linear-gradient(90deg,var(--black-5-alpha-0) 0%,var(--black-5) 100%);--white-100-grad:linear-gradient(90deg,var(--white-100-alpha-0) 0%,var(--white-100) 100%);--red-90-grad:linear-gradient(90deg,var(--red-90-alpha-50) 0%,var(--red-90) 100%);--orange-60-grad:linear-gradient(90deg,var(--orange-60-alpha-50) 0%,var(--orange-60) 100%);--teal-80-grad:linear-gradient(90deg,var(--teal-80-alpha-50) 0%,var(--teal-80) 100%);--box-shadow:0 8px 8px var(--black-100-alpha-15);--shadow-elevation-1:0 0 10px rgba(0,0,0,.2);--shadow-elevation-2:0 4 8px rgba(0,0,0,.25);--shadow-elevation-3:0 0 10px rgba(0,0,0,.75);--shadow-elevation-4:0 4px 8px rgba(0,0,0,.75);--black-100:#000;--black-100-alpha-80:#000c;--black-100-alpha-75:#000000bf;--black-100-alpha-50:#00000080;--black-100-alpha-25:#00000040;--black-100-alpha-15:#00000026;--black-100-alpha-10:#0000001a;--black-100-alpha-0:#0000;--black-98:#04080b;--black-98-alpha-0:#04080b00;--black-95:#111517;--black-95-alpha-0:#11151700;--black-90:#232a32;--black-80:#2c3032;--black-80-alpha-0:#2c303200;--black-70:#333;--black-70-alpha-0:#3330;--black-70-alpha-50:#33333380;--black-60:#434348;--black-60-alpha-50:#43434880;--black-50:#555;--black-50-alpha-10:#5555551a;--black-40:#697173;--black-40-alpha-50:#69717300;--black-35:#757575;--black-30:#838d8f;--black-30-alpha-30:#838d8f4d;--black-30-alpha-20:#838d8f33;--black-20:#acacac;--black-20-alpha-20:#acacac33;--black-10:#dbdbdb;--black-5:#f2f4f7;--black-5-alpha-0:#f2f4f700;--black-4:#f9f9f9;--white-96:#f3f4f7;--white-100:#fff;--white-100-alpha-75:#ffffffbf;--white-100-alpha-50:#ffffff80;--white-100-alpha-0:#fff0;--red-100:#c9392c;--red-100-alpha-75:#c9392cbf;--red-95:#e32b30;--red-90:#d23f31;--red-90-alpha-50:#d23f3180;--red-80:#d94d41;--orange-100:#ff1a00;--orange-90:#ea4215;--orange-80:#ff3c00;--orange-70:#d15e00;--orange-60:#ff7200;--orange-60-alpha-50:#ff720080;--orange-60-alpha-0:#ff720000;--yellow-100:#e59310;--yellow-100-alpha-50:#ff720080;--yellow-90:#efa818;--yellow-85:#fec20f;--yellow-80:#fcc131;--yellow-70:#dfbf18;--green-100:#3d5f12;--green-90:#5d921c;--green-80:#70c30e;--green-75:#85c90e;--green-60:#9ace49;--green-50:#a9b667;--teal-100:#0a7b44;--teal-100-alpha-75:#0a7b44bf;--teal-100-alpha-50:#0a7b4480;--teal-80:#0f9d58;--teal-80-alpha-50:#0f9d5880;--teal-75:#32a667;--teal-50:#00d885;--teal-45:#67d9a2;--blue-100:#410cda;--blue-80:#2867db;--blue-75:#1a98ff;--blue-75-alpha-20:#1a98ff33;--blue-75-alpha-66:#1a98ffa8;--blue-70:#5994ff;--blue-50:#7cb5ec;--blue-50-alpha-20:#7cb5ec33;--blue-10:#e8f5ff;--purple-100:#d423c3;--sa-body-bg-color:var(--white-96);--sa-body-bg-color-2:var(--white-100);--sa-link-color:var(--blue-80);--sa-card-bg-color:var(--white-100);--sa-card-bg-color-2:var(--black-5);--sa-invert-default-color:var(--white-100);--sa-text-color-1:var(--black-100);--sa-text-color-2:var(--black-35);--sa-text-color-3:var(--black-50);--sa-text-color-4:var(--black-70);--sa-negative-color:var(--red-100);--sa-positive-color:var(--teal-100);--sa-section-separator-color:var(--black-10);--sa-section-separator-thin-color:var(--black-10);--sa-very-bearish-color:var(--red-95);--sa-bearish-color:var(--orange-100);--sa-neutral-color:var(--yellow-90);--sa-bullish-color:var(--green-60);--sa-very-bullish-color:var(--green-90);--sa-modal-container-bg-color:var(--white-100);--sa-card-bg-transparent-color:hsla(0,0%,100%,0);--sa-content-hide-gradient:linear-gradient(to top,var(--white-100),hsla(0,0%,100%,.5));--sa-spinner-color-1:var(--black-10);--sa-input-border-color:var(--black-10);--sa-disabled-text-color:var(--black-10)}[data-color-scheme=dark]{--sa-body-bg-color:var(--black-98);--sa-body-bg-color-2:var(--black-98);--sa-link-color:var(--blue-70);--sa-card-bg-color:var(--black-95);--sa-card-bg-color-2:var(--black-80);--sa-invert-default-color:var(--black-100);--sa-text-color-1:var(--black-10);--sa-text-color-2:var(--black-30);--sa-text-color-3:var(--black-30);--sa-text-color-4:var(--black-30);--sa-negative-color:var(--red-80);--sa-positive-color:var(--teal-75);--sa-section-separator-color:var(--black-30);--sa-section-separator-thin-color:var(--black-80);--sa-modal-container-bg-color:var(--black-80);--sa-content-hide-gradient:linear-gradient(to top,var(--black-95),transparent);--sa-card-bg-transparent-color:transparent;--sa-spinner-color-1:var(--black-35);--sa-input-border-color:var(--black-30);--sa-disabled-text-color:var(--black-80)}:root{--sa-border-r-4:4px;--sa-border-r-8:8px;--sa-border-r-10:10px;--sa-border-r-12:12px;--input-size-xs:1.5rem;--input-size-sm:1.875rem;--input-size-md:2.25rem;--input-size-lg:2.75rem;--sa-chart-loading-color:var(--black-100);--sa-chart-axis-label-color:var(--sa-text-color-3);--sa-chart-loading-background-color:var(--black-100-alpha-10);--sa-chart-axis-line-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-10);--sa-chart-tooltip-bg-color:var(--white-100);--sa-chart-tooltip-color:var(--black-70);--sa-chart-series-start-gradient-color:var(--white-100);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-bg-color:transparent;--sa-chart-flag-plot-line-color:var(--black-20);--sa-chart-flag-plot-fill-color:var(--white-100);--sa-chart-axis-tick-color:var(--black-10);--sa-chart-axis-plot-color:var(--black-5);--sa-chart-plot-option-pie-border-color:var(--white-100);--sa-chart-annotation-tooltip-bg-color:var(--black-100)}[data-color-scheme=dark]{--sa-chart-loading-background-color:var(--black-100-alpha-50);--sa-chart-loading-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-90);--sa-chart-tooltip-bg-color:var(--black-80);--sa-chart-tooltip-color:var(--black-30);--sa-chart-series-start-gradient-color:var(--orange-60-alpha-0);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-axis-line-color:var(--black-80);--sa-chart-flag-plot-line-color:var(--black-80);--sa-chart-flag-plot-fill-color:var(--white-95);--sa-chart-axis-tick-color:var(--black-30);--sa-chart-axis-plot-color:var(--black-100);--sa-chart-plot-option-pie-border-color:var(--black-95);--sa-chart-annotation-tooltip-bg-color:var(--black-90)}:root{--badge-gray:var(--black-10);--badge-dark-gray:var(--black-50);--badge-dark-green:var(--green-100);--badge-green:var(--green-90);--badge-light-green:var(--green-80);--badge-lime:var(--green-75);--badge-light-lime:var(--green-60);--badge-olive:var(--green-50);--badge-light-orange:var(--yellow-80);--badge-orange:var(--yellow-90);--badge-dark-orange:var(--yellow-100);--badge-light-red:var(--orange-80);--badge-red:var(--orange-100);--badge-amber:var(--orange-90);--badge-dark-red:var(--red-95);--badge-mint:var(--teal-50)}*,:after,:before{box-sizing:border-box}html{-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%;-ms-overflow-style:scrollbar;-webkit-tap-highlight-color:#0000;-webkit-tap-highlight-color:var(--black-100-alpha-0);font-family:sans-serif;font-size:16px;height:100vh;line-height:1.15}html.ios-wrapper{width:100vw}#page_content_wrapper,.root,body,html{display:flex;flex-direction:column}#page_content_wrapper,.root,body{flex-grow:1;flex-shrink:0}@media print{.root,body{display:block}}.root,body,html{position:relative}@media(min-width:1024px){body{overflow-y:scroll}}article,aside,figcaption,figure,footer,header,nav,section{display:block}body{background-color:#fff;background-color:var(--white-100);color:#000;color:var(--black-100);font-family:-apple-system,BlinkMacSystemFont,Roboto,Arial,Segoe UI,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol;font-size:1rem;font-weight:400;line-height:1.5;margin:0;text-align:left}[data-color-scheme=dark] body{background-color:#000;background-color:var(--black-100);color:#dbdbdb;color:var(--black-10)}[tabindex=\"-1\"]:focus{outline:0!important}hr{box-sizing:initial;height:0;overflow:visible}h1,h2,h3,h4,h5,h6{margin-bottom:8px;margin-top:0}p{margin-bottom:18px;margin-top:0}abbr[data-original-title],abbr[title]{border-bottom:0;cursor:help;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}address{font-style:normal;line-height:inherit}address,dl,ol,ul{margin-bottom:18px}dl,ol,ul{margin-top:0}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}dt{font-weight:700}dd{margin-bottom:8px;margin-left:0}blockquote{margin:0 0 18px}dfn{font-style:italic}b,strong{font-weight:bolder}small{font-size:80%}sub,sup{font-size:75%;line-height:1;position:relative;vertical-align:initial}sub{bottom:-.25em}sup{top:-.5em}a{-webkit-text-decoration-skip:objects;background-color:transparent;color:#2867db;color:var(--sa-link-color)}a,a:focus,a:hover,a:visited{text-decoration:none}a:hover{text-decoration:underline}a:not([href]):not([tabindex]),a:not([href]):not([tabindex]):focus,a:not([href]):not([tabindex]):hover,a:not([href]):not([tabindex]):visited{color:inherit;text-decoration:none}a:not([href]):not([tabindex]):focus{outline:0}code,kbd,pre,samp{font-family:SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace;font-size:1em}pre{-ms-overflow-style:scrollbar;margin-bottom:18px;margin-top:0;overflow:auto}figure{margin:0 0 18px}img{background-color:#f3f4f7;background-color:var(--white-96);border-style:none;font-size:.75rem;vertical-align:middle}[data-color-scheme=dark] img{background-color:#232a32;background-color:var(--black-90)}svg{overflow:hidden;vertical-align:middle}iframe{border:none}table{border-collapse:collapse}caption{caption-side:bottom;color:#757575;color:var(--black-35);padding-bottom:12px;padding-top:12px;text-align:left}th{text-align:inherit}label{display:inline-block;margin-bottom:8px}button{border-radius:0;cursor:pointer;text-align:center}button,input,optgroup,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=reset],[type=submit],button,html [type=button]{-webkit-appearance:button}button{background:0 0;border:none;color:inherit;font:inherit;margin:0;overflow:hidden;padding:0;width:auto}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}button:focus{outline:1px dotted;outline:5px auto -webkit-focus-ring-color}@media(hover:none)and (pointer:coarse){a:active,a:focus,a:hover,button:active,button:focus,button:hover{outline:0!important;text-decoration:none!important}}input{border:1px solid transparent}input[type=password]{font-family:Arial,Helvetica Neue,Helvetica,sans-serif}input[type=checkbox],input[type=radio]{box-sizing:border-box;padding:0}input[type=date],input[type=datetime-local],input[type=month],input[type=time]{-webkit-appearance:listbox}textarea{overflow:auto;resize:vertical}fieldset{border:0;margin:0;min-width:0;padding:0}legend{color:inherit;display:block;font-size:1.5rem;line-height:inherit;margin-bottom:8px;max-width:100%;padding:0;white-space:normal;width:100%}progress{vertical-align:initial}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:none;outline-offset:-2px}[type=search]::-webkit-search-cancel-button,[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}output{display:inline-block}summary{cursor:pointer;display:list-item}template{display:none}[hidden]{display:none!important}[data-intent-mouse=true] [contentEditable=true]:focus,[data-intent-mouse=true] [tabindex=\"0\"]:focus,[data-intent-mouse=true] a[href]:focus,[data-intent-mouse=true] area[href]:focus,[data-intent-mouse=true] button:not([disabled]):focus,[data-intent-mouse=true] iframe:focus,[data-intent-mouse=true] input:not([disabled]):focus,[data-intent-mouse=true] select:not([disabled]):focus,[data-intent-mouse=true] textarea:not([disabled]):focus{outline:0}@-webkit-keyframes kef-shift-rightwards{0%{transform:translateX(-100%)}40%{transform:translateX(0)}60%{transform:translateX(0)}to{transform:translateX(100%)}}@keyframes kef-shift-rightwards{0%{transform:translateX(-100%)}40%{transform:translateX(0)}60%{transform:translateX(0)}to{transform:translateX(100%)}}@-webkit-keyframes kef-delay-visibility{0%{opacity:0}to{opacity:1}}@keyframes kef-delay-visibility{0%{opacity:0}to{opacity:1}}.loading{align-items:center;background-color:#f3f4f7;background-color:var(--white-96);display:flex;height:100vh;justify-content:center;left:0;overflow:hidden;position:fixed;top:0;width:100%}@media(hover:none)and (pointer:coarse)and (prefers-color-scheme:dark){.loading{background-color:#232a32;background-color:var(--black-90)}}.loadingDelayed{-webkit-animation:kef-delay-visibility 3s step-end 1;animation:kef-delay-visibility 3s step-end 1}@media screen and (prefers-reduced-motion:reduce){.loadingDelayed{-webkit-animation:none;animation:none}}.appLoading{--env-safe-area-inset-top:env(safe-area-inset-top);-webkit-animation:kef-shift-rightwards 1s ease-in-out infinite;animation:kef-shift-rightwards 1s ease-in-out infinite;-webkit-animation-delay:.8s;animation-delay:.8s;background:#ff7200;background:var(--orange-60);height:2px;opacity:1;position:fixed;right:0;top:0;top:var(--env-safe-area-inset-top,0);transform:translateX(100%);width:100%;z-index:1051}.invisible{-webkit-animation:none;animation:none;opacity:0}@media screen and (prefers-reduced-motion:reduce){.appLoading{-webkit-animation:none;animation:none}}.noScript{padding-top:80px;position:relative;text-align:center;z-index:1030}.noScriptDescription,.noScriptTitle{color:#555;color:var(--sa-text-color-3);font-size:1.125rem;margin-bottom:18px}.noScriptTitle{font-weight:700}[data-color-scheme=dark] .loading{background-color:#232a32;background-color:var(--black-90)}</style><meta name=\"theme-color\" content=\"#333333\" ><link rel=\"manifest\" href=\"/samw/manifest.e3ca8fbeb83bff354aee75d40707da84.json\" > <link rel=\"preload\" href=\"/samw/static/js/app.94f9e1ef.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.9889.cc80d138.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.5256.232e4e93.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.6318.b7a1ccd8.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.1857.376ad219.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.3090.64b3cc02.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.2059.4f2740f8.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.1901.0f43f675.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.1588.3bcec79a.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.8673.1a6685e1.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.8717.89756862.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.4593.fe709cd1.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.6736.58c0b45f.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.3413.8111ca7b.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.8241.e6a418ac.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.8553.756f9eaf.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.2313.72f2b8d6.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.2454.02a00b37.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.3379.fe58d6be.js\" as=\"script\"> <link rel=\"preload\" href=\"/samw/static/js/c.Article-S.274b756f.js\" as=\"script\"><link as=\"fetch\" crossorigin=\"\" href=\"/api/v3/breaking_news\" rel=\"preload\" type=\"application/json\" ><link as=\"fetch\" crossorigin=\"\" href=\"/api/v3/marketing_campaigns\" rel=\"preload\" type=\"application/json\" ><meta content=\"BellRing Brands, Inc. (NYSE:NYSE:BRBR) Q1 2022 Earnings Conference Call February 4, 2022 10:30 a.m.\" name=\"description\" ><meta content=\"noarchive, max-image-preview:large\" name=\"robots\" ><link href=\"https://seekingalpha.com/amp/article/4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript\" rel=\"amphtml\" ><meta content=\"SA Transcripts\" property=\"article:author:username\" ><meta content=\"https://static3.seekingalpha.com/images/users_profile/000/101/639/medium_pic.png\" property=\"article:author:image\" ><meta content=\"BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript\" name=\"twitter:title\" ><meta content=\"BellRing Brands, Inc. (NYSE:NYSE:BRBR) Q1 2022 Earnings Conference Call February 4, 2022 10:30 a.m.\" name=\"twitter:description\" ><meta content=\"summary\" name=\"twitter:card\" ><meta content=\"@SeekingAlpha\" name=\"twitter:site\" ><meta content=\"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png\" name=\"twitter:image\" ><meta content=\"BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript\" property=\"og:title\" ><meta content=\"BellRing Brands, Inc. (NYSE:NYSE:BRBR) Q1 2022 Earnings Conference Call February 4, 2022 10:30 a.m.\" property=\"og:description\" ><meta content=\"article\" property=\"og:type\" ><meta content=\"https://seekingalpha.com/article/4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript\" property=\"og:url\" ><link href=\"https://seekingalpha.com/javascripts/seeking.xml\" rel=\"search\" title=\"BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript\" type=\"application/opensearchdescription+xml\" ><link href=\"https://seekingalpha.com/article/4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript\" rel=\"canonical\" ><meta content=\"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png\" property=\"og:image\" ><script>var SA_PRELOAD_DATA = {\"abTests\":{\"data\":[{\"id\":\"387\",\"type\":\"abTest\",\"attributes\":{\"name\":\"piano_article_ab_test\",\"identifier\":\"piano_article_ab_test\",\"populationStatus\":3,\"variations\":{\"control\":[0,49],\"test_v1\":[50,99]},\"forceUsers\":{}}},{\"id\":\"397\",\"type\":\"abTest\",\"attributes\":{\"name\":\"piano_mid_article_banner\",\"identifier\":\"piano_mid_article_banner\",\"populationStatus\":3,\"variations\":{\"test_v1\":[0,99]},\"forceUsers\":{\"50396968\":\"test_v1\",\"49230603\":\"test_v1\"}}},{\"id\":\"459\",\"type\":\"abTest\",\"attributes\":{\"name\":\"loggedOutGroupMpw\",\"identifier\":\"loggedoutgroupmpw\",\"populationStatus\":3,\"variations\":{\"Loggedout_MPW_1\":[0,99]},\"forceUsers\":{}}},{\"id\":\"460\",\"type\":\"abTest\",\"attributes\":{\"name\":\"loggedInGroupMpw\",\"identifier\":\"loggedingroupmpw\",\"populationStatus\":3,\"variations\":{\"Test_MPW_1\":[0,49],\"Test_MPW_2\":[50,99]},\"forceUsers\":{}}},{\"id\":\"467\",\"type\":\"abTest\",\"attributes\":{\"name\":\"mpw test\",\"identifier\":\"mpw_test\",\"populationStatus\":3,\"variations\":{\"control\":[0,99]},\"forceUsers\":{\"53842239\":\"mpw_test\",\"49230603\":\"mpw_test\",\"51155277\":\"mpw_test\",\"41307086\":\"mpw_test\",\"542689\":\"mpw_test\",\"55749671\":\"mpw_test\",\"54641152\":\"mpw_test\",\"54659679\":\"mpw_test\",\"55040909\":\"mpw_test\",\"55040803\":\"mpw_test\",\"52953239\":\"mpw_test\",\"54095754\":\"mpw_test\",\"55510869\":\"mpw_test\",\"55689754\":\"mpw_test\",\"54804462\":\"mpw_test\"}}},{\"id\":\"500\",\"type\":\"abTest\",\"attributes\":{\"name\":\"Progressive Profiling Unit\",\"identifier\":\"progressive_profiling_unit\",\"populationStatus\":1,\"variations\":{\"control\":[0,49],\"test\":[50,99]},\"forceUsers\":{\"53726259\":\"test\",\"20264041\":\"control\",\"55040909\":\"test\"}}},{\"id\":\"507\",\"type\":\"abTest\",\"attributes\":{\"name\":\"Marketplace DDI internal landing page\",\"identifier\":\"marketplace_ddi_internal_landing_page\",\"populationStatus\":1,\"variations\":{\"ddi3\":[0,49],\"ddi5\":[50,99]},\"forceUsers\":{}}},{\"id\":\"519\",\"type\":\"abTest\",\"attributes\":{\"name\":\"crypto_nav_landing_pages\",\"identifier\":\"crypto_nav_landing_pages\",\"populationStatus\":3,\"variations\":{\"crypto_waves\":[0,49],\"crypto_waves_2\":[50,99]},\"forceUsers\":{}}},{\"id\":\"520\",\"type\":\"abTest\",\"attributes\":{\"name\":\"highlight_realtime_price_change\",\"identifier\":\"highlight_realtime_price_change\",\"populationStatus\":2,\"variations\":{\"highlight\":[0,49],\"control\":[50,99]},\"forceUsers\":{}}},{\"id\":\"555\",\"type\":\"abTest\",\"attributes\":{\"name\":\"premium_rc\",\"identifier\":\"premium_rc\",\"populationStatus\":1,\"variations\":{\"control\":[0,99]},\"forceUsers\":{\"1033943\":\"show\",\"4839411\":\"show\",\"3035031\":\"show\",\"4106561\":\"show\",\"728729\":\"show\",\"48113790\":\"show\",\"223670\":\"show\",\"590654\":\"show\",\"34638465\":\"show\",\"638449\":\"show\",\"929265\":\"show\",\"1364131\":\"show\",\"1115549\":\"show\",\"48196727\":\"show\",\"19802721\":\"show\",\"54026\":\"show\",\"21811041\":\"show\",\"1013654\":\"show\",\"504158\":\"show\",\"5387831\":\"show\",\"134376\":\"show\",\"534854\":\"show\",\"35724435\":\"show\",\"1621281\":\"show\",\"19865501\":\"show\",\"2119651\":\"show\",\"14564542\":\"show\",\"5055561\":\"show\",\"2364061\":\"show\",\"48956829\":\"show\",\"6462171\":\"show\",\"1225171\":\"show\",\"20979921\":\"show\",\"658952\":\"show\",\"159614\":\"show\",\"32857495\":\"show\",\"32779035\":\"show\",\"50948520\":\"show\",\"49260162\":\"show\",\"5674961\":\"show\",\"50530778\":\"show\",\"1099207\":\"show\",\"4623221\":\"show\",\"11203961\":\"show\",\"45830526\":\"show\",\"6567451\":\"show\",\"7769251\":\"show\",\"17654562\":\"show\",\"3152021\":\"show\",\"1011\":\"show\",\"509846\":\"show\",\"993871\":\"show\",\"159987\":\"show\",\"865490\":\"show\",\"34422895\":\"show\",\"792389\":\"show\",\"53090029\":\"show\",\"1091646\":\"show\",\"52887910\":\"show\",\"952512\":\"show\",\"5182441\":\"show\",\"44620196\":\"show\",\"529342\":\"show\",\"1108555\":\"show\",\"966900\":\"show\",\"35455075\":\"show\",\"875473\":\"show\",\"709762\":\"show\",\"35884835\":\"show\",\"5598481\":\"show\",\"1497531\":\"show\",\"47666662\":\"show\",\"787105\":\"show\",\"15658142\":\"show\",\"1608291\":\"show\",\"5061551\":\"show\",\"3702501\":\"show\",\"31747005\":\"show\",\"13921732\":\"show\",\"10220941\":\"show\",\"1128375\":\"show\",\"880112\":\"show\",\"4515971\":\"show\",\"1104349\":\"show\",\"516598\":\"show\",\"7965571\":\"show\",\"47950542\":\"show\",\"3625721\":\"show\",\"953363\":\"show\",\"12951131\":\"show\",\"635618\":\"show\",\"751894\":\"show\",\"5946521\":\"show\",\"486351\":\"show\",\"29523295\":\"show\",\"6099061\":\"show\",\"886663\":\"show\",\"47427928\":\"show\",\"41173805\":\"show\",\"32283015\":\"show\",\"3982501\":\"show\",\"986070\":\"show\",\"54965949\":\"show\",\"19096961\":\"show\",\"10291931\":\"show\",\"8417401\":\"show\",\"54101627\":\"show\",\"47331984\":\"show\",\"20755131\":\"show\",\"8918611\":\"show\",\"801435\":\"show\",\"16206862\":\"show\",\"541410\":\"show\",\"748497\":\"show\",\"47484314\":\"show\",\"44075116\":\"show\",\"42118116\":\"show\",\"55306843\":\"show\",\"12819881\":\"show\",\"54654632\":\"show\",\"885017\":\"show\",\"637\":\"show\",\"1116852\":\"show\",\"54659679\":\"show\",\"54641152\":\"show\"}}},{\"id\":\"561\",\"type\":\"abTest\",\"attributes\":{\"name\":\"nav_button_crypto_pmb\",\"identifier\":\"nav_button_crypto_pmb\",\"populationStatus\":3,\"variations\":{\"ireit\":[0,99]},\"forceUsers\":{\"54641002\":\"alpha_ratings\",\"56157743\":\"energy_income_authority\",\"56158127\":\"energy_income_authority\",\"54911303\":\"epb_macro_research\",\"54659679\":\"epb_macro_research\"}}},{\"id\":\"575\",\"type\":\"abTest\",\"attributes\":{\"name\":\"pro cancellation benefits\",\"identifier\":\"pro_cancellation_benefits\",\"populationStatus\":1,\"variations\":{\"test\":[0,79],\"control\":[80,99]},\"forceUsers\":{}}},{\"id\":\"576\",\"type\":\"abTest\",\"attributes\":{\"name\":\"newsletter_settings_page_layout\",\"identifier\":\"newsletter_settings_page_layout\",\"populationStatus\":1,\"variations\":{\"control\":[0,99]},\"forceUsers\":{\"51297972\":\"show\"}}},{\"id\":\"591\",\"type\":\"abTest\",\"attributes\":{\"name\":\"exit_popup\",\"identifier\":\"exit_popup\",\"populationStatus\":0,\"variations\":{\"test\":[0,49],\"control\":[50,99]},\"forceUsers\":{}}},{\"id\":\"611\",\"type\":\"abTest\",\"attributes\":{\"name\":\"premium_strip\",\"identifier\":\"premium_strip\",\"populationStatus\":3,\"variations\":{\"premium_strip_a\":[0,99]},\"forceUsers\":{\"53159021\":\"premium_strip_b\",\"56143080\":\"stock_warnings\",\"53533984\":\"control\"}}},{\"id\":\"615\",\"type\":\"abTest\",\"attributes\":{\"name\":\"mp cancellation benefits\",\"identifier\":\"mp_cancellation_benefits\",\"populationStatus\":1,\"variations\":{\"control\":[0,19],\"test\":[20,99]},\"forceUsers\":{\"53533984\":\"test\",\"55214764\":\"test\",\"49951178\":\"test\",\"53328065\":\"test\"}}},{\"id\":\"616\",\"type\":\"abTest\",\"attributes\":{\"name\":\"news_analysis_single_card\",\"identifier\":\"news_analysis_single_card\",\"populationStatus\":1,\"variations\":{\"new_layout\":[0,49],\"control\":[50,99]},\"forceUsers\":{\"54261807\":\"new_layout\",\"54790794\":\"new_layout\",\"52559588\":\"new_layout\",\"54653323\":\"new_layout\",\"54261805\":\"control\",\"20395961\":\"new_layout\",\"3\":\"new_layout\",\"41173805\":\"new_layout\",\"48090760\":\"new_layout\",\"51346110\":\"new_layout\",\"SA_Internal\":\"control\"}}},{\"id\":\"629\",\"type\":\"abTest\",\"attributes\":{\"name\":\"mp_discounts_strip\",\"identifier\":\"mp_discounts_strip\",\"populationStatus\":1,\"variations\":{\"control\":[0,99]},\"forceUsers\":{}}},{\"id\":\"631\",\"type\":\"abTest\",\"attributes\":{\"name\":\"annual cancellation step three ver two\",\"identifier\":\"annual_cancellation_step_three_ver_two\",\"populationStatus\":1,\"variations\":{\"test_a\":[0,99]},\"forceUsers\":{\"48708094\":\"test_a\",\"35037695\":\"test_b\",\"55260065\":\"test_a\",\"2668\":\"control\",\"37138496\":\"test_a\",\"53226313\":\"test_a\",\"52322389\":\"test_a\",\"49156155\":\"test_b\",\"6633531\":\"test_a\",\"55469371\":\"test_b\",\"55453855\":\"test_a\",\"53276849\":\"test_a\",\"52754017\":\"test_a\"}}},{\"id\":\"641\",\"type\":\"abTest\",\"attributes\":{\"name\":\"mp cancellation benefits ver two\",\"identifier\":\"mp_cancellation_benefits_ver_two\",\"populationStatus\":1,\"variations\":{\"control\":[0,99]},\"forceUsers\":{}}},{\"id\":\"645\",\"type\":\"abTest\",\"attributes\":{\"name\":\"onboarding\",\"identifier\":\"onboarding\",\"populationStatus\":1,\"variations\":{\"control\":[0,49],\"portfolio_newsletters_app_interests\":[50,74],\"portfoliounskippable_newsletters_app_interests\":[75,99]},\"forceUsers\":{\"55640586\":\"first_variant\"}}},{\"id\":\"648\",\"type\":\"abTest\",\"attributes\":{\"name\":\"mn_condensed_rr\",\"identifier\":\"mn_condensed_rr\",\"populationStatus\":2,\"variations\":{\"control\":[0,49],\"condensed_rr\":[50,99]},\"forceUsers\":{\"54911930\":\"condensed_rr\",\"53159370\":\"condensed_rr\"}}},{\"id\":\"653\",\"type\":\"abTest\",\"attributes\":{\"name\":\"jw_player\",\"identifier\":\"jw_player\",\"populationStatus\":2,\"variations\":{\"show\":[0,99]},\"forceUsers\":{\"49301678\":\"show\",\"54743849\":\"show\",\"51155266\":\"show\",\"SA_Internal\":\"show\"}}},{\"id\":\"665\",\"type\":\"abTest\",\"attributes\":{\"name\":\"price_alerts\",\"identifier\":\"price_alerts\",\"populationStatus\":1,\"variations\":{\"show\":[0,99]},\"forceUsers\":{\"39655946\":\"show\",\"53244437\":\"show\",\"53295545\":\"show\",\"53295514\":\"show\",\"SA_Internal\":\"show\",\"50801997\":\"show\",\"603782\":\"show\",\"54743849\":\"show\",\"54654306\":\"show\",\"54654326\":\"show\",\"51580790\":\"show\",\"42499726\":\"show\",\"55110834\":\"show\",\"50754626\":\"show\",\"49349690\":\"show\",\"47867963\":\"show\",\"53156755\":\"show\"}}},{\"id\":\"668\",\"type\":\"abTest\",\"attributes\":{\"name\":\"taboola_liftigniter\",\"identifier\":\"taboola_liftigniter\",\"populationStatus\":2,\"variations\":{\"control\":[0,49],\"taboola\":[50,99]},\"forceUsers\":{\"51155277\":\"taboola\",\"50801997\":\"taboola\",\"603782\":\"taboola\",\"51155270\":\"taboola\",\"50468466\":\"taboola\",\"55554444\":\"taboola\",\"55554148\":\"taboola\",\"55894305\":\"taboola\",\"54306001\":\"taboola\",\"55896968\":\"taboola\",\"55938195\":\"taboola\",\"49301678\":\"control\",\"56024840\":\"taboola\",\"54711561\":\"control\",\"51155266\":\"control\",\"56117829\":\"taboola\",\"50424773\":\"taboola\",\"56120299\":\"taboola\",\"52354550\":\"control\",\"56158287\":\"taboola\",\"56165510\":\"taboola\",\"56192170\":\"taboola\",\"54790794\":\"taboola\",\"55587480\":\"taboola\",\"56212576\":\"taboola\",\"56243750\":\"taboola\",\"54653323\":\"control\",\"55199428\":\"taboola\",\"56285953\":\"taboola\",\"56296498\":\"taboola\",\"56297520\":\"taboola\",\"53963085\":\"taboola\",\"55560267\":\"taboola\",\"54523256\":\"taboola\"}}},{\"id\":\"669\",\"type\":\"abTest\",\"attributes\":{\"name\":\"symbol_author_rating_price_chart\",\"identifier\":\"symbol_author_rating_price_chart\",\"populationStatus\":2,\"variations\":{\"enabled\":[0,99]},\"forceUsers\":{\"54615845\":\"enabled\",\"53159370\":\"enabled\",\"9393711\":\"enabled\",\"39655946\":\"enabled\"}}},{\"id\":\"670\",\"type\":\"abTest\",\"attributes\":{\"name\":\"symbol_wallst_rating_price_chart\",\"identifier\":\"symbol_wallst_rating_price_chart\",\"populationStatus\":2,\"variations\":{\"enabled\":[0,99]},\"forceUsers\":{\"53159370\":\"enabled\",\"9393711\":\"enabled\",\"39655946\":\"enabled\"}}},{\"id\":\"671\",\"type\":\"abTest\",\"attributes\":{\"name\":\"market_news_JWPlayer\",\"identifier\":\"market_news_jwplayer\",\"populationStatus\":2,\"variations\":{\"show\":[0,99]},\"forceUsers\":{\"SA_Internal\":\"show\"}}},{\"id\":\"672\",\"type\":\"abTest\",\"attributes\":{\"name\":\"portfolio_JWPlayer\",\"identifier\":\"portfolio_jwplayer\",\"populationStatus\":2,\"variations\":{\"show\":[0,99]},\"forceUsers\":{\"SA_Internal\":\"show\"}}},{\"id\":\"675\",\"type\":\"abTest\",\"attributes\":{\"name\":\"symbol_analysis_card\",\"identifier\":\"symbol_analysis_card\",\"populationStatus\":2,\"variations\":{\"simple\":[0,99]},\"forceUsers\":{\"51801056\":\"simple\",\"56073134\":\"simple\"}}},{\"id\":\"680\",\"type\":\"abTest\",\"attributes\":{\"name\":\"home_news_articles_swap\",\"identifier\":\"home_news_articles_swap\",\"populationStatus\":1,\"variations\":{\"news_first\":[0,49],\"control\":[50,99]},\"forceUsers\":{\"51155266\":\"news_first\",\"51155277\":\"news_first\",\"41173805\":\"news_first\",\"20395961\":\"news_first\",\"3\":\"news_first\"}}},{\"id\":\"685\",\"type\":\"abTest\",\"attributes\":{\"name\":\"stock_warnings_strip_action\",\"identifier\":\"stock_warnings_strip_action\",\"populationStatus\":3,\"variations\":{\"control\":[0,99]},\"forceUsers\":{\"56143080\":\"test\"}}},{\"id\":\"692\",\"type\":\"abTest\",\"attributes\":{\"name\":\"upgrade_to_pro_mobile\",\"identifier\":\"upgrade_to_pro_mobile\",\"populationStatus\":1,\"variations\":{\"variant_d\":[0,99]},\"forceUsers\":{}}},{\"id\":\"693\",\"type\":\"abTest\",\"attributes\":{\"name\":\"upgrade_to_pro_desktop\",\"identifier\":\"upgrade_to_pro_desktop\",\"populationStatus\":1,\"variations\":{\"variant_a\":[0,99]},\"forceUsers\":{\"55221594\":\"variant_a\"}}},{\"id\":\"695\",\"type\":\"abTest\",\"attributes\":{\"name\":\"mobile_bottom_strip\",\"identifier\":\"mobile_bottom_strip\",\"populationStatus\":3,\"variations\":{\"test\":[0,99]},\"forceUsers\":{\"55485653\":\"test\",\"55417348\":\"test\"}}},{\"id\":\"698\",\"type\":\"abTest\",\"attributes\":{\"name\":\"dunning_strip\",\"identifier\":\"dunning_strip\",\"populationStatus\":1,\"variations\":{\"test\":[0,79],\"control\":[80,99]},\"forceUsers\":{\"48834593\":\"test\",\"462530\":\"test\"}}},{\"id\":\"703\",\"type\":\"abTest\",\"attributes\":{\"name\":\"dunning_popup_in_app\",\"identifier\":\"dunning_popup_in_app\",\"populationStatus\":1,\"variations\":{\"test\":[0,49],\"control\":[50,99]},\"forceUsers\":{\"56367042\":\"test\"}}},{\"id\":\"704\",\"type\":\"abTest\",\"attributes\":{\"name\":\"dunning_strip_in_app\",\"identifier\":\"dunning_strip_in_app\",\"populationStatus\":1,\"variations\":{\"control\":[0,99]},\"forceUsers\":{\"56367042\":\"test\"}}},{\"id\":\"706\",\"type\":\"abTest\",\"attributes\":{\"name\":\"mobile_app_bottom_vs_top_nav\",\"identifier\":\"mobile_app_bottom_vs_top_nav\",\"populationStatus\":2,\"variations\":{\"control\":[0,99]},\"forceUsers\":{\"51155274\":\"bottom_nav\",\"54261809\":\"bottom_nav\",\"49301678\":\"bottom_nav\",\"49486635\":\"bottom_nav\",\"9393711\":\"bottom_nav\",\"49612369\":\"bottom_nav\",\"2632411\":\"bottom_nav\",\"50290484\":\"bottom_nav\",\"53763409\":\"bottom_nav\",\"54211627\":\"bottom_nav\",\"51155266\":\"bottom_nav\",\"51155270\":\"top_nav_reorder\",\"54911930\":\"bottom_nav\"}}},{\"id\":\"707\",\"type\":\"abTest\",\"attributes\":{\"name\":\"symbol_rating_preview_for_free_users\",\"identifier\":\"symbol_rating_preview_for_free_users\",\"populationStatus\":3,\"variations\":{\"test\":[0,49],\"control\":[50,99]},\"forceUsers\":{\"54745807\":\"test\"}}}]},\"moneData\":{\"params\":\"author_page=control\\u0026etf_data_tables=enabled\\u0026financial_statements=show\\u0026responsive_earnings_calendar_page=control\\u0026ssr_poc=yes\"}}</script><link href=\"/samw/static/styles/8673.7be0f197.css\" rel=\"stylesheet\" ><link href=\"/samw/static/styles/8241.01572508.css\" rel=\"stylesheet\" ><link href=\"/samw/static/styles/Article-S.c37b76aa.css\" rel=\"stylesheet\" ><script>window.SSR_DATA = {\"article\":{\"response\":{\"data\":{\"id\":\"4484494\",\"type\":\"fullArticle\",\"attributes\":{\"publishOn\":\"2022-02-04T12:54:04-05:00\",\"isLockedPro\":false,\"commentCount\":0,\"gettyImageUrl\":null,\"themes\":{\"transcripts\":{\"path\":\"\\u002Fearnings\\u002Fearnings-call-transcripts\",\"slug\":\"transcripts\",\"title\":\"Transcripts\",\"sasource\":\"theme_breadcrumb\"},\"consumer-goods\":{\"path\":\"\\u002Fearnings\\u002Fearnings-call-transcripts?sector=consumer-goods\",\"slug\":\"consumer-goods\",\"title\":\"Consumer\",\"sasource\":\"theme_breadcrumb\"},\"sa-transcripts\":{\"slug\":\"sa-transcripts\",\"non_theme\":true},\"brbr\":{\"slug\":\"brbr\",\"non_theme\":true},\"has-audio\":{\"slug\":\"has-audio\",\"non_theme\":true},\"us\":{\"slug\":\"us\",\"non_theme\":true}},\"title\":\"BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript\",\"summary\":[],\"lastModified\":\"2022-02-04T12:54:05-05:00\",\"closestTradingDate\":\"2022-02-04\",\"isEarningsSlides\":false,\"isExclusive\":false,\"isTranscript\":true,\"excludedByTag\":false,\"transcriptPath\":\"https:\\u002F\\u002Fstatic.seekingalpha.com\\u002Fcdn\\u002Fs3\\u002Ftranscripts_audio\\u002F4484494.mp3\",\"likesCount\":0,\"disabledStatus\":\"allowed\",\"disabledMessage\":null,\"status\":\"published\",\"disclosure\":\"\",\"articleActionableItem\":null,\"inEmbargo\":false,\"isNoindex\":false,\"isNoarchive\":true,\"content\":\"\\u003Cp\\u003EBellRing Brands, Inc. (\\u003Cspan class=\\\"ticker-hover-wrapper\\\"\\u003ENYSE:\\u003Ca href=\\\"https:\\u002F\\u002Fseekingalpha.com\\u002Fsymbol\\u002FBRBR\\\" title=\\\"BellRing Brands, Inc.\\\"\\u003EBRBR\\u003C\\u002Fa\\u003E\\u003C\\u002Fspan\\u003E) Q1 2022 Earnings Conference Call February 4, 2022 10:30 AM ET\\u003C\\u002Fp\\u003E \\u003Cp\\u003E\\u003Cstrong\\u003ECompany Participants\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp\\u003EJennifer Meyer - Investor Relations\\u003C\\u002Fp\\u003E \\u003Cp\\u003EDarcy Davenport - President and Chief Executive Officer\\u003C\\u002Fp\\u003E \\u003Cp\\u003EPaul Rode - Chief Financial Officer\\u003C\\u002Fp\\u003E \\u003Cp\\u003E\\u003Cstrong\\u003EConference Call Participants\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp\\u003EAndrew Lazar - Barclays Capital\\u003C\\u002Fp\\u003E \\u003Cp\\u003EPamela Kaufman - Morgan Stanley\\u003C\\u002Fp\\u003E \\u003Cp\\u003EJason English - Goldman Sachs\\u003C\\u002Fp\\u003E \\u003Cp\\u003EJim Salera - Stephens, Inc.\\u003C\\u002Fp\\u003E \\u003Cp\\u003EBill Chappell - Truist Securities\\u003C\\u002Fp\\u003E \\u003Cp\\u003EChristopher Growe - Stifel Nicolaus\\u003C\\u002Fp\\u003E \\u003Cp\\u003ERob Dickerson - Jefferies\\u003C\\u002Fp\\u003E \\u003Cp\\u003EKenneth Zaslow - Bank of Montreal\\u003C\\u002Fp\\u003E \\u003Cp\\u003EKaumil Gajrawala - Credit Suisse\\u003C\\u002Fp\\u003E \\u003Cp\\u003EJohn Baumgartner - Mizuho\\u003C\\u002Fp\\u003E \\u003Cp\\u003EBryan Spillane - Bank of America\\u003C\\u002Fp\\u003E \\u003Cp\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp\\u003EWelcome to BellRing Brands' First Quarter 2022 Earnings Conference Call and Webcast. Hosting the call today from BellRing Brands are Darcy Davenport, President and Chief Executive Officer; and Paul Rode, Chief Financial Officer.\\u003C\\u002Fp\\u003E \\u003Cp\\u003EToday's call is being recorded and will be available for replay beginning at 1:30 p.m. Eastern Time. The dial-in number is (800) 839-8318. No pass code is required.\\u003C\\u002Fp\\u003E \\u003Cp\\u003EAt this time, all participants have been placed in a listen-only mode. It is now my pleasure to turn the floor over to Jennifer Meyer, Investor Relations of BellRing Brands, for introductions. You may begin.\\u003C\\u002Fp\\u003E \\u003Cp\\u003E\\u003Cstrong\\u003EJennifer Meyer\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp\\u003EGood morning, and thank you for joining us today for BellRing Brands' first quarter fiscal '22 earnings call. With me today are Darcy Davenport, our President and CEO; and Paul Rode, our CFO. Darcy and Paul will begin with prepared remarks, and afterwards, we'll have a brief question-and-answer session. The press release and supplemental slide presentation that support these remarks are posted on our Web site in both the Investor Relations and the SEC filings sections at bellring.com. In addition, the release and slides are available on the SEC's Web site.\\u003C\\u002Fp\\u003E \\u003Cp\\u003EBefore we continue, I would like to remind you that this call will contain forward-looking statements, which are\\u003Cspan class=\\\"paywall-full-content\\\"\\u003E subject to risks and uncertainties that should be carefully considered by investors as actual results could differ materially from these statements. Additional information regarding these risks and uncertainties is discussed under the Forward-Looking Statements section in the press release we issued yesterday and other press releases we have issued with respect to Post's proposed distribution of its interest in BellRing Brands, which are posted on our Web site.\\u003C\\u002Fspan\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe also urge you to read both the registration statements, the proxy statement, and prospectuses, the related amendments of these filings and other documents related to the proposed distribution of Post interest in BellRing Brands that have been and will be filed with the SEC when they become available, because they will contain important information. These forward-looking statements are current as of the date of this call, and management undertakes no obligation to update these statements. As a reminder, this call is being recorded, and an audio replay will be available on our Web site.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EAnd finally, this call will discuss certain non-GAAP measures. For a reconciliation of these non-GAAP measures to the nearest GAAP measure, see our press release issued yesterday and posted on our Web site.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWith that, I will turn the call over to Darcy.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EDarcy Davenport\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks, Jennifer, and thank you all for joining us. Last evening, we reported our first quarter results, and posted a supplemental presentation to our Web site. This presentation is designed to provide more insight into our business, [consumption of] [Ph], and key metrics, and now include both Premier Protein and Dymatize. Our first quarter came in slightly ahead of expectations, with sales of $307 million, and adjusted EBITDA of $60 million. Net sales grew 9% over prior year, led by Dymatize, which was up 41%; Premier Protein grew 5%, both brands benefiting from pricing actions. This single-digit growth for Premier Protein was expected as we lap prior year promotions that aren't repeating.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOur adjusted EBITDA margins were healthy despite significant cost headwinds. As you saw in yesterday's press release, we reaffirmed our fiscal '22 guidance for both net sales and adjusted EBITDA to grow between 9% and 13%. Other than a slight shift in Dymatize sales from second quarter into first, we don't expect major deviations to the cadence we communicated last quarter. Not surprisingly, inflation ramped up across freight and dairy proteins this quarter. As a result, we announced further price increases on shakes and powders, which will mainly benefit the second-half of the year. We expect Q2 sales to be similar to Q1, and to sequentially grow, reflecting the incremental pricings actions and new capacity.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe will experience margin pressure in Q2 until the price increases are implemented. Overall, we believe the balance of the year leans toward upside, however we have seen how quickly circumstances can change in this environment. While our confidence in the year has grown, at this point we are reaffirming our guidance. The key drivers that would add opportunity or risk to the year are our ability to deliver our expected production, elasticity relating to upcoming pricing actions, and additional inflation.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ENow turning to our category brand highlights and updates on capacity expansion. We continue to see robust growth in the convenient nutrition category. Ready-to-drink beverages and ready-to-mix powders both grew 17% versus year ago. Strong consumer tailwinds around wellness and healthier food solutions are driving this growth. RTD beverages added 2.3 points to household penetration, and saw growth in purchase size and volume. Ready-to-mix powders continue to be fueled by an increased interest in proactive health and fitness. Our brands are growing despite supply chain challenges.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EPremier Protein shake consumption grew 10% across tracked and untracked channels, with ecommerce and mass leading the way. Brand metrics remained strong, demonstrating our high consumer loyalty. Household penetration and repeat rates are holding steady, and velocities are at 45% versus year-ago. Our TDPs have started to rebound as we have increased trade inventory levels this quarter. Despite these encouraging signs, we expect Premier Protein RTD shake consumption, in Q2, to lag prior year because we're lapping significant promotional periods.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EMoving to Dymatize, Dymatize had a fantastic quarter, with consumption in the U.S. up 48% across tracked and untracked channels. All key channels contributed with double-digit growth, and brand velocities remained strong. Dymatize ISO100 launched two exciting new flavors this quarter: Dunkin' Cappuccino and Mocha Latte, both flavors which were co-developed with Dunkin are off to a great start.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOur operating environment remains challenging. Supply chain disruptions largely around labor availability at our existing co-manufacturers are impacting our ability to rebuild inventory as fast as we want. First quarter production came in slightly below our expectations mainly due to COVID-driven labor shortages. However, we are encouraged with the improvement in January.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOur capacity expansions are progressing well and remain on track. As you may remember, we have capacity coming online each quarter starting Q2. We are comfortable with our ramp up assumptions despite COVID-related challenges. We also made significant progress identifying and vetting additional growth partners who are expected to bring on capacity in fiscal '23 and '24. Finally, I would like to share a brief update on Post distribution of its interest in BellRing.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOverall, the transaction remains on track. We have scheduled a special meeting of BellRing stockholders on March 8th to vote on the transaction. Post will announce additional details about the spin-off in coming weeks. We believe upon completion of the transaction, BellRing will have increased strategic flexibility to manage our capital structure and should benefit from more liquidity in our shares.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EIn closing, we all have been tested over the last two years. I have been impressed by how our employees, manufacturing, and logistics partners and customers have navigated this period. I believe we will look back on '22 as a pivotal year for our brands and our company; one where we solidified the foundation of the business so we can really see what our brands are capable in the future. I continue to believe that we are in the early innings of our category and brand's growth. Premier Protein and Dymatize are perfectly positioned to attract households into the category and improve consumer's health along the way.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you and I look forward to updating you on our progress throughout the year. I will now turn the call over to Paul.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EPaul Rode\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks, Darcy, and good morning, everyone. Net sales for the quarter were $306.5 million, up 8.5%. Adjusted EBITDA was 59.8 million, a slight decline to prior year. And EBITDA margin was 19.5%. Premier Protein net sales grew 4.5% driven by higher average net selling prices reflecting reduced promotional activity and price increases. Recall while we face capacity constraints, we have temporarily reduced tetra shake SKUs and promotional marketing.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThis resulted in expected volume declines for Premier Protein in the quarter. Despite this decline, shipment exceeded consumption in the quarter and resulted in increased retail inventory. Dymatize net sales grew 41% with volumes up 8%. Net sales outpaced volume growth benefiting from higher average net selling prices which reflected price increases and a favorable mix.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EStrong velocities and distribution gains drove volume growth. Gross profit of 92 million was flat to last year with a decrease in gross profit margin to 30.1%. The gross margin decline results from higher dairy protein cost as well as increased freight which was mitigated by higher net selling prices. SG&amp;A expenses of $37 million included 2 million of separation cost.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EPrior year SG&amp;A expenses include 4.6 million restructuring and facility closure cost. Both items were treated as adjustments for non-GAAP measures. Excluding these items, SG&amp;A increased 1 million and was favorable 50 basis points as percentage sales. Our cash flow in the first quarter was unfavorably impacted by higher working capital, a decrease in payables, and an increase in powder inventories brought these results.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe expect further working capital increases throughout the year as we rebuild our RTD shake inventory levels. During the quarter, we have an attractive entry point and repurchased 800,000 shares of class A common stock at an average price of $23.34 per share. Our remaining share repurchase authorization is 42 million. As of December 31, net debt was 489 million and net leverage was 2.1x. During the first quarter, we repaid debt of 90 million using cash on hand.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ETurning to our outlook, we are maintaining our guidance for net sales 1.36 to 1.41 billion and adjusted EBITDA of 255 to 265 million. As Darcy highlighted, the year is progressing slightly ahead of expectations with net sales and adjusted EBITDA growth weighted to the second-half. Inflation has outpaced our initial estimates, so we expect additional cost headwinds for both shakes and powders.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHowever, we are executing a price increase to help offset these impacts which will benefit gross margins in the second-half. During the second quarter, we expect high single digit net sales growth as higher net pricing and volume growth for our powder portfolio is partially offset by volume declines in RTD shakes as we lacked promotional activity.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe expect adjusted EBITDA to grow significantly from prior year benefiting from the pullback of promotions and marketing. Second quarter adjusted EBITDA is expected to decline sequentially driven by inflation ahead of pricing as well as modestly higher SG&amp;A.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EFinally, as Darcy mentioned, Post's distribution of its interest in BellRing remains on track. We expect approximately $400 million of cash will be distributed to BellRing's stockholders, including Post. As a result, we expect net debt of BellRing will increase to an amount not to exceed four times adjusted EBITDA. More details will be provided over the coming weeks.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EIn closing, we are encouraged by the solid start to the fiscal year. While we and our industry are facing short-term challenges and historical inflation, our optimism and outlook for our business has never been brighter.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EI will now turn it over to the operator for questions.\\u003C\\u002Fp\\u003E \\u003Cp id=\\\"question-answer-session\\\" class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EQuestion-and-Answer Session\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E[Operator Instructions] We will take our first question today from Andrew Lazar with Barclays. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EAndrew Lazar\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning, everybody.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EMorning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EAndrew Lazar\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, thanks for the question. I guess first off, I know that, Darcy, you've referred to 2021 as kind of a year where BellRing sort of had almost two years of growth sort of compressed into one year. And a lot of that had a lot to do with, well, of course having the capacity, but also a lot of the incremental shelf space gains in a lot of key -- sort of key customers that you benefited from. I'm curious if you could kind of maybe characterize how that looks as we go through this year? Are there major shelf reset windows where you think there can still be incremental progress made? And, obviously, how does the capacity situation play into your ability to sort of take advantage of those windows? But I'm assuming others are having sort of similar issues as you are. And then I've just got a follow-up.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESure. So, that right now, as you know, we reduced our skews, our tetra skews this year because of our capacity constraints. We have been able to hold, for the most part, about 90% of our space. Basically, customers are spreading out our facing on our core items because they're one of the most productive skews on the shelf. So, we're not in a place right now that, for the next year, we're going to be expanding our shelf space on our tetra skews. What's, I think, encouraging is we do have some innovation coming on outside of the 30-gram line toward the end of the year. But for the most part, this year, as it's a catch-up year for the 30-gram shake line. And so, we're not going to be expanding shelf space considerably.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EAndrew Lazar\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGot it. And then I think when you took some of the initial price increases heading into this year, at least for planning purposes, you had assumed that competitors would not necessarily follow, so it was kind of a prudent, conservative stance heading in. I guess, are you making a similar assumption with some of the incremental pricing that you're taking or -- and how do you think about your elasticity assumptions for this next round of pricing, at least from how you're forecasting and modeling it internally? Thanks so much.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe are. We're assuming that we included some modest elasticity in our assumptions, so staying on the conservative side. In our first round, we tended to be the first to move on pricing in the category, and then most competitors followed fairly soon afterwards. But we have an approach to when we take pricing, we assume elasticity. And then when we see what happens in the marketplace place we adjust those assumptions.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EAndrew Lazar\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThe next question comes from Pamela Kaufman with Morgan Stanley. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EPamela Kaufman\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EMorning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EPamela Kaufman\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYou mentioned that production in the first quarter was slightly below expectations. Can you talk about how much of your fiscal '22 top line outlook is dependent on additional capacity coming online over the next few quarters? And it seems like the balance has shifted more towards pricing now given the incremental pricing you've taken in the quarter. So, is that kind of the right way to think about the composition of your top line outlook for the year?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESo, I'll hit the first -- the production question first. The production below expectations in Q1 was related to -- it was mostly in our existing co-manufacturers. So, the new capacity that is coming online starts in Q2.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EAnd then, your question around how much is associated with existing versus new, the vast majority of our production this coming year is from existing co-manufacturers. I think what's encouraging is that we are seeing an improvement in January with our existing co-manufacturers. It really was related to kind of the Omicron variant, and having absences, we are still seeing some absences, but what's encouraging in January is despite the fact that we are seeing absences and in kind of labor shortages, we're still getting the production. So, that tells me that we're being prioritized over other customers. So, that was the first one.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThe second piece is just the composition of our growth. It depends on which brand we're talking about. From a Premier standpoint, the growth was predominantly coming from pricing, originally, and that was good, that will obviously be the case, with our upcoming incremental pricing that we took, that we announced this quarter. But from Dymatize, it's a mix. So, it's a mix between volume and pricing.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EPaul, anything else that you wanted to add?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESo, obviously, with the price increase, that does obviously push a bit more towards pricing, but as Darcy talked about in her prepared remarks, the increases obviously gives us confidence in the year, but we're waiting to kind of see how things play out with less disease, and those kinds of things. But it gives us obviously a lot of confidence.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EPamela Kaufman\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks. And given some of the supply challenges in tetra packs, have you explored other options for packaging? I know you also sell bottled RTDs. Can you more meaningfully shift your mix to that format?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESo, we do have bottles. But bottles are constrained too, so it's really across the end, because of the dramatic demand increase that happened last year, both bottles and tetras are constrained. So, it's not as easy, and our tetra business is so large that the idea of just shifting to another package size is just -- it's just not feasible. I think we are moving. We're making some kind of co-man shifts on our bottle business, which will dramatically increase our ability to satisfy the increasing demand for our bottles. So, again, it's not as easy as just shifting, but I am confident in our increase that we have planned from a tetra standpoint. It's later in the year and then into '23, and like I said, bottles are also increasing.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EPamela Kaufman\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you. Our next question comes from Jason English with Goldman Sachs. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJason English\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHey folks, good morning. Thanks for stepping me in.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning, Jason.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJason English\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EI've got couple of questions. First, you all confused me on some of the comments and guidance, it was probably my fault as I'm distracted over here, I'm trying to juggle too many balls. But can you go back and I think you said sales, similar Q1 to Q2 but sequentially growing, which seemed like they can coexist? And then there was also some comments on EBITDA which sounded upbeat, but then you commented sequentially lower on price cost likes, et cetera. Do you kind of come back revisit clarify those to me, please.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESure, I'll hit the net sales. And I'm going to let Paul hit EBITDA. Net sales you nailed, it's that Q2 similar to Q1 and then sequentially growing and then Paul do you want to talk about EBITDA?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, so, our comments on EBITDA the second quarter, we expect to be sequentially down from the first quarter, which is consistent with our initial expectation going into the year and that is because there is incremental inflation on our proteins primarily. So, to step up from Q1 into Q2 ahead of our pricing, and then we do expect a modest increase in SG&amp;A. So, the comment was that EBITDA will be sequentially down from Q1.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJason English\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, but it always kind of is with seasonality, but was there a year-in-year comment in there though that I missed too?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThere was not year-over-year obviously there's, it's a different dynamic because in last year in the second quarter, it is almost the second quarter we've promoted heavily in the second quarter typically, that is not the case this year. So, there's a benefit on pricing both from reducing the promotion spend, as well as the list price increases that we took on powders in October and back on shakes back in April. So, we have the benefit of pricings. But we also have significantly higher inflation in the second quarter versus last year in particular; whey protein was at its low point, which is our powder product in the second quarter of last year. And it's significantly higher this year. So, that's the dynamics going on with EBITDA.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJason English\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGot it, okay.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EIt is lower because of marketing spend. So, that is the one piece I did miss to mention is that we're also, we typically spend pretty heavily in marketing in the second quarter, because we do TV advertising, and we're not planning to do that this year. So, that's another element of EBITDA increase from last year, but again sequentially down to Q1.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJason English\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EUnderstood, and bigger picture question for you, Darcy, I remember around the time of separation, you talked about your aspirations to have Premier reach, I think curtain from on those but perhaps reach a 10% sort of penetration level. The penetration growth I'm looking at for the brand has been phenomenal. I think it's actually accelerated during COVID. And you're now north of 8%, so are we approaching sort of an upward governing limit of where you think this can go or is there now more scope for penetration growth as perhaps you're envisioning just a few years ago?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, I think this brand continually surprise us. I think that not only do I think that there's more upside from a category standpoint, but we're increasing our penetration faster than I would have predicted. So, yes, I think that, we're going to, I believe that we can get up to I mean, so one of the -- some of the comparisons I have used are some of the mainstream brands like [Clif and Kind] [Ph] in the nutrition bar space. And they are right above 10%, 11%, 12% and so I use that as a barometer. And I still use that as a barometer of where we can get to, you know, the kind of medium-term.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJason English\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGot it. Okay, thank you. I'll pass it on.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe'll go now to Ben Bienvenu with Stephens. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJim Salera\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHey, guys, good morning. Jim Salera on for Ben, I wanted to ask a little bit on the production side and inflation, how long of a lead time will there'll be to get fill rates and service levels back to normal, assuming the Omicron production kind of shakes out in the second quarter. So, it actually is normal at the end of the second quarter to fill rates get back to normal levels in the third quarter, fourth quarter, that's still looking into the next year?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, our fill rates and service levels will continue to increase. We are already seeing kind of month on month, small increases. And we'll continue to see that throughout the year, I think we'll be in a much. I mean this quarter, our trade inventory levels improved. And again we'll continue to see that by, I would say Q3 they're going to look a lot better, beginning of Q3, they're going to be looking a lot better.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJim Salera\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you. And in fact I could ask one more, you guys have any visibility into freight costs in the back half of the year, whether it's you anticipated to be kind of where it's been at for the first-half, it's going to go up maybe a little bit late there?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, we do expect the freight will go up into the third quarter. And then based on the evidence we've seen, it kind of flattens out at that point. And so from a year-over-year perspective, we have more of a headwind in the first-half than we have in the second-half. So, that's our current thinking.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJim Salera\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGot it, thanks, guys. I will pass it on.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThe next question comes from Bill Chappell with Truist Securities. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EBill Chappell\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks. Good morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EBill Chappell\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHi, Darcy, I guess this goes on Premier Protein. What do you envision elasticity looks like in that category as you rise prices, because it means you have a highly loyal base and a pretty high market share within the drinks side of it. Are people just buying less general, if they are -- there's elasticity, are they switching to lower priced brands? Are they switching to some other form, just try to understand I mean it doesn't seem like there would be a whole lot of elasticity especially with your base but I assume you're factoring some in one way or the other with higher prices?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EToday, we have seen no elasticity. We have been watching it and basically we increased price and volume went up. However, we are not assuming that's going to continue. So, we are assuming some modest elasticity until we see it in marketplace and kind of the facts and circumstances that we see in the marketplace based on what competitors do, et cetera. How much the retailer reflects that shelf, then we will make any adjustments to our assumptions.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EBill Chappell\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay. Thanks. And then, just look kind of on that -- on the cost front. You're trying to understand for lack of better term, so how much of this is short-term in nature, but certainly everything from labor to freight to -- but when it's coming from the co-man, how much do you think rolls off as the commodities get better in six months or conversely laborers kind of here to stay at a higher rate. Any thoughts there in terms of as you're thinking about, kind of profitability going forward?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, so I've written into two pieces. So, from a commodity front, what we're seeing is Whey protein and even milk proteins are at historical highs. Whey protein has been pretty tight, the supply and demand dynamic and so that, that's got to get better, but it doesn't look like it's likely until fiscal '23 or early that's the kind of the current thinking. So, I do think there's some opportunity to us obviously as we get on the other side, because we're kind of protein rates on our powder business that are 2x or plus what they were just a year ago. So, that's got to come back down. So, obviously that's one element, no protein, but kind of steadily going up besides our shakes and so that that was -- that one, we'll have to keep an eye on, but it seems like both those markets should come back down. So, it seemed like there should be a transitory piece of that on our co-mans, your relationships, they're typically long-term contracts and I don't want to get into specifics because it varies by customer, but we're a little bit insulated from that, but as labor costs obviously stay high. It will obviously get absorbed at some point as it's passed along to us, but that's totally that the production cost is somewhere 15%-20% of our overall cost, which really the commodities that are driving the profitability.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EBill Chappell\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGot it. Thanks so much for the color.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe'll go now to Chris Growe with Stifel. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EChristopher Growe\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you. Good morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EChristopher Growe\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHi, I just had a quick question for you and sorry if I missed this, but have you said just to get an order of magnitude on the size of the price increases you have in place the new ones for shakes and for powders?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGo ahead Darcy, go ahead. Sorry.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYou can tell we're not together. That so the second round of pricing is slightly higher than the ones we took before. We didn't specifically just add order of magnitude. The first one was single digits on premier protein double-digits on Dymatize. And this round is slightly higher than that.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EChristopher Growe\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay. And that's most significant, something in the third quarter kind of going in place during the second quarter. Is that right?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ECorrect.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ECorrect.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EChristopher Growe\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay. And then, I just was curious. You have a chart in your, the slide deck around showing TDPs and how they started to increase. So, I just want to get a sense of, it sounds like your -- the supply of product was a little below what you thought, doesn't mean it didn't grow, obviously it did grow, the more available, does that line keep going up to -- do you keep -- continue to see an increase in TDPs as you get more and more supply availability. I guess that's what's going to determine that, rebuild there?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes. I mean, generally. I think there will be. So, you'll see a slight increase as our fill rates and service levels increase. However, we do expect TDPs to be down versus year ago because of that temporary reduction SKUs.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EChristopher Growe\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes. Okay. And I guess just to be clear on that, then this is I'm thinking like for the second quarter. If you're promoting less, that presumably would negatively affect TDPs. Again, not that it can't grow, but it would certainly have a year-over-year effect on TDPs, is that right?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EI mean, the promotion won't have anything to do with the TDPs, if I'm understanding your question, but just the number of SKUs on the shelf, so -- \\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EChristopher Growe\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe will see. So, I mean that is really what's affecting the TDPs.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EChristopher Growe\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay, I got it. Thank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe will go now to Rob Dickerson with Jefferies. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003ERob Dickerson\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGreat, thanks. Just have a quick question on the inventory side. Darcy, you're saying, it sounds like basically, maybe all production this year started from existing suppliers, sounds like maybe some of them are getting a little bit better as you kind of get through to consumption still obviously, up decently, volumes are down, say when that's a gap. So, I'm just curious like, kind of in terms of the inventory situation you have with retailers, when we compare that with the reduction SKUs, it's like, you feel like you're in a pretty good place as you look forward through the year. Right, like you've reduced the SKUs. They really recharge or burning for a little bit inventory, but as you right size the SKU is relative to your capacities, like there shouldn't be kind of further decline, right, just given that a blower capacity relative to consumption demand, like if that catches jobs you know, what I mean.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESo Rob, are you asking about? I mean, I would say our strategy is sound, meaning that we do not expect any change to the number of SKUs that we're going to have and we believe that the fill rate and service levels will continuously increase throughout the year. We will also gradually increase our safety stock throughout the year. Is that what you're asking?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003ERob Dickerson\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, I just want to make sure that you reduce the SKUs, right. If you've looked in, you forecasted yourself that the amount of capacity you have.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003ERob Dickerson\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EShould be able to continue to sell those SKUs that you plan to have on shelf this year.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes. That, yes. Absolutely, that's correct. The one thing I will just know is that when you're looking at consumption, we have pretty high, we have some high highs and we've increases when we have promotions. And so, when you're looking at consumption, you'd have to factor in that you're going to see some negatives on premiere, when we're lacking promotions. And that is expected. And so I think that, it's just, it's good to have that in the back of your mind when you're looking at the kind of track channel consumption on a week-to-week basis.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003ERob Dickerson\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay, fair enough. And then, I guess back to Jason's question quickly, there's a lot in there to kind of EBITDA sequentially. And what have you -- I mean, it's like, if we're thinking about Q2, just in absolute EBITDA dollars, would you say that maybe kind of similar to sales sequentially from Q1 to Q2, that maybe EBITDA would see like a similar absolute dollar number. I mean, I know you're not specifically guiding to that number, but obviously with just kind of where the full-year EBITIDA guide is, right, it does imply material back half improvement?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESo no, I would not quite characterize it that way. So, we, just to be clear, we expect the EBITDA to decline sequentially from Q1 to Q2. We expect it to be higher than last year because we're lacking a lot of marketing that we do expect it to decline and that is, again because of higher inflation. And so, that day is the primary piece, but now we expect it to be down. Keep in mind that we've said that, we expect that sales and EBITDA growth will be weighted to the second-half of the fiscal year. We do expect it to be switching down.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003ERob Dickerson\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ERight. So, I mean, kind of next year where you came in Q1 and Q2, despite all the moving pieces of volatility. I mean, it seems like the business is still tracking, kind of as you expected coming out of Q4.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, I mean -- \\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThe first-half is tracking. Yes, the first-half of tracking like we expected with the slight shift of Dymatize sales into Q1 from Q2, but yes, the first-half is tracking as we expected.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EI mean, Rob. I would just say a big picture. This year and going much like we expected, slight movement of sales from Q2 to Q1 and that is just, it's really nothing. It's just a little sales phasing. And then we saw inflation kick up higher than we expected, although we saw the -- we saw that coming on the last call, and therefore we took price and that affects the back half. So, I mean, but all other than the inflation and the pricing action, the cadence is largely what we expected.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003ERob Dickerson\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EPerfect. Thank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThanks.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe'll go now to Ken Zaslow with Bank of Montreal. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKenneth Zaslow\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHi, good morning, guys.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKenneth Zaslow\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ETwo questions, one is can you walk us through the capacity build over the next 18 to 24 months of how it works exactly how much incremental capacity is coming online, through the next -- on a quarter-by-quarter basis?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, so basically, we have increased capacity every quarter four through '23. I mean, and so we see increased and that mostly comes from the existing co-mans are pretty stable. So, the increases come from new co-mans, they start slotting in, in Q2 of this year. There is not a huge benefit this year in '22, so let's still call it 90% of our production is coming from existing for '22. But then, those new co-mans start increasing and become contributors, real contributors in '23. Then we also bring on additional co-mans in '23. So, we basically add three new ones in '22. And we add two more in '23. And the big ones, which are new facilities like MFI, we talk to -- sorry, Michael Foods would come on in later '23. They start up later in the year, and so become kind of smaller contributors in '23, but bigger contributors in '24.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKenneth Zaslow\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWould you say that 2023 additional capacity is 5%, 10%, 15%. And then when you get to '24. How would you kind of just do that?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHold on. I'm calculating.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKenneth Zaslow\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ETake your time.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ESo, call it less in '22, new capacity is less than 10%, it becomes yes, 20% to 25% of the -- of '23. And then continue -- and then it ramps up from there. And remember, we can still affect, so because some of the new capacity in '23, they're actually new Greenfield facilities, that timeline is basically 24 months. We are still talking to partners for kind of late '23 and '24.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKenneth Zaslow\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay. My second question is, if you believe this capacity coming online, you answered an earlier question that you think household penetration kind of you look to certain brands in this 10% and it's 100 basis points from where you are right now, 25% more capacity coming online. You obviously don't really believe that 10% is your high watermark. I mean, that doesn't -- I mean, you obviously believe that you're building capacity because there's demand and that demand is going to take you above that 10% household penetration, I'm assuming. So, again, why would you even know that there is a limit to the demand of what it is, why limit yourself to a household penetration? It seems like you've hit a tipping point and I'm not going to be difficult; it just seems odd to come up with some arbitrary 10% just I don't know, just a thought. I'll leave it there.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, I totally agree. I completely agree and I don't and by the way, I don't see it as a limit. I think, it is a step along the way. And I truly believe that this brand has -- I think, the category in general is just -- I mean, I said earnings, but it has so much more upside. And I've used this analogy before, but even within our category. nutrition bars have mainstreamed much faster than any other forms within the category and they are at close to 50%. So, 45% household penetration, where our RTD shakes are only at 25, powders or even lower. So, there's no reason why shakes can't get close to nutrition bars. And so I think that the upside is immense. And I think Premier Protein is perfectly positioned to take advantage of that, because it's a mainstream approachable brand that shows that it appeals to kind of every needs, state, and kind of every consumer within the category. So, I do not believe that 10% is the limit at all. I think it's a step along the way.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKenneth Zaslow\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGreat, appreciate it.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe'll go now to Kaumil Gajrawala with Credit Suisse. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKaumil Gajrawala\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHey, everybody. Good morning. First one a very quick one, when you talk about these capacity additions for '23, '24. Is that fiscal or calendar?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EFiscal.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKaumil Gajrawala\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EFiscal, got it. And then one of the things that we didn't talk about as it relates to capacity is if there were any key ingredients or inputs or materials packaging, that have created bottlenecks. I know in the past they have, I think you mentioned those little foil wrappers, things like that. Is that all resolved now or is it still some areas of things to watch out for?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, there's nothing that's problematic at the moment. We extended lead times early on to try to prevent those things from happening. Yes, we haven't seen any impacts.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EKaumil Gajrawala\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay, great. That's all. Thank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOur next question comes from John Baumgartner with Mizuho. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJohn Baumgartner\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EGood morning, thanks for the question.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHey, John.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJohn Baumgartner\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EMaybe first off, hi Darcy, congrats on the time. I'd like to ask about powders against the broader evolution of the category maybe you are moving beyond COVID volatility into the new normal, with work from home and such, and how you think about the role for powder within the category. Have you seen a core consumer for powder change at all pre versus post COVID? How do you see powders and RTD coexisting as powders grow from here and then for BellRing, how can you best I guess make powder products complementary to the RTD business?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes, it's a great question. So, I'm going to pick up where I was talking about the potential of our RTDs versus nutrition bars, powders have even lower household penetration than RTDs. So, I think that is and where Premier helped mainstream or has started to help mainstream RTDs, I also believe that powders are at kind of earlier stage of that mainstream trajectory. So, they're different than all of the different forms are have kind of unique occasions. So, if you think of bars are more snacking, RTDs are more meal replacement, although can be used kind of in between meals, but more meal replacement. Well, powders are mostly used with food, with smoothies, after workouts where they're consumed RTDs and nutrition bars mostly on the go, powders at home. So, they're very complementary. And we have been very successful on Premier Protein with powders, obviously, Dymatize is our number one powder brand. Both of them go after unique and complementary consumers. And then of course, as I was saying before they have kind of unique and complementary occasions as well.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJohn Baumgartner\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay, great. And I guess from supply chain perspective, there's a lot of focus now understandably, on the month-to-month and quarter-to-quarter. But aside from just I guess simply increasing volume availability. Are there opportunities underway here with the changes in supplier base now, I guess through F23, F24 that sort of place you in a better position, either format wise or profit wise to come out of this recalibration with new channels for growth, whether it's out of home C stores in consumption, is there opportunity to sort of affect the change in the composition of your capabilities and channels for the longer-term sort of coming out of this year?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EAbsolutely, so I think that, I said this in my prepared remarks just about how I think we're going to look back at '21 as a really pivotal year because I think that what we're going to look back on is really kind of laying the foundation, laying the table for kind of outsized growth in the future. Building at where we currently from a production standpoint, for instance, we have five locations now in 4-ish years we will be doubling that. We are expanding our bottle -- our bottle capacity dramatically which will allow us to go -- we can really sell bottles or tetras within kind of convenience and up and down the street et cetera. But we start being able to match products to different places and then expanding our distribution from there. So, yes, I believe this year is more about capability building so then we could take advantage of that in the future.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EJohn Baumgartner\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EOkay. Thanks for your time. Appreciate it.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EDarcy Davenport\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EThank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe will go now to Bryan Spillane with Bank of America. Your line is open.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EBryan Spillane\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EHi. Thanks, Operator. Good morning. I just had one question and it's if you look at fiscal -- we look at the current fiscal year and just the amount of consumer-facing spend that you are anticipating this year, I guess so both promotions and advertising and marketing. What is that relative to normal? And I guess what I am trying to get at is as we move past the supply constraints, how much more marketing would we have to add back as we go forward?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EYes. So, on the marketing side, I think in '21 we spent around 3% of net sales on what we call advertising promotion. This year we are pulling back on that around 2%. Going forward obviously we want [indiscernible] we also think that will drive top line growth as well as we've seen from our recent past that's it's very -- our products are very receptive to marketing. And so, we think it would drive obviously top line. But, yes, we would expect over the longer term to at least spend back to 3% level and perhaps look to increase that over time as our [indiscernible].\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EBryan Spillane\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EIs the order [of magnitude] [Ph] if I remember this correctly at the time of the separation, right, you had been through a supply chain or supply constraints prior to the separation. And then the next fiscal year, margin step back because there was more marketing spend that went in? So, just like order of magnitude will it look like that?\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"answer\\\"\\u003EPaul Rode\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003ENo. So, the situation was a little bit different back then. So, we did see fiscal year because fiscal year, I think it was fiscal ['18] [Ph] that had a stepped up margin. But a part of that was too because protein cost had come down so we benefited from a price increase as well as from favorable protein cost. But, no, I don't think our margin structure should be impacted. Obviously, it sometimes depends on what commodities do and we will have to make sure we are right sizing that. At least historical high prices, it gets harder to get back to the gross margins that we had experienced in the past. But, I do think over the long term, things will even out. And we should see gross margins back where they have been historically coming at 33-34 range, which allows us to spend marketing at higher level and promotion.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003E\\u003Cspan class=\\\"question\\\"\\u003EBryan Spillane\\u003C\\u002Fspan\\u003E\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EAll right, thank you.\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003E\\u003Cstrong\\u003EOperator\\u003C\\u002Fstrong\\u003E\\u003C\\u002Fp\\u003E \\u003Cp class=\\\"paywall-full-content\\\"\\u003EWe have no further questions in queue at this time. This will conclude today's program. Thank you for your participation, and you may disconnect at any time.\\u003C\\u002Fp\\u003E\",\"twitContent\":\"$BRBR - BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript. https:\\u002F\\u002Fseekingalpha.com\\u002Farticle\\u002F4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript?source=tweet \",\"innerMarketing\":null,\"marketingBullet\":null,\"isPaywalled\":false,\"isReit\":false,\"videoData\":null,\"isAmphtml\":true},\"relationships\":{\"author\":{\"data\":{\"id\":\"44211\",\"type\":\"author\"}},\"sentiments\":{\"data\":[]},\"primaryTickers\":{\"data\":[{\"id\":\"600231\",\"type\":\"tag\"}]},\"secondaryTickers\":{\"data\":[]},\"otherTags\":{\"data\":[{\"id\":\"96991\",\"type\":\"tag\"},{\"id\":\"17829\",\"type\":\"tag\"},{\"id\":\"49\",\"type\":\"tag\"},{\"id\":\"586376\",\"type\":\"tag\"},{\"id\":\"326\",\"type\":\"tag\"}]},\"coAuthors\":{\"data\":[]},\"presentations\":{\"data\":[]},\"updates\":{\"data\":[]},\"corrections\":{\"data\":[]}},\"links\":{\"self\":\"\\u002Farticle\\u002F4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript\",\"canonical\":\"https:\\u002F\\u002Fseekingalpha.com\\u002Farticle\\u002F4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript\",\"uriImage\":null,\"schemaImage\":null}},\"included\":[{\"id\":\"44211\",\"type\":\"author\",\"attributes\":{\"company\":null,\"slug\":\"sa-transcripts\",\"userId\":101639,\"tagId\":96991,\"image\":{\"small\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fsmall_pic.png\",\"medium\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fmedium_pic.png\",\"big\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fbig_pic.png\",\"extra_large\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fextra_large_pic.png\"},\"nick\":\"SA Transcripts\",\"bio\":\"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team\",\"memberSince\":2007,\"contributorSince\":2013,\"followersCount\":126386},\"relationships\":{\"user\":{\"data\":{\"id\":\"101639\",\"type\":\"user\"}},\"authorResearch\":{\"data\":null},\"authorSponsorProgram\":{\"data\":null}},\"links\":{\"self\":\"\\u002Fauthor\\u002Fsa-transcripts\",\"profileUrl\":\"\\u002Fauthor\\u002Fsa-transcripts\",\"site\":null,\"linkedinUrl\":null,\"twitterUrl\":null}},{\"id\":\"600231\",\"type\":\"tag\",\"attributes\":{\"slug\":\"brbr\",\"name\":\"BRBR\",\"company\":\"BellRing Brands, Inc.\",\"tagKind\":\"Tags::Ticker\",\"equityType\":\"stocks\",\"exchange\":\"NYSE\",\"fundTypeId\":0,\"isDefunct\":false,\"isBdc\":false,\"isReit\":false,\"isEtf\":false},\"relationships\":{\"sector\":{},\"subIndustry\":{}},\"links\":{\"self\":\"\\u002Fsymbol\\u002FBRBR\"}},{\"id\":\"96991\",\"type\":\"tag\",\"attributes\":{\"slug\":\"sa-transcripts\",\"name\":\"SA Transcripts\",\"company\":null,\"tagKind\":\"Tags::AuthorTag\"},\"links\":{\"self\":\"\\u002Fauthor\\u002Fsa-transcripts\"}},{\"id\":\"17829\",\"type\":\"tag\",\"attributes\":{\"slug\":\"consumer-goods\",\"name\":\"Consumer Goods\",\"company\":null,\"tagKind\":\"Tags::Sector\"},\"links\":{\"self\":\"\\u002Farticles?filters=consumer-goods\"}},{\"id\":\"49\",\"type\":\"tag\",\"attributes\":{\"slug\":\"transcripts\",\"name\":\"Transcripts\",\"company\":null,\"tagKind\":\"Tag\"},\"links\":{\"self\":\"\\u002Ftag\\u002Ftranscripts\"}},{\"id\":\"586376\",\"type\":\"tag\",\"attributes\":{\"slug\":\"has-audio\",\"name\":\"Has Audio\",\"company\":null,\"tagKind\":\"Tag\"},\"links\":{\"self\":\"\\u002Ftag\\u002Fhas-audio\"}},{\"id\":\"326\",\"type\":\"tag\",\"attributes\":{\"slug\":\"us\",\"name\":\"United States\",\"company\":null,\"tagKind\":\"Tags::Country\"},\"links\":{\"self\":\"\\u002Farticles?filters=us\"}}],\"meta\":{\"proStatus\":0,\"ads\":{\"targeting\":{},\"zone\":\"\"},\"page\":{\"title\":\"BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript\",\"description\":\"BellRing Brands, Inc. (NYSE:NYSE:BRBR) Q1 2022 Earnings Conference Call February 4, 2022 10:30 AM ETCompany ParticipantsJennifer Meyer - Investor RelationsDarcy Davenport - President and...\"},\"path\":\"\\u002Fapi\\u002Fv3\\u002Farticles\\u002F4484494\"}},\"authorData\":{\"response\":{\"data\":{\"id\":\"44211\",\"type\":\"fullAuthor\",\"attributes\":{\"company\":null,\"slug\":\"sa-transcripts\",\"userId\":101639,\"tagId\":96991,\"image\":{\"small\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fsmall_pic.png\",\"medium\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fmedium_pic.png\",\"big\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fbig_pic.png\",\"extra_large\":\"https:\\u002F\\u002Fstatic3.seekingalpha.com\\u002Fimages\\u002Fusers_profile\\u002F000\\u002F101\\u002F639\\u002Fextra_large_pic.png\"},\"nick\":\"SA Transcripts\",\"bio\":\"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team\",\"memberSince\":2007,\"contributorSince\":2013,\"followersCount\":126386,\"count\":{\"followers\":126438,\"articles\":294138,\"sponsored\":0,\"instablogs\":0,\"following\":4,\"comments\":1,\"likes\":0,\"comment_likes\":1,\"news\":0},\"createdAt\":\"2013-02-20T14:49:48-05:00\",\"showHeadlines\":null,\"podcasts\":{}},\"relationships\":{\"user\":{\"data\":{\"id\":\"101639\",\"type\":\"user\"}},\"userBioTags\":{\"data\":[{\"id\":\"958652\",\"type\":\"userBioTag\"}]},\"authorResearch\":{\"data\":null},\"authorSponsorProgram\":{\"data\":null}},\"links\":{\"self\":\"\\u002Fauthor\\u002Fsa-transcripts\",\"profileUrl\":\"\\u002Fauthor\\u002Fsa-transcripts\",\"site\":{\"url\":\"https:\\u002F\\u002Fseekingalpha.com\\u002Fearnings\\u002Fearnings-call-transcripts\",\"name\":\"Recent earnings call transcripts\",\"clicks\":38681},\"linkedinUrl\":\"\",\"twitterUrl\":\"\"}},\"included\":[{\"id\":\"958652\",\"type\":\"userBioTag\",\"attributes\":{\"priority\":0,\"name\":\"We cover over 4K calls\\u002Fquarter\"}}],\"meta\":{\"ads\":{\"targeting\":{\"a\":\"sa-transcripts\"}}},\"headers\":{\"connection\":[\"close\"],\"content-length\":[\"842\"],\"content-type\":[\"application\\u002Fjson; charset=utf-8\"],\"x-frame-options\":[\"SAMEORIGIN\"],\"x-xss-protection\":[\"1; mode=block\"],\"x-content-type-options\":[\"nosniff\"],\"x-download-options\":[\"noopen\"],\"x-permitted-cross-domain-policies\":[\"none\"],\"referrer-policy\":[\"strict-origin-when-cross-origin\"],\"content-security-policy\":[\"default-src https: wss: data: blob: 'unsafe-inline' 'unsafe-eval'; report-uri https:\\u002F\\u002Fseekingalpha.com\\u002Freport\\u002Fcsp\"],\"strict-transport-security\":[\"max-age=63072000; includeSubDomains; preload\"],\"surrogate-control\":[\"max-age=2629746, stale-while-revalidate=30, stale-if-error=86400\"],\"etag\":[\"W\\u002F\\\"5ec5128cb45cb8fa8eb8544c8329e064\\\"\"],\"x-runtime\":[\"0.122431\"],\"allow\":[\"GET, POST, HEAD, PUT, PATCH, DELETE, OPTIONS\"],\"content-encoding\":[\"gzip\"],\"x-sa-save-s-max-age\":[\"2629746.000\"],\"x-sa-save-cache-control\":[\"max-age=0, public\"],\"surrogate-key\":[\"author\\u002F44211 user\\u002F101639 author\\u002F* sa_api\"],\"cache-control\":[\"max-age=0, public\"],\"x-save-ttl\":[\"2629746.000\"],\"accept-ranges\":[\"bytes\"],\"date\":[\"Fri, 06 May 2022 14:13:25 GMT\"],\"age\":[\"27\"],\"x-sa-save-vary\":[\"sa-cache-key, sa-ab-tests, sa-ssl, authorization, accept-encoding, x-requested-with, Accept-Encoding\"],\"sa-cache-key\":[\",ssr\"],\"set-cookie\":[\"machine_cookie=9630970809218; expires=Thu, 06 May 2027 14:13:25 GMT; path=\\u002F;\",\"machine_cookie_ts=1651846405; expires=Thu, 06 May 2027 14:13:25 GMT; path=\\u002F;\"],\"fastly-debug-path\":[\"(D cache-sea4480-SEA 1651846406) (F cache-sea4448-SEA 1651846378)\"],\"fastly-debug-ttl\":[\"(H cache-sea4480-SEA 2629718.714 86400.000 27)\"],\"fastly-debug-digest\":[\"714b17363bfb3b0f0896150d3a4b8a9df2707d3d577d18bb9b94d63d6a065992\"],\"x-served-by\":[\"cache-sea4480-SEA\"],\"x-cache\":[\"HIT\"],\"x-cache-hits\":[\"2\"],\"x-timer\":[\"S1651846406.933095,VS0,VE0\"],\"vary\":[\"User-Agent, Accept-Encoding\"],\"x-request-id\":[\"UgOBUlgeSopePXkT\"]}},\"type\":\"fullAuthor\"}}};</script></head><body><div class=\"appLoading invisible\" id=\"app-loader\"></div><span><svg style=\"position:absolute;width:0;height:0\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><defs><symbol viewBox=\"0 0 34 28\" id=\"alpha\"><path d=\"M28.77 24.7c3.44 2.03 3.64-3.92 3.64-3.92.75-.28 1.22-.5 1.22-.5 1.82 8.27-3.64 7.7-3.64 7.7-4.26.42-6.08-6.03-6.08-6.03-6.02 7.4-12.96 5.8-12.96 5.8C-.95 26.33.02 13.99.02 13.99.96.29 12.5 0 12.5 0c8.35.06 10.72 8.35 10.72 8.35.11.46 4.95-7.77 4.95-7.77h2.74c-5.58 11.31-5.35 15.94-5.35 15.94-.46 6.08 3.2 8.18 3.2 8.18zM5 13.99c0 6.4 3.44 11.67 8 11.54 6.41-.19 8.26-5.2 8.26-11.6 0-6.4-3.7-11.65-8.26-11.6C7.38 2.4 5 7.6 5 14z\"></path></symbol><symbol viewBox=\"0 0 20 24\" id=\"bell\"><path d=\"M16.88 10.49c0-3.54-2.02-5.98-3.54-6.4-1.52-.43-1.46-2.05-1.46-2.05C11.88.91 11.04 0 10 0S8.12.91 8.12 2.04c0 0 .06 1.62-1.46 2.05-1.52.42-3.54 2.86-3.54 6.4C3.12 18 0 17.56 0 20.16h20c0-2.6-3.12-2.15-3.12-9.67zM6.46 21.12A3.72 3.72 0 0010 24a3.7 3.7 0 003.54-2.88H6.46z\"></path></symbol><symbol viewBox=\"0 0 31 25\" id=\"chat\"><path d=\"M28.92 5.18a14.04 14.04 0 00-5.64-3.79A21.22 21.22 0 0015.5 0c-2.1 0-4.1.28-6.02.82a17.31 17.31 0 00-4.95 2.22 11.4 11.4 0 00-3.3 3.33A7.42 7.42 0 000 10.41c0 1.63.52 3.16 1.57 4.58a12.47 12.47 0 004.28 3.58 9.93 9.93 0 01-1.48 3.02c-.17.23-.35.44-.54.65l-.6.62a56.87 56.87 0 00-.67.7l-.12.14-.1.15c-.06.08-.09.13-.08.15a.3.3 0 01-.04.16c-.03.1-.02.16.01.2v.02c.04.18.15.35.3.47a.7.7 0 00.53.14A19.33 19.33 0 0013 20.7c.87.1 1.7.14 2.51.14 2.81 0 5.41-.46 7.78-1.4a13.88 13.88 0 005.64-3.78A7.84 7.84 0 0031 10.4c0-1.88-.7-3.63-2.08-5.23z\"></path></symbol><symbol viewBox=\"0 0 5 21\" id=\"info\"><circle cx=\"2.5\" cy=\"2.5\" r=\"2.5\"></circle><circle cx=\"2.5\" cy=\"10.5\" r=\"2.5\"></circle><circle cx=\"2.5\" cy=\"18.5\" r=\"2.5\"></circle></symbol><symbol viewBox=\"0 0 9 10\" id=\"lock\"><path d=\"M7.77 4.36h-.36V3.08A3 3 0 004.5 0a3 3 0 00-2.9 3.08v1.28h-.37c-.4 0-.73.34-.73.77v4.1c0 .43.33.77.73.77h6.54c.4 0 .73-.34.73-.77v-4.1a.75.75 0 00-.73-.77zm-5.12 0V3.08A1.9 1.9 0 014.5 1.12a1.9 1.9 0 011.85 1.96v1.28h-3.7z\"></path></symbol><symbol viewBox=\"0 0 131 26\" id=\"logo\"><path fill=\"currentColor\" d=\"M.4 18a9.26 9.26 0 01-.4 1.82C.7 20.58 2.34 21 3.34 21c2.8 0 5.07-1.74 5.07-4.68 0-4.37-6.46-2.85-6.46-6.63 0-1.45 1.17-2.4 2.58-2.4 1.21 0 2.12.68 2.55 1.79h.2c.17-.58.31-1.15.56-1.68a4.6 4.6 0 00-2.94-.99c-2.46 0-4.55 1.3-4.55 3.94 0 4.64 6.42 2.95 6.42 6.77 0 1.62-1.19 3-2.85 3-1.6 0-2.52-.82-3.32-2.14H.4zm11.33-3.28c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.59 3.6a4.55 4.55 0 01-3.04 1.42c-2.48 0-3.73-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.89-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.52-1.2l.03-1.08zm3.92-3.6c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.58 3.6a4.54 4.54 0 01-3.03 1.42c-2.48 0-3.74-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.9-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.53-1.2l.01-1.08zm3.77-13.07c-.31.03-.56.07-.83.07-.28 0-.55-.04-.82-.07v15.41c.27-.02.54-.06.82-.06.27 0 .52.04.83.06v-4.18c0-.89.28-.95.73-.43 1.32 1.5 2.94 3.32 3.92 4.61.33-.02.66-.06 1.03-.06.33 0 .61.04 1 .06v-.1c-1.62-1.85-3.34-3.9-4.82-5.6 1.9-1.79 3.7-3.22 4.52-3.96v-.14c-.31.01-.56.06-.8.06-.3 0-.56-.05-.82-.06l-1.6 1.76-1.28 1.3c-.26.26-1.35 1.43-1.78 1.2-.19-.1-.1-.4-.1-.67v-9.2zm10.37 2.22c0-.58-.5-1.05-1.04-1.05a1.05 1.05 0 000 2.1c.55 0 1.04-.48 1.04-1.05zm-.22 3.5c-.31.03-.56.07-.82.07-.3 0-.56-.04-.83-.06v9.8c.27-.02.54-.06.83-.06.26 0 .5.04.82.06v-9.8zm1.63 9.47c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-4.76c0-2.53.54-4.1 2.7-4.1 1.92 0 2.27 1.5 2.27 3.4v5.46c.26-.02.53-.06.82-.06.26 0 .51.04.82.06V14.5c0-2.7-.92-4-3.3-4-1.46 0-2.59.74-3.3 1.99v-1.87c-.31.02-.56.06-.83.06-.28 0-.55-.04-.82-.06v9.8zm11.21-6.68c0-1.56.84-2.7 2.32-2.7 1.62 0 2.2 1.22 2.2 2.8 0 1.4-.79 2.69-2.28 2.69-1.5 0-2.3-1.34-2.24-2.8zm6.9-3.18c-.48.08-.97.1-1.47.04l-2.85-.1c-2.99-.1-4.14 1.27-4.14 3.26 0 1.51.76 2.36 1.99 2.93-.8.35-1.41.78-1.41 1.77 0 1.25.65 1.55 1.25 1.66v.16c-1.28.23-2.14 1-2.14 2.48 0 2.16 2.03 3.02 3.72 3.02 3.13 0 5.2-1.64 5.2-4.04 0-1.75-1.12-2.73-3.54-2.73h-1.32c-1.23 0-1.97-.12-1.97-.99 0-1.19 1.24-.98 1.48-.98 2.38 0 4.37-.95 4.37-3.18 0-1.15-.57-2.05-1.41-2.7l2.25.18v-.78zm-4.34 9.7c1.54 0 3.02.14 3.02 2.28 0 1.93-1.77 2.62-3.24 2.62-1.7 0-2.95-.82-2.95-2.48 0-1.66 1.04-2.44 3.17-2.42zm19.16-5.92h-4.5l2.23-5.25 2.28 5.25zm-1.53-7.94h-.47l-6.4 14.34c.22-.02.45-.06.71-.06.25 0 .47.04.76.06.58-1.93 1.32-3.73 2.03-5.54h5.21a77.59 77.59 0 012.16 5.54c.35-.02.7-.06 1.09-.06.34 0 .67.04 1.06.06L75.77 6.42zm7.73 14.24c.26-.02.52-.06.81-.06.27 0 .51.04.82.06V5.26c-.3.02-.55.06-.82.06-.29 0-.55-.04-.82-.07v15.41zm5.13-2.03h.04c.68 1.28 1.69 1.97 3.16 1.97 2.63 0 4.43-2.03 4.43-5.4 0-2.45-1.47-4.7-4.12-4.7-2.48 0-3.12 1.5-3.47 2.2h-.04v-2.07c-.3.02-.55.06-.82.06-.28 0-.55-.04-.82-.06V25.7c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-7.06zm0-2.83c0-1.9.62-4.6 3-4.6 2.21 0 2.83 2.08 2.83 4.09 0 2.38-.74 4.45-2.81 4.45-2.1 0-3.02-1.74-3.02-3.94zm9.46 4.86c.26-.02.53-.06.82-.06.26 0 .51.04.82.06v-5.58c0-2.13.84-3.28 2.68-3.28 1.75 0 2.28 1.13 2.28 3.4v5.46c.27-.02.53-.06.82-.06.27 0 .52.04.82.06v-5.93c0-2.58-.92-4-3.3-4-1.45 0-2.58.74-3.3 2V5.24c-.31.03-.56.07-.82.07-.29 0-.56-.04-.82-.07v15.41zm15.23-2.34c0 .15-.41.5-.56.64-.39.4-1.08.78-1.64.78-1.25 0-2-.63-2-1.93 0-1.86 2.08-2.07 3.48-2.34l.72-.14v3zm1.64-4.36c0-2.32-1.17-3.45-3.33-3.45-1.2 0-2.31.45-3.3 1.13v1.15h.23c.14-.45.94-1.42 2.44-1.42 1.54 0 2.4.88 2.4 2.4 0 .99-.56 1.1-2.18 1.38-1.93.3-3.8.61-3.8 2.95 0 1.52 1.28 2.5 2.74 2.5 1.23 0 2.17-.43 3.03-1.29l.19-.18c.16 1.2 1.05 1.37 2.11 1.19.23-.04.47-.15.62-.2v-.46c-1.21.27-1.15-.14-1.15-.94v-4.76z\"></path><path color=\"currentColor\" d=\"M116.78 6.12c.38-5.99 5.1-6.12 5.1-6.12 3.4.02 4.37 3.65 4.37 3.65.04.2 2.02-3.4 2.02-3.4h1.12c-2.28 4.95-2.19 6.98-2.19 6.98-.19 2.66 1.31 3.57 1.31 3.57 1.4.9 1.49-1.71 1.49-1.71.3-.12.5-.22.5-.22.74 3.62-1.49 3.37-1.49 3.37-1.74.18-2.48-2.64-2.48-2.64-2.46 3.24-5.3 2.54-5.3 2.54-4.85-.62-4.45-6.02-4.45-6.02m2.03 0c0 2.8 1.4 5.1 3.26 5.05 2.62-.08 3.38-2.27 3.38-5.08 0-2.8-1.51-5.1-3.38-5.07-2.3.03-3.26 2.3-3.26 5.1\"></path></symbol><symbol fill=\"none\" viewBox=\"0 0 14 12\" id=\"premium\"><path stroke=\"#00D885\" d=\"M9 2h4v4\"></path><path stroke=\"#00D885\" d=\"M13 2L7.24 7.65 5.32 5.76 1 10\"></path></symbol><symbol viewBox=\"0 0 22 26\" id=\"presentation\"><path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M9 0h4v2H9V0zm4 9a1 1 0 011-1h3a1 1 0 110 2h-3a1 1 0 01-1-1zm0 3a1 1 0 011-1h3a1 1 0 110 2h-3a1 1 0 01-1-1zm-4 5v2h.14l-4.79 4.8c-.3.29-.3.77 0 1.07.29.3.77.3 1.06 0L11 19.28l5.59 5.6a.76.76 0 001.06-1.09L12.85 19H13v-2h7a1 1 0 001-1V5h1V3H0v2h1v11a1 1 0 001 1h7zM19 6H3v9h16V6zm-9.5 6.67A3 3 0 0010 11H7V8a3 3 0 102.5 4.67z\"></path><path opacity=\".5\" d=\"M11 10a3 3 0 00-3-3v3h3z\"></path></symbol><symbol viewBox=\"0 0 23 16\" id=\"pressRelease\"><path fill-rule=\"evenodd\" d=\"M16.52 3.16a.5.5 0 00.03.7l.15.14c.2.2.52.18.7-.02l2.61-2.8a.5.5 0 00-.03-.7l-.14-.14a.5.5 0 00-.71.03l-2.6 2.79zM1.21 8.1l9.96-6.64c.15-.16.31-.28.5-.34 1.27-.38 3.1 1.88 4.07 5.06.97 3.18.73 6.08-.55 6.46-.19.06-.39.06-.6 0l-3.25.02a3.01 3.01 0 11-6.02.04l-2.7.01c-.64.2-1.47-.68-1.86-1.95C.37 9.49.57 8.3 1.21 8.1zm5.32 4.59a1.8 1.8 0 002.33 1.9 1.8 1.8 0 001.27-1.92l-3.6.02zm8.05-6.16c.78 2.55.9 4.77.26 4.96-.64.2-1.78-1.7-2.56-4.25s-.9-4.77-.26-4.96c.64-.2 1.79 1.7 2.56 4.25zm3.94-1.2a.5.5 0 00-.33.63l.06.2a.5.5 0 00.62.32l3.65-1.11a.5.5 0 00.33-.63l-.06-.2a.5.5 0 00-.62-.33l-3.65 1.12zm-.44 3.1a.5.5 0 01.6-.37l3.72.86a.5.5 0 01.37.6l-.04.2a.5.5 0 01-.6.38l-3.72-.86a.5.5 0 01-.38-.6l.05-.2z\"></path></symbol><symbol viewBox=\"0 0 35 12\" id=\"pro\"><path fill=\"#fff\" d=\"M4.17.09H0V11.9h.85V8.06h3.32c2.93 0 4.7-1.5 4.7-3.98C8.86 1.57 7.1.1 4.16.1zm0 7.18H.85V.87h3.32C6.67.86 8 2.02 8 4.06c0 2.03-1.33 3.2-3.83 3.2zm16.6 4.64l-2.91-4.14a3.62 3.62 0 002.72-3.7c0-2.5-1.76-3.99-4.68-3.99h-4.18v11.83h.85V8.04h3.33c.4 0 .76-.03 1.13-.08l2.77 3.95h.97zm-8.2-4.63V.86h3.33c2.49 0 3.82 1.17 3.82 3.21 0 2.03-1.33 3.22-3.82 3.22h-3.33zM28.63 12c3.46 0 6.05-2.55 6.05-6s-2.6-6-6.05-6c-3.48 0-6.06 2.57-6.06 6s2.58 6 6.06 6zm0-.8a5.07 5.07 0 01-5.2-5.2c0-3 2.22-5.2 5.2-5.2A5.07 5.07 0 0133.8 6c0 3-2.22 5.2-5.18 5.2z\"></path></symbol><symbol viewBox=\"0 0 32 32\" id=\"search\"><path d=\"m27.64 25.91-7.16-7.16a9.13 9.13 0 0 0-.8-12.06A9.12 9.12 0 0 0 13.18 4c-2.45 0-4.75.96-6.49 2.7A9.12 9.12 0 0 0 4 13.18c0 2.45.96 4.76 2.7 6.5a9.12 9.12 0 0 0 12.05.8l7.16 7.15a1.22 1.22 0 0 0 1.73 0c.48-.48.48-1.25 0-1.73zM8.42 17.95a6.7 6.7 0 0 1 0-9.53 6.7 6.7 0 0 1 9.52 0 6.7 6.7 0 0 1 1.98 4.77 6.7 6.7 0 0 1-11.5 4.76z\"></path></symbol><symbol viewBox=\"0 0 28 24\" id=\"temple\"><path d=\"M14.16.39l11.35 4.08a.98.98 0 01.6 1.27 1 1 0 01-1.28.59l-11.14-4-11.42 4.1A1 1 0 011 5.83a.98.98 0 01.59-1.26L13.3.35a1 1 0 01.85.04zM24 8a1 1 0 01-1 1H4a1 1 0 110-2h19a1 1 0 011 1zM8 11a1 1 0 01-1 1v5a1 1 0 01-2 0v-5a1 1 0 010-2h2a1 1 0 011 1zm14 10a1 1 0 100-2H5a1 1 0 000 2h17zm2 3a1 1 0 000-2H3a1 1 0 000 2h21zM13 11a1 1 0 01-1 1v5a1 1 0 01-2 0v-5a1 1 0 010-2h2a1 1 0 011 1zm4 1a1 1 0 000-2h-2a1 1 0 000 2v5a1 1 0 002 0v-5zm6-1a1 1 0 01-1 1v5a1 1 0 01-2 0v-5a1 1 0 010-2h2a1 1 0 011 1z\"></path></symbol><symbol viewBox=\"0 0 20 23\" id=\"transcripts\"><path d=\"M12.98 7.9a1 1 0 00.14-.12l5.66-5.66A1 1 0 0017.36.71l-5.08 5.08-3.16-3.15a1 1 0 00-1.08-.23 1 1 0 00-.68.3L1.71 8.36a1 1 0 101.41 1.42l5.16-5.16 3.28 3.28a1 1 0 001.41 0zM1 13a1 1 0 100 2h18a1 1 0 100-2H1zm0 4a1 1 0 100 2h18a1 1 0 100-2H1zm-1 5a1 1 0 011-1h8a1 1 0 110 2H1a1 1 0 01-1-1z\"></path></symbol><symbol fill=\"none\" id=\"warning\"><path d=\"M18 36a18 18 0 1 0 0-36 18 18 0 0 0 0 36z\" fill=\"#C9392C\"></path><path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M19.7 9.7a2 2 0 0 0-3.4 0L8.2 22.97A2 2 0 0 0 9.92 26h16.16a2 2 0 0 0 1.7-3.04L19.72 9.7zm-.46 7.51v-3.94h-2.11v3.94c0 .43.02.85.08 1.27.05.41.12.83.2 1.26h1.54c.09-.43.16-.85.2-1.26.06-.42.09-.84.09-1.27zm-2.27 4.56a1.18 1.18 0 0 0 0 .93c.07.15.16.27.27.38a1.4 1.4 0 0 0 .92.34 1.39 1.39 0 0 0 .91-.34c.12-.11.2-.23.27-.38a1.1 1.1 0 0 0 0-.93 1.1 1.1 0 0 0-.27-.37 1.3 1.3 0 0 0-.91-.34c-.18 0-.35.03-.5.1a1.1 1.1 0 0 0-.69.61z\" fill=\"#fff\"></path></symbol></defs></svg></span><div class=\"root\" id=\"root\"><div class=\"wB blA blR blU\"><header class=\"emA fuA dzC hideTopBars\"><nav aria-label=\"Main\" class=\"emB\"><div class=\"juA kaB cfA kaA\"><div class=\"cuA bmDP bmEU juB blA blC blK cuC\" data-test-id=\"grid-container\"><div class=\"juC blA blC\"><div><div class=\"jvA\"><button class=\"jvB blA blC\" data-test-id=\"hamburger-menu-button\" type=\"button\" aria-label=\"Main menu\" aria-controls=\"hamburger-menu\" aria-haspopup=\"true\" aria-expanded=\"false\"><span class=\"jvC bpD\"><span class=\"jvD bpC\"></span></span></button></div></div><a data-test-id=\"logo\" title=\"Home\" aria-label=\"Seeking Alpha - Go to Homepage\" class=\"jsA blA blR\" href=\"/?source=content_type%3Areact%7Csource%3Asite_navigation\"><span class=\"jsH blA blO\"><svg class=\"jsB jsI jsD\"><use xlink:href=\"#logo\"></use></svg></span><span class=\"jsK\">Seeking Alpha - Go to Homepage</span></a></div><div class=\"juC blA blC\"></div></div></div><div class=\"dzB cfA dzC dzA\"><div class=\"cuA bmDP bmEU kyA kyB cuC\" data-test-id=\"grid-container\"><nav aria-label=\"Primary\" class=\"kyC kyD\" data-test-id=\"sub-navigation\"><ul class=\"tuA blU blA blK bmCC\"><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-trending\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"trending\" data-test-id=\"trending\" href=\"/?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Atrending\">Trending</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-my-portfolio\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"my-portfolio\" data-test-id=\"my-portfolio\" href=\"/account/portfolio/summary?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Amy-portfolio\">My Portfolio</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xlA blA blR xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-my-authors\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"my-authors\" data-test-id=\"my-authors\" href=\"/account/people?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Amy-authors\">My Authors</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-top-stocks\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"top-stocks\" data-test-id=\"top-stocks\" href=\"/screeners?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Atop-stocks\">Top Stocks</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-latest-news\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"latest-news\" data-test-id=\"latest-news\" href=\"/market-news?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Alatest-news\">Latest News</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-markets\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"markets\" data-test-id=\"markets\" href=\"/market-outlook?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Amarkets\">Markets</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-stock-ideas\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"stock-ideas\" data-test-id=\"stock-ideas\" href=\"/stock-ideas?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Astock-ideas\">Stock Ideas</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-dividends\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"dividends\" data-test-id=\"dividends\" href=\"/dividends?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Adividends\">Dividends</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-etfs\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"et-fs\" data-test-id=\"et-fs\" href=\"/etfs-and-funds?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Aet-fs\">ETFs</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-education\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"education\" data-test-id=\"education\" href=\"/education?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Aeducation\">Education</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li><li class=\"bbzD blW\"><div class=\"xmA blA blC xmM bbzA bmC bmB1 bm0 bmBL\"><div class=\"ttA bbzC xmB\" data-test-id=\"head-nav-link-button-watch-and-listen\"><div class=\"bihB blA blC\"><a class=\"bnqA blA blC\" aria-expanded=\"false\" aria-haspopup=\"true\" data-scroll-id=\"watch-listen\" data-test-id=\"watch-listen\" href=\"/podcast?source=content_type%253Aall%257Cfirst_level_url%253Ahome%257Csection%253Anavbar_header%257Csection_asset%253Awatch-listen\">Watch &amp; Listen</a></div><div class=\"xmD ttD bmH bmB6 bmW bmBH bbzB xmO\" style=\"transform:translate3d(0px, 0px, 0px)\"></div></div></div></li></ul></nav></div><div class=\"dzF\"></div><div></div></div></nav></header><main class=\"wD blA blR blU cfA wE\" id=\"content\"><div class=\"jB\"></div><div class=\"cA blA blR blU cardsLayout\"><div class=\"cpA blA blR blU\"><article class=\"cuA bmDP bmEU knA cuE\" data-test-id=\"article-page\"><script type=\"application/ld+json\">{\"@context\":\"https://schema.org\",\"@type\":\"NewsArticle\",\"mainEntityOfPage\":{\"@type\":\"WebPage\",\"@id\":\"https://seekingalpha.com/article/4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript\"},\"author\":{\"@type\":\"Person\",\"name\":\"SA Transcripts\",\"url\":\"https://seekingalpha.com/author/sa-transcripts\"},\"publisher\":{\"@type\":\"Organization\",\"name\":\"Seeking Alpha\",\"logo\":{\"@type\":\"ImageObject\",\"height\":60,\"url\":\"https://seekingalpha.com/samw/static/images/PublisherLogo.1a0fb372.png\",\"width\":360}},\"datePublished\":\"2022-02-04T17:54:04.000Z\",\"dateModified\":\"2022-02-04T17:54:05.000Z\",\"description\":\"BellRing Brands, Inc. (NYSE:NYSE:BRBR) Q1 2022 Earnings Conference Call February 4, 2022 10:30 AM ETCompany ParticipantsJennifer Meyer - Investor RelationsDarcy Davenport - President and...\",\"headline\":\"BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript\",\"about\":[{\"@type\":\"Corporation\",\"name\":\"BellRing Brands, Inc.\",\"tickerSymbol\":\"NYSE:BRBR\",\"url\":\"https://seekingalpha.com/symbol/BRBR\"}],\"image\":{\"@type\":\"ImageObject\",\"url\":\"https://seekingalpha.com/samw/static/images/DefaultArticleImage.f1f9250c.png\",\"height\":1200,\"width\":1200}}</script><div class=\"mnA mnK mnE mnI\" data-test-id=\"grid-row\"><div class=\"mlB mlDX\" data-test-id=\"grid-col\"><div class=\"siA fuA bpA\" data-test-id=\"left-rail\"><div></div></div></div><div class=\"mlB8 mlDX\" data-test-id=\"grid-col\"><div class=\"\" data-test-id=\"article-section\"><section class=\"shA blA blK blR gaA bmDP bmEU isB isJ bmN isK isC bmF8\" data-test-id=\"card-container\"><div class=\"isO blA blN\"><div class=\"isM\"><div class=\"ulA bmL bm5 bmBQ\"><div class=\"ulB bmGK\"><a data-test-id=\"logo\" title=\"Home\" class=\"jsA blA blR\" href=\"/?source=content_type%3Areact%7Csource%3Asite_navigation\"><span class=\"jsH blA blO\"><svg class=\"jsB jsJ jsD\"><use xlink:href=\"#logo\"></use></svg></span></a></div><header class=\"bcqA blA blD blK blR\"><div class=\"znB bmGI blA blC blI\"><div class=\"bgqA\" data-test-id=\"themes-list\"><ul class=\"bgqB blA\"><li class=\"bgqC blA blC bmF8\"><a data-test-id=\"theme-links-item\" class=\"fkA bixA fkF bm2 bmBN ciI ciX ciD\" href=\"/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle\"><span class=\"bgqD oqC\">Transcripts</span></a></li><li class=\"bgqC blA blC bmF8\"><a data-test-id=\"theme-links-item\" class=\"fkA bixA fkF bm2 bmBN ciI ciX ciD\" href=\"/earnings/earnings-call-transcripts?sector=consumer-goods&amp;source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Aconsumer-goods%7Cfirst_level_url%3Aarticle\"><span class=\"bgqD oqC\">Consumer</span></a></li></ul></div><button aria-expanded=\"false\" aria-label=\"Share options\" class=\"ioC ioA blW blA blC blH ioL ciK ciZ ciA ioG znA\" data-test-id=\"custom-share-button\" type=\"button\"><span class=\"ioP icA\"><svg viewBox=\"0 0 18 18\" xmlns=\"http://www.w3.org/2000/svg\" class=\"znC bmD0\"><path d=\"M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z\"></path></svg></span></button></div><div class=\"zsB blA blK\"><h1 class=\"zsA bmGI ciQ ciBA ciD ciCE ciDZ ciEH\" data-test-id=\"post-title\">BellRing Brands, Inc. (BRBR) CEO Darcy Davenport on Q1 2022 Results - Earnings Call Transcript</h1></div><div class=\"zsC blA blK bmGI ciJ ci0 ciA\" data-test-id=\"post-page-meta\"><div><span class=\"zsD zsF bpB\" data-test-id=\"post-date\">Feb. 04, 2022 12:54 PM ET</span><span class=\"zsF bpB\" data-test-id=\"post-primary-tickers\"><a class=\"bndA\" href=\"/symbol/BRBR?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3ABRBR\">BellRing Brands, Inc. (BRBR)</a></span></div></div></header><div class=\"bfjA\"><div class=\"bjaD blA blD blK bmGI\" data-test-id=\"author-brief\"><div class=\"bjaF blA\"><a class=\"bjaA bhwA\" href=\"/author/sa-transcripts?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Aauthor%7Cbutton%3Aavatar\"><div class=\"qxA blA blC blH qxF\"><img alt=\"SA Transcripts profile picture\" class=\"qxB blA blC blH\" data-test-id=\"user-pic\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\"></div></a><div class=\"bjaE blA blH blR bmD2\"><a class=\"bjaA bhwA bjaB ciK ciZ ciD bmF4 bhwB\" data-test-id=\"author-name\" href=\"/author/sa-transcripts?source=content_type%3Areact%7Cfirst_level_url%3Aarticle%7Csection%3Aauthor%7Cbutton%3Aname\">SA Transcripts</a><div class=\"bjaG blA blM\"><div class=\"bfeA ciI ciX ciA bjaC bpB ciI ciX ciA\">126.44K Followers</div></div></div></div><button data-state-text=\"Unfollow\" data-test-id=\"follow-button\" class=\"fkB ceA fkH bm2 bmBN ciJ ciY ciD weA bmG bmB5 bm5 bmBQ bgpA blW bjaH bmDP fuA\" type=\"button\"><span class=\"\">Follow</span></button></div></div><div><div class=\"niA blA\" data-test-id=\"article-content\"><div class=\"niB blU\"><div class=\"niH\" data-test-id=\"content-container\"><p>BellRing Brands, Inc. (<span class=\"ticker-hover-wrapper\">NYSE:<a href=\"https://seekingalpha.com/symbol/BRBR\" title=\"BellRing Brands, Inc.\">BRBR</a></span>) Q1 2022 Earnings Conference Call February 4, 2022 10:30 AM ET</p> <p><strong>Company Participants</strong></p> <p>Jennifer Meyer - Investor Relations</p> <p>Darcy Davenport - President and Chief Executive Officer</p> <p>Paul Rode - Chief Financial Officer</p> <p><strong>Conference Call Participants</strong></p> <p>Andrew Lazar - Barclays Capital</p> <p>Pamela Kaufman - Morgan Stanley</p> <p>Jason English - Goldman Sachs</p> <p>Jim Salera - Stephens, Inc.</p> <p>Bill Chappell - Truist Securities</p> <p>Christopher Growe - Stifel Nicolaus</p> <p>Rob Dickerson - Jefferies</p> <p>Kenneth Zaslow - Bank of Montreal</p> <p>Kaumil Gajrawala - Credit Suisse</p> <p>John Baumgartner - Mizuho</p> <p>Bryan Spillane - Bank of America</p> <p><strong>Operator</strong></p> <p>Welcome to BellRing Brands' First Quarter 2022 Earnings Conference Call and Webcast. Hosting the call today from BellRing Brands are Darcy Davenport, President and Chief Executive Officer; and Paul Rode, Chief Financial Officer.</p> <p>Today's call is being recorded and will be available for replay beginning at 1:30 p.m. Eastern Time. The dial-in number is (800) 839-8318. No pass code is required.</p> <p>At this time, all participants have been placed in a listen-only mode. It is now my pleasure to turn the floor over to Jennifer Meyer, Investor Relations of BellRing Brands, for introductions. You may begin.</p> <p><strong>Jennifer Meyer</strong></p> <p>Good morning, and thank you for joining us today for BellRing Brands' first quarter fiscal '22 earnings call. With me today are Darcy Davenport, our President and CEO; and Paul Rode, our CFO. Darcy and Paul will begin with prepared remarks, and afterwards, we'll have a brief question-and-answer session. The press release and supplemental slide presentation that support these remarks are posted on our Web site in both the Investor Relations and the SEC filings sections at bellring.com. In addition, the release and slides are available on the SEC's Web site.</p> <p>Before we continue, I would like to remind you that this call will contain forward-looking statements, which are<span class=\"paywall-full-content\"> subject to risks and uncertainties that should be carefully considered by investors as actual results could differ materially from these statements. Additional information regarding these risks and uncertainties is discussed under the Forward-Looking Statements section in the press release we issued yesterday and other press releases we have issued with respect to Post's proposed distribution of its interest in BellRing Brands, which are posted on our Web site.</span></p> <p class=\"paywall-full-content\">We also urge you to read both the registration statements, the proxy statement, and prospectuses, the related amendments of these filings and other documents related to the proposed distribution of Post interest in BellRing Brands that have been and will be filed with the SEC when they become available, because they will contain important information. These forward-looking statements are current as of the date of this call, and management undertakes no obligation to update these statements. As a reminder, this call is being recorded, and an audio replay will be available on our Web site.</p> <p class=\"paywall-full-content\">And finally, this call will discuss certain non-GAAP measures. For a reconciliation of these non-GAAP measures to the nearest GAAP measure, see our press release issued yesterday and posted on our Web site.</p> <p class=\"paywall-full-content\">With that, I will turn the call over to Darcy.</p> <p class=\"paywall-full-content\"><strong>Darcy Davenport</strong></p> <p class=\"paywall-full-content\">Thanks, Jennifer, and thank you all for joining us. Last evening, we reported our first quarter results, and posted a supplemental presentation to our Web site. This presentation is designed to provide more insight into our business, [consumption of] [Ph], and key metrics, and now include both Premier Protein and Dymatize. Our first quarter came in slightly ahead of expectations, with sales of $307 million, and adjusted EBITDA of $60 million. Net sales grew 9% over prior year, led by Dymatize, which was up 41%; Premier Protein grew 5%, both brands benefiting from pricing actions. This single-digit growth for Premier Protein was expected as we lap prior year promotions that aren't repeating.</p> <p class=\"paywall-full-content\">Our adjusted EBITDA margins were healthy despite significant cost headwinds. As you saw in yesterday's press release, we reaffirmed our fiscal '22 guidance for both net sales and adjusted EBITDA to grow between 9% and 13%. Other than a slight shift in Dymatize sales from second quarter into first, we don't expect major deviations to the cadence we communicated last quarter. Not surprisingly, inflation ramped up across freight and dairy proteins this quarter. As a result, we announced further price increases on shakes and powders, which will mainly benefit the second-half of the year. We expect Q2 sales to be similar to Q1, and to sequentially grow, reflecting the incremental pricings actions and new capacity.</p> <p class=\"paywall-full-content\">We will experience margin pressure in Q2 until the price increases are implemented. Overall, we believe the balance of the year leans toward upside, however we have seen how quickly circumstances can change in this environment. While our confidence in the year has grown, at this point we are reaffirming our guidance. The key drivers that would add opportunity or risk to the year are our ability to deliver our expected production, elasticity relating to upcoming pricing actions, and additional inflation.</p> <p class=\"paywall-full-content\">Now turning to our category brand highlights and updates on capacity expansion. We continue to see robust growth in the convenient nutrition category. Ready-to-drink beverages and ready-to-mix powders both grew 17% versus year ago. Strong consumer tailwinds around wellness and healthier food solutions are driving this growth. RTD beverages added 2.3 points to household penetration, and saw growth in purchase size and volume. Ready-to-mix powders continue to be fueled by an increased interest in proactive health and fitness. Our brands are growing despite supply chain challenges.</p> <p class=\"paywall-full-content\">Premier Protein shake consumption grew 10% across tracked and untracked channels, with ecommerce and mass leading the way. Brand metrics remained strong, demonstrating our high consumer loyalty. Household penetration and repeat rates are holding steady, and velocities are at 45% versus year-ago. Our TDPs have started to rebound as we have increased trade inventory levels this quarter. Despite these encouraging signs, we expect Premier Protein RTD shake consumption, in Q2, to lag prior year because we're lapping significant promotional periods.</p> <p class=\"paywall-full-content\">Moving to Dymatize, Dymatize had a fantastic quarter, with consumption in the U.S. up 48% across tracked and untracked channels. All key channels contributed with double-digit growth, and brand velocities remained strong. Dymatize ISO100 launched two exciting new flavors this quarter: Dunkin' Cappuccino and Mocha Latte, both flavors which were co-developed with Dunkin are off to a great start.</p> <p class=\"paywall-full-content\">Our operating environment remains challenging. Supply chain disruptions largely around labor availability at our existing co-manufacturers are impacting our ability to rebuild inventory as fast as we want. First quarter production came in slightly below our expectations mainly due to COVID-driven labor shortages. However, we are encouraged with the improvement in January.</p> <p class=\"paywall-full-content\">Our capacity expansions are progressing well and remain on track. As you may remember, we have capacity coming online each quarter starting Q2. We are comfortable with our ramp up assumptions despite COVID-related challenges. We also made significant progress identifying and vetting additional growth partners who are expected to bring on capacity in fiscal '23 and '24. Finally, I would like to share a brief update on Post distribution of its interest in BellRing.</p> <p class=\"paywall-full-content\">Overall, the transaction remains on track. We have scheduled a special meeting of BellRing stockholders on March 8th to vote on the transaction. Post will announce additional details about the spin-off in coming weeks. We believe upon completion of the transaction, BellRing will have increased strategic flexibility to manage our capital structure and should benefit from more liquidity in our shares.</p> <p class=\"paywall-full-content\">In closing, we all have been tested over the last two years. I have been impressed by how our employees, manufacturing, and logistics partners and customers have navigated this period. I believe we will look back on '22 as a pivotal year for our brands and our company; one where we solidified the foundation of the business so we can really see what our brands are capable in the future. I continue to believe that we are in the early innings of our category and brand's growth. Premier Protein and Dymatize are perfectly positioned to attract households into the category and improve consumer's health along the way.</p> <p class=\"paywall-full-content\">Thank you and I look forward to updating you on our progress throughout the year. I will now turn the call over to Paul.</p> <p class=\"paywall-full-content\"><strong>Paul Rode</strong></p> <p class=\"paywall-full-content\">Thanks, Darcy, and good morning, everyone. Net sales for the quarter were $306.5 million, up 8.5%. Adjusted EBITDA was 59.8 million, a slight decline to prior year. And EBITDA margin was 19.5%. Premier Protein net sales grew 4.5% driven by higher average net selling prices reflecting reduced promotional activity and price increases. Recall while we face capacity constraints, we have temporarily reduced tetra shake SKUs and promotional marketing.</p> <p class=\"paywall-full-content\">This resulted in expected volume declines for Premier Protein in the quarter. Despite this decline, shipment exceeded consumption in the quarter and resulted in increased retail inventory. Dymatize net sales grew 41% with volumes up 8%. Net sales outpaced volume growth benefiting from higher average net selling prices which reflected price increases and a favorable mix.</p> <p class=\"paywall-full-content\">Strong velocities and distribution gains drove volume growth. Gross profit of 92 million was flat to last year with a decrease in gross profit margin to 30.1%. The gross margin decline results from higher dairy protein cost as well as increased freight which was mitigated by higher net selling prices. SG&amp;A expenses of $37 million included 2 million of separation cost.</p> <p class=\"paywall-full-content\">Prior year SG&amp;A expenses include 4.6 million restructuring and facility closure cost. Both items were treated as adjustments for non-GAAP measures. Excluding these items, SG&amp;A increased 1 million and was favorable 50 basis points as percentage sales. Our cash flow in the first quarter was unfavorably impacted by higher working capital, a decrease in payables, and an increase in powder inventories brought these results.</p> <p class=\"paywall-full-content\">We expect further working capital increases throughout the year as we rebuild our RTD shake inventory levels. During the quarter, we have an attractive entry point and repurchased 800,000 shares of class A common stock at an average price of $23.34 per share. Our remaining share repurchase authorization is 42 million. As of December 31, net debt was 489 million and net leverage was 2.1x. During the first quarter, we repaid debt of 90 million using cash on hand.</p> <p class=\"paywall-full-content\">Turning to our outlook, we are maintaining our guidance for net sales 1.36 to 1.41 billion and adjusted EBITDA of 255 to 265 million. As Darcy highlighted, the year is progressing slightly ahead of expectations with net sales and adjusted EBITDA growth weighted to the second-half. Inflation has outpaced our initial estimates, so we expect additional cost headwinds for both shakes and powders.</p> <p class=\"paywall-full-content\">However, we are executing a price increase to help offset these impacts which will benefit gross margins in the second-half. During the second quarter, we expect high single digit net sales growth as higher net pricing and volume growth for our powder portfolio is partially offset by volume declines in RTD shakes as we lacked promotional activity.</p> <p class=\"paywall-full-content\">We expect adjusted EBITDA to grow significantly from prior year benefiting from the pullback of promotions and marketing. Second quarter adjusted EBITDA is expected to decline sequentially driven by inflation ahead of pricing as well as modestly higher SG&amp;A.</p> <p class=\"paywall-full-content\">Finally, as Darcy mentioned, Post's distribution of its interest in BellRing remains on track. We expect approximately $400 million of cash will be distributed to BellRing's stockholders, including Post. As a result, we expect net debt of BellRing will increase to an amount not to exceed four times adjusted EBITDA. More details will be provided over the coming weeks.</p> <p class=\"paywall-full-content\">In closing, we are encouraged by the solid start to the fiscal year. While we and our industry are facing short-term challenges and historical inflation, our optimism and outlook for our business has never been brighter.</p> <p class=\"paywall-full-content\">I will now turn it over to the operator for questions.</p> <p id=\"question-answer-session\" class=\"paywall-full-content\"><strong>Question-and-Answer Session</strong></p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">[Operator Instructions] We will take our first question today from Andrew Lazar with Barclays. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Andrew Lazar</span></strong></p> <p class=\"paywall-full-content\">Good morning, everybody.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Andrew Lazar</span></strong></p> <p class=\"paywall-full-content\">Yes, thanks for the question. I guess first off, I know that, Darcy, you've referred to 2021 as kind of a year where BellRing sort of had almost two years of growth sort of compressed into one year. And a lot of that had a lot to do with, well, of course having the capacity, but also a lot of the incremental shelf space gains in a lot of key -- sort of key customers that you benefited from. I'm curious if you could kind of maybe characterize how that looks as we go through this year? Are there major shelf reset windows where you think there can still be incremental progress made? And, obviously, how does the capacity situation play into your ability to sort of take advantage of those windows? But I'm assuming others are having sort of similar issues as you are. And then I've just got a follow-up.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Sure. So, that right now, as you know, we reduced our skews, our tetra skews this year because of our capacity constraints. We have been able to hold, for the most part, about 90% of our space. Basically, customers are spreading out our facing on our core items because they're one of the most productive skews on the shelf. So, we're not in a place right now that, for the next year, we're going to be expanding our shelf space on our tetra skews. What's, I think, encouraging is we do have some innovation coming on outside of the 30-gram line toward the end of the year. But for the most part, this year, as it's a catch-up year for the 30-gram shake line. And so, we're not going to be expanding shelf space considerably.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Andrew Lazar</span></strong></p> <p class=\"paywall-full-content\">Got it. And then I think when you took some of the initial price increases heading into this year, at least for planning purposes, you had assumed that competitors would not necessarily follow, so it was kind of a prudent, conservative stance heading in. I guess, are you making a similar assumption with some of the incremental pricing that you're taking or -- and how do you think about your elasticity assumptions for this next round of pricing, at least from how you're forecasting and modeling it internally? Thanks so much.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">We are. We're assuming that we included some modest elasticity in our assumptions, so staying on the conservative side. In our first round, we tended to be the first to move on pricing in the category, and then most competitors followed fairly soon afterwards. But we have an approach to when we take pricing, we assume elasticity. And then when we see what happens in the marketplace place we adjust those assumptions.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Andrew Lazar</span></strong></p> <p class=\"paywall-full-content\">Thank you.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Thanks.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">The next question comes from Pamela Kaufman with Morgan Stanley. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Pamela Kaufman</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Pamela Kaufman</span></strong></p> <p class=\"paywall-full-content\">You mentioned that production in the first quarter was slightly below expectations. Can you talk about how much of your fiscal '22 top line outlook is dependent on additional capacity coming online over the next few quarters? And it seems like the balance has shifted more towards pricing now given the incremental pricing you've taken in the quarter. So, is that kind of the right way to think about the composition of your top line outlook for the year?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">So, I'll hit the first -- the production question first. The production below expectations in Q1 was related to -- it was mostly in our existing co-manufacturers. So, the new capacity that is coming online starts in Q2.</p> <p class=\"paywall-full-content\">And then, your question around how much is associated with existing versus new, the vast majority of our production this coming year is from existing co-manufacturers. I think what's encouraging is that we are seeing an improvement in January with our existing co-manufacturers. It really was related to kind of the Omicron variant, and having absences, we are still seeing some absences, but what's encouraging in January is despite the fact that we are seeing absences and in kind of labor shortages, we're still getting the production. So, that tells me that we're being prioritized over other customers. So, that was the first one.</p> <p class=\"paywall-full-content\">The second piece is just the composition of our growth. It depends on which brand we're talking about. From a Premier standpoint, the growth was predominantly coming from pricing, originally, and that was good, that will obviously be the case, with our upcoming incremental pricing that we took, that we announced this quarter. But from Dymatize, it's a mix. So, it's a mix between volume and pricing.</p> <p class=\"paywall-full-content\">Paul, anything else that you wanted to add?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">So, obviously, with the price increase, that does obviously push a bit more towards pricing, but as Darcy talked about in her prepared remarks, the increases obviously gives us confidence in the year, but we're waiting to kind of see how things play out with less disease, and those kinds of things. But it gives us obviously a lot of confidence.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Pamela Kaufman</span></strong></p> <p class=\"paywall-full-content\">Thanks. And given some of the supply challenges in tetra packs, have you explored other options for packaging? I know you also sell bottled RTDs. Can you more meaningfully shift your mix to that format?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">So, we do have bottles. But bottles are constrained too, so it's really across the end, because of the dramatic demand increase that happened last year, both bottles and tetras are constrained. So, it's not as easy, and our tetra business is so large that the idea of just shifting to another package size is just -- it's just not feasible. I think we are moving. We're making some kind of co-man shifts on our bottle business, which will dramatically increase our ability to satisfy the increasing demand for our bottles. So, again, it's not as easy as just shifting, but I am confident in our increase that we have planned from a tetra standpoint. It's later in the year and then into '23, and like I said, bottles are also increasing.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Pamela Kaufman</span></strong></p> <p class=\"paywall-full-content\">Thank you. Our next question comes from Jason English with Goldman Sachs. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jason English</span></strong></p> <p class=\"paywall-full-content\">Hey folks, good morning. Thanks for stepping me in.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Good morning, Jason.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jason English</span></strong></p> <p class=\"paywall-full-content\">I've got couple of questions. First, you all confused me on some of the comments and guidance, it was probably my fault as I'm distracted over here, I'm trying to juggle too many balls. But can you go back and I think you said sales, similar Q1 to Q2 but sequentially growing, which seemed like they can coexist? And then there was also some comments on EBITDA which sounded upbeat, but then you commented sequentially lower on price cost likes, et cetera. Do you kind of come back revisit clarify those to me, please.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Sure, I'll hit the net sales. And I'm going to let Paul hit EBITDA. Net sales you nailed, it's that Q2 similar to Q1 and then sequentially growing and then Paul do you want to talk about EBITDA?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Yes, so, our comments on EBITDA the second quarter, we expect to be sequentially down from the first quarter, which is consistent with our initial expectation going into the year and that is because there is incremental inflation on our proteins primarily. So, to step up from Q1 into Q2 ahead of our pricing, and then we do expect a modest increase in SG&amp;A. So, the comment was that EBITDA will be sequentially down from Q1.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jason English</span></strong></p> <p class=\"paywall-full-content\">Yes, but it always kind of is with seasonality, but was there a year-in-year comment in there though that I missed too?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">There was not year-over-year obviously there's, it's a different dynamic because in last year in the second quarter, it is almost the second quarter we've promoted heavily in the second quarter typically, that is not the case this year. So, there's a benefit on pricing both from reducing the promotion spend, as well as the list price increases that we took on powders in October and back on shakes back in April. So, we have the benefit of pricings. But we also have significantly higher inflation in the second quarter versus last year in particular; whey protein was at its low point, which is our powder product in the second quarter of last year. And it's significantly higher this year. So, that's the dynamics going on with EBITDA.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jason English</span></strong></p> <p class=\"paywall-full-content\">Got it, okay.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">It is lower because of marketing spend. So, that is the one piece I did miss to mention is that we're also, we typically spend pretty heavily in marketing in the second quarter, because we do TV advertising, and we're not planning to do that this year. So, that's another element of EBITDA increase from last year, but again sequentially down to Q1.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jason English</span></strong></p> <p class=\"paywall-full-content\">Understood, and bigger picture question for you, Darcy, I remember around the time of separation, you talked about your aspirations to have Premier reach, I think curtain from on those but perhaps reach a 10% sort of penetration level. The penetration growth I'm looking at for the brand has been phenomenal. I think it's actually accelerated during COVID. And you're now north of 8%, so are we approaching sort of an upward governing limit of where you think this can go or is there now more scope for penetration growth as perhaps you're envisioning just a few years ago?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes, I think this brand continually surprise us. I think that not only do I think that there's more upside from a category standpoint, but we're increasing our penetration faster than I would have predicted. So, yes, I think that, we're going to, I believe that we can get up to I mean, so one of the -- some of the comparisons I have used are some of the mainstream brands like [Clif and Kind] [Ph] in the nutrition bar space. And they are right above 10%, 11%, 12% and so I use that as a barometer. And I still use that as a barometer of where we can get to, you know, the kind of medium-term.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jason English</span></strong></p> <p class=\"paywall-full-content\">Got it. Okay, thank you. I'll pass it on.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Thanks.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">We'll go now to Ben Bienvenu with Stephens. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jim Salera</span></strong></p> <p class=\"paywall-full-content\">Hey, guys, good morning. Jim Salera on for Ben, I wanted to ask a little bit on the production side and inflation, how long of a lead time will there'll be to get fill rates and service levels back to normal, assuming the Omicron production kind of shakes out in the second quarter. So, it actually is normal at the end of the second quarter to fill rates get back to normal levels in the third quarter, fourth quarter, that's still looking into the next year?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes, our fill rates and service levels will continue to increase. We are already seeing kind of month on month, small increases. And we'll continue to see that throughout the year, I think we'll be in a much. I mean this quarter, our trade inventory levels improved. And again we'll continue to see that by, I would say Q3 they're going to look a lot better, beginning of Q3, they're going to be looking a lot better.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jim Salera</span></strong></p> <p class=\"paywall-full-content\">Thank you. And in fact I could ask one more, you guys have any visibility into freight costs in the back half of the year, whether it's you anticipated to be kind of where it's been at for the first-half, it's going to go up maybe a little bit late there?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Yes, we do expect the freight will go up into the third quarter. And then based on the evidence we've seen, it kind of flattens out at that point. And so from a year-over-year perspective, we have more of a headwind in the first-half than we have in the second-half. So, that's our current thinking.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Jim Salera</span></strong></p> <p class=\"paywall-full-content\">Got it, thanks, guys. I will pass it on.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Thank you.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">The next question comes from Bill Chappell with Truist Securities. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Bill Chappell</span></strong></p> <p class=\"paywall-full-content\">Thanks. Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Bill Chappell</span></strong></p> <p class=\"paywall-full-content\">Hi, Darcy, I guess this goes on Premier Protein. What do you envision elasticity looks like in that category as you rise prices, because it means you have a highly loyal base and a pretty high market share within the drinks side of it. Are people just buying less general, if they are -- there's elasticity, are they switching to lower priced brands? Are they switching to some other form, just try to understand I mean it doesn't seem like there would be a whole lot of elasticity especially with your base but I assume you're factoring some in one way or the other with higher prices?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Today, we have seen no elasticity. We have been watching it and basically we increased price and volume went up. However, we are not assuming that's going to continue. So, we are assuming some modest elasticity until we see it in marketplace and kind of the facts and circumstances that we see in the marketplace based on what competitors do, et cetera. How much the retailer reflects that shelf, then we will make any adjustments to our assumptions.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Bill Chappell</span></strong></p> <p class=\"paywall-full-content\">Okay. Thanks. And then, just look kind of on that -- on the cost front. You're trying to understand for lack of better term, so how much of this is short-term in nature, but certainly everything from labor to freight to -- but when it's coming from the co-man, how much do you think rolls off as the commodities get better in six months or conversely laborers kind of here to stay at a higher rate. Any thoughts there in terms of as you're thinking about, kind of profitability going forward?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Yes, so I've written into two pieces. So, from a commodity front, what we're seeing is Whey protein and even milk proteins are at historical highs. Whey protein has been pretty tight, the supply and demand dynamic and so that, that's got to get better, but it doesn't look like it's likely until fiscal '23 or early that's the kind of the current thinking. So, I do think there's some opportunity to us obviously as we get on the other side, because we're kind of protein rates on our powder business that are 2x or plus what they were just a year ago. So, that's got to come back down. So, obviously that's one element, no protein, but kind of steadily going up besides our shakes and so that that was -- that one, we'll have to keep an eye on, but it seems like both those markets should come back down. So, it seemed like there should be a transitory piece of that on our co-mans, your relationships, they're typically long-term contracts and I don't want to get into specifics because it varies by customer, but we're a little bit insulated from that, but as labor costs obviously stay high. It will obviously get absorbed at some point as it's passed along to us, but that's totally that the production cost is somewhere 15%-20% of our overall cost, which really the commodities that are driving the profitability.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Bill Chappell</span></strong></p> <p class=\"paywall-full-content\">Got it. Thanks so much for the color.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">We'll go now to Chris Growe with Stifel. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Christopher Growe</span></strong></p> <p class=\"paywall-full-content\">Thank you. Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Christopher Growe</span></strong></p> <p class=\"paywall-full-content\">Hi, I just had a quick question for you and sorry if I missed this, but have you said just to get an order of magnitude on the size of the price increases you have in place the new ones for shakes and for powders?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Go ahead Darcy, go ahead. Sorry.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">You can tell we're not together. That so the second round of pricing is slightly higher than the ones we took before. We didn't specifically just add order of magnitude. The first one was single digits on premier protein double-digits on Dymatize. And this round is slightly higher than that.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Christopher Growe</span></strong></p> <p class=\"paywall-full-content\">Okay. And that's most significant, something in the third quarter kind of going in place during the second quarter. Is that right?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Correct.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Correct.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Christopher Growe</span></strong></p> <p class=\"paywall-full-content\">Okay. And then, I just was curious. You have a chart in your, the slide deck around showing TDPs and how they started to increase. So, I just want to get a sense of, it sounds like your -- the supply of product was a little below what you thought, doesn't mean it didn't grow, obviously it did grow, the more available, does that line keep going up to -- do you keep -- continue to see an increase in TDPs as you get more and more supply availability. I guess that's what's going to determine that, rebuild there?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes. I mean, generally. I think there will be. So, you'll see a slight increase as our fill rates and service levels increase. However, we do expect TDPs to be down versus year ago because of that temporary reduction SKUs.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Christopher Growe</span></strong></p> <p class=\"paywall-full-content\">Yes. Okay. And I guess just to be clear on that, then this is I'm thinking like for the second quarter. If you're promoting less, that presumably would negatively affect TDPs. Again, not that it can't grow, but it would certainly have a year-over-year effect on TDPs, is that right?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">I mean, the promotion won't have anything to do with the TDPs, if I'm understanding your question, but just the number of SKUs on the shelf, so -- </p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Christopher Growe</span></strong></p> <p class=\"paywall-full-content\">Yes.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">We will see. So, I mean that is really what's affecting the TDPs.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Christopher Growe</span></strong></p> <p class=\"paywall-full-content\">Okay, I got it. Thank you.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Thanks.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">We will go now to Rob Dickerson with Jefferies. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Rob Dickerson</span></strong></p> <p class=\"paywall-full-content\">Great, thanks. Just have a quick question on the inventory side. Darcy, you're saying, it sounds like basically, maybe all production this year started from existing suppliers, sounds like maybe some of them are getting a little bit better as you kind of get through to consumption still obviously, up decently, volumes are down, say when that's a gap. So, I'm just curious like, kind of in terms of the inventory situation you have with retailers, when we compare that with the reduction SKUs, it's like, you feel like you're in a pretty good place as you look forward through the year. Right, like you've reduced the SKUs. They really recharge or burning for a little bit inventory, but as you right size the SKU is relative to your capacities, like there shouldn't be kind of further decline, right, just given that a blower capacity relative to consumption demand, like if that catches jobs you know, what I mean.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">So Rob, are you asking about? I mean, I would say our strategy is sound, meaning that we do not expect any change to the number of SKUs that we're going to have and we believe that the fill rate and service levels will continuously increase throughout the year. We will also gradually increase our safety stock throughout the year. Is that what you're asking?</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Rob Dickerson</span></strong></p> <p class=\"paywall-full-content\">Yes, I just want to make sure that you reduce the SKUs, right. If you've looked in, you forecasted yourself that the amount of capacity you have.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Rob Dickerson</span></strong></p> <p class=\"paywall-full-content\">Should be able to continue to sell those SKUs that you plan to have on shelf this year.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes. That, yes. Absolutely, that's correct. The one thing I will just know is that when you're looking at consumption, we have pretty high, we have some high highs and we've increases when we have promotions. And so, when you're looking at consumption, you'd have to factor in that you're going to see some negatives on premiere, when we're lacking promotions. And that is expected. And so I think that, it's just, it's good to have that in the back of your mind when you're looking at the kind of track channel consumption on a week-to-week basis.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Rob Dickerson</span></strong></p> <p class=\"paywall-full-content\">Okay, fair enough. And then, I guess back to Jason's question quickly, there's a lot in there to kind of EBITDA sequentially. And what have you -- I mean, it's like, if we're thinking about Q2, just in absolute EBITDA dollars, would you say that maybe kind of similar to sales sequentially from Q1 to Q2, that maybe EBITDA would see like a similar absolute dollar number. I mean, I know you're not specifically guiding to that number, but obviously with just kind of where the full-year EBITIDA guide is, right, it does imply material back half improvement?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">So no, I would not quite characterize it that way. So, we, just to be clear, we expect the EBITDA to decline sequentially from Q1 to Q2. We expect it to be higher than last year because we're lacking a lot of marketing that we do expect it to decline and that is, again because of higher inflation. And so, that day is the primary piece, but now we expect it to be down. Keep in mind that we've said that, we expect that sales and EBITDA growth will be weighted to the second-half of the fiscal year. We do expect it to be switching down.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Rob Dickerson</span></strong></p> <p class=\"paywall-full-content\">Right. So, I mean, kind of next year where you came in Q1 and Q2, despite all the moving pieces of volatility. I mean, it seems like the business is still tracking, kind of as you expected coming out of Q4.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes, I mean -- </p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">The first-half is tracking. Yes, the first-half of tracking like we expected with the slight shift of Dymatize sales into Q1 from Q2, but yes, the first-half is tracking as we expected.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">I mean, Rob. I would just say a big picture. This year and going much like we expected, slight movement of sales from Q2 to Q1 and that is just, it's really nothing. It's just a little sales phasing. And then we saw inflation kick up higher than we expected, although we saw the -- we saw that coming on the last call, and therefore we took price and that affects the back half. So, I mean, but all other than the inflation and the pricing action, the cadence is largely what we expected.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Rob Dickerson</span></strong></p> <p class=\"paywall-full-content\">Perfect. Thank you.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Thanks.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">We'll go now to Ken Zaslow with Bank of Montreal. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kenneth Zaslow</span></strong></p> <p class=\"paywall-full-content\">Hi, good morning, guys.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Good morning.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kenneth Zaslow</span></strong></p> <p class=\"paywall-full-content\">Two questions, one is can you walk us through the capacity build over the next 18 to 24 months of how it works exactly how much incremental capacity is coming online, through the next -- on a quarter-by-quarter basis?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes, so basically, we have increased capacity every quarter four through '23. I mean, and so we see increased and that mostly comes from the existing co-mans are pretty stable. So, the increases come from new co-mans, they start slotting in, in Q2 of this year. There is not a huge benefit this year in '22, so let's still call it 90% of our production is coming from existing for '22. But then, those new co-mans start increasing and become contributors, real contributors in '23. Then we also bring on additional co-mans in '23. So, we basically add three new ones in '22. And we add two more in '23. And the big ones, which are new facilities like MFI, we talk to -- sorry, Michael Foods would come on in later '23. They start up later in the year, and so become kind of smaller contributors in '23, but bigger contributors in '24.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kenneth Zaslow</span></strong></p> <p class=\"paywall-full-content\">Would you say that 2023 additional capacity is 5%, 10%, 15%. And then when you get to '24. How would you kind of just do that?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Hold on. I'm calculating.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kenneth Zaslow</span></strong></p> <p class=\"paywall-full-content\">Take your time.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">So, call it less in '22, new capacity is less than 10%, it becomes yes, 20% to 25% of the -- of '23. And then continue -- and then it ramps up from there. And remember, we can still affect, so because some of the new capacity in '23, they're actually new Greenfield facilities, that timeline is basically 24 months. We are still talking to partners for kind of late '23 and '24.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kenneth Zaslow</span></strong></p> <p class=\"paywall-full-content\">Okay. My second question is, if you believe this capacity coming online, you answered an earlier question that you think household penetration kind of you look to certain brands in this 10% and it's 100 basis points from where you are right now, 25% more capacity coming online. You obviously don't really believe that 10% is your high watermark. I mean, that doesn't -- I mean, you obviously believe that you're building capacity because there's demand and that demand is going to take you above that 10% household penetration, I'm assuming. So, again, why would you even know that there is a limit to the demand of what it is, why limit yourself to a household penetration? It seems like you've hit a tipping point and I'm not going to be difficult; it just seems odd to come up with some arbitrary 10% just I don't know, just a thought. I'll leave it there.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes, I totally agree. I completely agree and I don't and by the way, I don't see it as a limit. I think, it is a step along the way. And I truly believe that this brand has -- I think, the category in general is just -- I mean, I said earnings, but it has so much more upside. And I've used this analogy before, but even within our category. nutrition bars have mainstreamed much faster than any other forms within the category and they are at close to 50%. So, 45% household penetration, where our RTD shakes are only at 25, powders or even lower. So, there's no reason why shakes can't get close to nutrition bars. And so I think that the upside is immense. And I think Premier Protein is perfectly positioned to take advantage of that, because it's a mainstream approachable brand that shows that it appeals to kind of every needs, state, and kind of every consumer within the category. So, I do not believe that 10% is the limit at all. I think it's a step along the way.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kenneth Zaslow</span></strong></p> <p class=\"paywall-full-content\">Great, appreciate it.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Thank you.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">We'll go now to Kaumil Gajrawala with Credit Suisse. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kaumil Gajrawala</span></strong></p> <p class=\"paywall-full-content\">Hey, everybody. Good morning. First one a very quick one, when you talk about these capacity additions for '23, '24. Is that fiscal or calendar?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Fiscal.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kaumil Gajrawala</span></strong></p> <p class=\"paywall-full-content\">Fiscal, got it. And then one of the things that we didn't talk about as it relates to capacity is if there were any key ingredients or inputs or materials packaging, that have created bottlenecks. I know in the past they have, I think you mentioned those little foil wrappers, things like that. Is that all resolved now or is it still some areas of things to watch out for?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Yes, there's nothing that's problematic at the moment. We extended lead times early on to try to prevent those things from happening. Yes, we haven't seen any impacts.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Kaumil Gajrawala</span></strong></p> <p class=\"paywall-full-content\">Okay, great. That's all. Thank you.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Thank you.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">Our next question comes from John Baumgartner with Mizuho. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">John Baumgartner</span></strong></p> <p class=\"paywall-full-content\">Good morning, thanks for the question.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Hey, John.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">John Baumgartner</span></strong></p> <p class=\"paywall-full-content\">Maybe first off, hi Darcy, congrats on the time. I'd like to ask about powders against the broader evolution of the category maybe you are moving beyond COVID volatility into the new normal, with work from home and such, and how you think about the role for powder within the category. Have you seen a core consumer for powder change at all pre versus post COVID? How do you see powders and RTD coexisting as powders grow from here and then for BellRing, how can you best I guess make powder products complementary to the RTD business?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Yes, it's a great question. So, I'm going to pick up where I was talking about the potential of our RTDs versus nutrition bars, powders have even lower household penetration than RTDs. So, I think that is and where Premier helped mainstream or has started to help mainstream RTDs, I also believe that powders are at kind of earlier stage of that mainstream trajectory. So, they're different than all of the different forms are have kind of unique occasions. So, if you think of bars are more snacking, RTDs are more meal replacement, although can be used kind of in between meals, but more meal replacement. Well, powders are mostly used with food, with smoothies, after workouts where they're consumed RTDs and nutrition bars mostly on the go, powders at home. So, they're very complementary. And we have been very successful on Premier Protein with powders, obviously, Dymatize is our number one powder brand. Both of them go after unique and complementary consumers. And then of course, as I was saying before they have kind of unique and complementary occasions as well.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">John Baumgartner</span></strong></p> <p class=\"paywall-full-content\">Okay, great. And I guess from supply chain perspective, there's a lot of focus now understandably, on the month-to-month and quarter-to-quarter. But aside from just I guess simply increasing volume availability. Are there opportunities underway here with the changes in supplier base now, I guess through F23, F24 that sort of place you in a better position, either format wise or profit wise to come out of this recalibration with new channels for growth, whether it's out of home C stores in consumption, is there opportunity to sort of affect the change in the composition of your capabilities and channels for the longer-term sort of coming out of this year?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Absolutely, so I think that, I said this in my prepared remarks just about how I think we're going to look back at '21 as a really pivotal year because I think that what we're going to look back on is really kind of laying the foundation, laying the table for kind of outsized growth in the future. Building at where we currently from a production standpoint, for instance, we have five locations now in 4-ish years we will be doubling that. We are expanding our bottle -- our bottle capacity dramatically which will allow us to go -- we can really sell bottles or tetras within kind of convenience and up and down the street et cetera. But we start being able to match products to different places and then expanding our distribution from there. So, yes, I believe this year is more about capability building so then we could take advantage of that in the future.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">John Baumgartner</span></strong></p> <p class=\"paywall-full-content\">Okay. Thanks for your time. Appreciate it.</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Darcy Davenport</span></strong></p> <p class=\"paywall-full-content\">Thank you.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">We will go now to Bryan Spillane with Bank of America. Your line is open.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Bryan Spillane</span></strong></p> <p class=\"paywall-full-content\">Hi. Thanks, Operator. Good morning. I just had one question and it's if you look at fiscal -- we look at the current fiscal year and just the amount of consumer-facing spend that you are anticipating this year, I guess so both promotions and advertising and marketing. What is that relative to normal? And I guess what I am trying to get at is as we move past the supply constraints, how much more marketing would we have to add back as we go forward?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">Yes. So, on the marketing side, I think in '21 we spent around 3% of net sales on what we call advertising promotion. This year we are pulling back on that around 2%. Going forward obviously we want [indiscernible] we also think that will drive top line growth as well as we've seen from our recent past that's it's very -- our products are very receptive to marketing. And so, we think it would drive obviously top line. But, yes, we would expect over the longer term to at least spend back to 3% level and perhaps look to increase that over time as our [indiscernible].</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Bryan Spillane</span></strong></p> <p class=\"paywall-full-content\">Is the order [of magnitude] [Ph] if I remember this correctly at the time of the separation, right, you had been through a supply chain or supply constraints prior to the separation. And then the next fiscal year, margin step back because there was more marketing spend that went in? So, just like order of magnitude will it look like that?</p> <p class=\"paywall-full-content\"><strong><span class=\"answer\">Paul Rode</span></strong></p> <p class=\"paywall-full-content\">No. So, the situation was a little bit different back then. So, we did see fiscal year because fiscal year, I think it was fiscal ['18] [Ph] that had a stepped up margin. But a part of that was too because protein cost had come down so we benefited from a price increase as well as from favorable protein cost. But, no, I don't think our margin structure should be impacted. Obviously, it sometimes depends on what commodities do and we will have to make sure we are right sizing that. At least historical high prices, it gets harder to get back to the gross margins that we had experienced in the past. But, I do think over the long term, things will even out. And we should see gross margins back where they have been historically coming at 33-34 range, which allows us to spend marketing at higher level and promotion.</p> <p class=\"paywall-full-content\"><strong><span class=\"question\">Bryan Spillane</span></strong></p> <p class=\"paywall-full-content\">All right, thank you.</p> <p class=\"paywall-full-content\"><strong>Operator</strong></p> <p class=\"paywall-full-content\">We have no further questions in queue at this time. This will conclude today's program. Thank you for your participation, and you may disconnect at any time.</p></div><div class=\"above_now_read-piano-placeholder niE\"></div></div></div></div><div class=\"piano-paywall-container\"></div><div class=\"below_ad-piano-placeholder\"></div><div></div><div class=\"ziD blA blC bmGM paywall-full-content\"></div><footer class=\"ziA blA blK fuA paywall-full-content\" data-test-id=\"post-footer\"><span class=\"zjA zjB blA blC bmN bmCC bmW bmBH\"><button class=\"bkoA bfaA blA blC bkoC\" data-test-id=\"like-button\" type=\"button\"><svg viewBox=\"0 0 19 16\" xmlns=\"http://www.w3.org/2000/svg\" class=\"bkoE\"><path d=\"M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z\"></path></svg><span class=\"bkoD\">Like</span></button></span><button aria-expanded=\"false\" aria-label=\"Share options\" class=\"ioC ioA blW blA blC blH ioL ciK ciZ ciA ioG\" data-test-id=\"custom-share-button\" type=\"button\"><span class=\"ioP icA\"><span class=\"zjA zjB blA blC bmN bmCC bmW bmBH\"><svg viewBox=\"0 0 18 18\" xmlns=\"http://www.w3.org/2000/svg\" class=\"zjD\"><path d=\"M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z\"></path></svg><span class=\"zjC bmD2\">Share</span></span></span></button><button aria-expanded=\"false\" aria-label=\"Print options\" class=\"ioC ioA blW blA blC blH ioL ciK ciZ ciA ioG\" data-test-id=\"print-dropdown\" type=\"button\"><span class=\"ioP icA\"><span class=\"zjA zjB blA blC bmN bmCC bmW bmBH\"><svg viewBox=\"0 0 14 13\" xmlns=\"http://www.w3.org/2000/svg\" class=\"zjD\"><path d=\"M11.2 0H2.8v2.8h8.4V0zM0 3.5v6.3h2.8v2.8h8.4V9.8H14V3.5H0zm9.8 7.7H4.2V7.7h5.6v3.5zm2.48-4.93h-1.4v-1.4h1.4v1.4z\"></path></svg><span class=\"zjC bmD2\">Print</span></span></span></button><a class=\"zjA zjB blA blC bmN bmCC bmW bmBH ziB\" data-test-id=\"comment-button\" href=\"/article/4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript#comments\"><svg viewBox=\"0 0 16 15\" xmlns=\"http://www.w3.org/2000/svg\" class=\"zjD ziF\"><path d=\"M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z\" fill=\"none\"></path></svg><span class=\"zjC bmD2\">Comment</span></a></footer></div></div></div></section></div></div><div class=\"mlP mlBI mlDX\" data-test-id=\"grid-col\"><div class=\"siB fuA blA blR bmCA\" data-test-id=\"right-rail\"><div></div></div></div></div></article></div></div></main><div class=\"bkA\"></div><div class=\"bkB\"></div></div><div class=\"dA bmG4 bmDP bmEU bmFZ bm1 bmBM blA blI\" id=\"google-one-tap-popup-container\"></div><div class=\"fA bpA\" id=\"px-captcha-wrapper\"><div class=\"fB bmG4 bmDP bmEU bmFZ bmL bmCA\"><div><div id=\"px-captcha\"></div><div><div class=\"fC bmGG\">To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.</div><div class=\"fC bmGG\">Is this happening to you frequently? Please <a href=\"https://seekingalpha.userecho.com/?source=captcha\">report it on our feedback forum.</a></div><div class=\"fC bmGG\">If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.</div></div><div class=\"px-reference-id\"></div></div></div></div></div><noscript><iframe height=\"0\" src=\"https://www.googletagmanager.com/ns.html?id=GTM-PFXR76F\" style=\"display:none;visibility:hidden\" title=\"google-tag-manager\" width=\"0\"></iframe></noscript><script async src=\"/samw/static/js/app.94f9e1ef.js\"></script></body></html>\n"
     ]
    }
   ],
   "source": [
    "url = \"https://seekingalpha.com/article/4484494-bellring-brands-inc-brbr-ceo-darcy-davenport-on-q1-2022-results-earnings-call-transcript\"\n",
    "page = requests.get(url)\n",
    "print(page.text)\n",
    "soup = BeautifulSoup(page.text)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "7ea5bc6c",
   "metadata": {},
   "outputs": [],
   "source": [
    "import codecs\n",
    "\n",
    "f=codecs.open(\"data/article/4507624.html\", 'r')\n",
    "page = f.read()\n",
    "soup = BeautifulSoup(page)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "de5e309d",
   "metadata": {},
   "outputs": [],
   "source": [
    "def found_content_container(tag):\n",
    "    if not tag.has_attr(\"data-test-id\") :\n",
    "        return False\n",
    "    return tag[\"data-test-id\"] == \"content-container\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "56e63ca6",
   "metadata": {},
   "outputs": [],
   "source": [
    "content_container = soup.find_all(found_content_container)\n",
    "if len(content_container) !=1:\n",
    "    raise ValueError(\"Could not found content container\")\n",
    "content_container = content_container[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fe4777f2",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "92160bfa",
   "metadata": {},
   "outputs": [],
   "source": [
    "## work with recent but not old"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "b1d8150f",
   "metadata": {},
   "outputs": [],
   "source": [
    "content_container = soup.find_all(found_content_container)\n",
    "content_container_child = [ child for child in content_container[0].children]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "cd3dca3d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# found first tag in tag content containing text that is operator\n",
    "# hence the start of the transcript\n",
    "\n",
    "index_start=0\n",
    "found = False\n",
    "\n",
    "while not found:\n",
    "    if \"Operator\" in content_container_child[index_start].get_text() :\n",
    "        found = True\n",
    "    index_start+=1\n",
    "    if index_start == len(content_container_child) : \n",
    "        raise ValueError(\"Parser error: start of transcipt not found\")\n",
    "index_start -=1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "314b8cb0",
   "metadata": {},
   "outputs": [],
   "source": [
    "earning_call_transcipt = content_container_child[index_start:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "e6c2dbd7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Operator\n",
      " \n",
      "Good afternoon and welcome to Ardelyx's First Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session after the prepared remarks. As a reminder, today's call is being recorded.\n",
      " \n",
      "I would now like to turn the call over to Justin Renz, Chief Financial Officer of Ardelyx. You may now begin.\n",
      " \n",
      "Justin Renz\n",
      " \n",
      "Thank you and good afternoon, everyone and welcome to our first quarter financial results call. During this call, we will refer to the press release we issued earlier today, which is available in the Investors section of the company's website at ardelyx.com.\n",
      " \n",
      "On the call with me today with prepared remarks are Mike Raab, President and CEO; and Susan Rodriguez, Chief Commercial Officer; Dr. Laura Williams, Chief Medical Officer; Dr. David Rosenbaum, Chief Development Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer, who will join us for the question-and-answer period.\n",
      " \n",
      "During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors in our quarterly report filed on Form 10-Q earlier today, which can also be found on our website at ardelyx.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.\n",
      " \n",
      "With that, let me pass the call over to Mike.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Thank you, Justin and good afternoon, everyone. We're thrilled to provide you an update on what has been a highly productive quarter filled with positive developments on multiple fronts.\n",
      " \n",
      "2022 is off to a great start. IBSRELA launches underway and progressing well after just a few weeks on the market and for XPHOZAH we welcome the news from the FDA that an advisory committee will be convened to review and advise on the clinical meaningfulness of our data. These are important catalysts which have the potential to significantly build shareholder value in 2022.\n",
      " \n",
      "The most significant driver of value growth for Ardelyx is in our anticipated success and commercialization of IBSRELA. Indeed. This is a remarkable time for the company as we now are seeing the results of years of research for our internally discovered and developed drug candidate, transformed into a promising new therapeutic that is now in the hands of pharmacies and patients. It with great confidence that the torch so to speak has in pass to our highly capable and talented commercial team led by Susan Rodriguez.\n",
      " \n",
      "In the initial days of launch, I had the pleasure of going into the field and observing firsthand not only the skill and professionalism of our sales team, but also the physician receptivity and excitement as they gain awareness of IBSRELA. I've asked Susan to later on the call provide a robust update on the progress we've made since our official launch of IBSRELA on April 4th of this year. We can say that my observations thus far are consistent with the market research that Susan and her team have conducted regarding the need and attractiveness of a new therapy like IBSRELA.\n",
      " \n",
      "Turning out briefly to XPHOZAH. I'd like to review where we stand in regards to our formula dispute resolution efforts. At the end of April, Dr. Stein, the Director of the Office of New Drugs, center for drug evaluation research of the FDA, provided an interim response to a second level of appeal for the complete response letter for XPHOZAH. In which he indicated the need to convene the Cardiovascular and Renal Drug Advisory Committee augmented with expert clinicians to gain additional insights into the clinical meaningfulness of the phosphate lowering effect observed in our Phase 3 clinical program for XPHOZAH.\n",
      " \n",
      "We welcome this advisory panel, as it will allow for Dr. Stein to receive input from treating clinicians in order to understand their perspective of the clinical meaningfulness and significance of the phosphate reduction we have demonstrated with XPHOZAH. We are confident in the nephrology community’s belief in the novel mechanism of action of XPHOZAH and the important role that it can play in addressing a critical unmet medical need in the management of hyperphosphatemia. We await direction from Dr. Stein on the timing of this meeting, and look forward to the discussion.\n",
      " \n",
      "Turning out to RDX013. We completed our analysis of the safety and efficacy from our Phase 2 dose ranging trial for RDX013 for the treatment of hyperkalemia in chronic kidney disease patients who are not on dialysis. While the results of the study demonstrated an acceptable safety and tolerability profile for RDX013, and supported an important proof-of-concept in its ability to lower serum potassium levels with statistically significant results compared to placebo. After eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. When appropriate, the next steps for the program will be to continue work on new formulations and to evaluate the efficacy of RDX013 in a future Phase 2 study.\n",
      " \n",
      "In April, we were pleased to announce that we had reached an agreement with our Japanese partner, KKC, to amend our license agreement, providing us the potential for important near-term non-diluted capital. As we announced in April, in consideration for reduction in royalty rate due Ardelyx upon net sales in Japan, KKC will pay us up to an additional $40 million payable in two tranches. The first following their filing of tenapanor for marketing approval in Japan and the second payment due following the approval to market tenapanor for hyperphosphatemia in Japan.\n",
      " \n",
      "KKC is finalizing Phase 3 clinical program for tenapanor for hyperphosphatemia and has disclosed its current expectation to file for marketing approval within the second half of this year, and a current expectation that would receive the decision regarding this application in the second half of 2023.\n",
      " \n",
      "In summary, as we kicked off 2022 with a launch of IBSRELA and now is a revenue generating company, with the opportunity to support clinical meaningfulness of our clinical data for XPHOZAH at an advisory committee, a pipeline of internally discovered drug candidates and a strengthening cash position. We see IBSRELA as a highly differentiated company in our industry, uniquely positioned for success with dedicated, talented teams across the company.\n",
      " \n",
      "Now, I'd like to pass the call to Susan to provide a commercial update on the launch of IBSRELA. Susan?\n",
      " \n",
      "Susan Rodriguez\n",
      " \n",
      "Thanks Mike. I echo Mike's sentiments about our strong start to 2022. We've launched IBSRELA, our first-in-class novel mechanism therapy for the treatment of Irritable Bowel Syndrome with constipation IBS-C in adults, with initial stocking and the Salesforce mobilized across the country. Commercial efforts are focused on the 9,000 HCPs who account for approximately 50% of the prescriptions written for IBS-C indicated products, with broad-based product distribution, a targeted specialty Salesforce and omnichannel tactics. Marketing messages center on the multifactorial pathophysiology of IBS-C and the role the novel triple action mechanism of IBSRELA can play to address important medical unmet needs.\n",
      " \n",
      "Revenue reported in Q1 reflects some of the initial stocking of IBSRELA in advance of our April 4th commercial launch. Early market response has been favorable. Interest across our gastroenterology targets is high, with our Salesforce team given quality time to review the novel product profile and robust clinical data for its IBSRELA. HCPs express the need for expanded options to treat IBS-C, respond favorably to the information presented on IBSRELA and share that there are many patients that they believe can benefit from a novel mechanism approach. A foundation of use for IBSRELA is being built.\n",
      " \n",
      "The market environment we are launching into is favorable. The market building investments linked to the introduction of GCC agonist over the past decade has transformed the management of IBS-C converting what was once an OTC market to an established prescription therapy market consolidated largely around two branded therapies with a concentration of high writing HCPs. Within the context of this established prescription market, these HCPs persistently report that approximately a third of patients under their care continue to have symptoms and are considered to be inadequately managed. This relatively uncluttered market with conditions that enable a targeted approach with a stated need for expanded therapeutic options is an ideal opportunity for IBSRELA with its differentiated first-in-class mechanism and compelling clinical profile.\n",
      " \n",
      "Our research indicates that 56% of high prescribers consider IBS-C a difficult condition to treat, and 83% reported that there was a significant unmet need in the treatment of IBS-C. 75% of these high prescribers reported a favorable response to the IBSRELA profile, rating its novel mechanism and efficacy data as the most compelling attributes and projected use of IBSRELA in a meaningful subset of their patients.\n",
      " \n",
      "While we're still in the early weeks of launch, HCP response on the ground aligns with these research findings. We are positioning IBSRELA as a first-in-class NHE3 inhibitor with a triple action in treating IBS-C. We are emphasizing the novel mechanism of IBSRELA as differentiated from existing therapies. With clinical data that demonstrates significant improvement in abdominal pain, bloating and constipation, with a quick onset of action, sustained efficacy and an acceptable safety and tolerability profile. Our physician education is also centered around clinical results, demonstrating improved patient quality of life versus placebo and patient reported treatment satisfaction. Our objective is to establish IBSRELA with its new mechanistic approach and triple acting effect as a meaningful new treatment option for HCPs who treat patients with IBS-C.\n",
      " \n",
      "Our Salesforce efforts targeted at the highest writers will be further amplified by omnichannel tactics, leveraging the rapidly advancing dynamics in the marketplace on how and where HCPs receive their information.\n",
      " \n",
      "Our distribution network is another key element to our commercial strategy, which includes both retail and specialty channels to accommodate office and patient preferences and align to their existing processes for handling specialty products.\n",
      " \n",
      "As the launch progresses, I'd like to reiterate what to expect. Patient access is key to market traction. As a novel product our access strategy is centered on the value proposition of addressing the existing clinical unmet needs among actively treated patients. We will not rebate to match existing agents, but instead we'll work with payers to minimize the step through requirements. From a payer landscape perspective, prior authorization and step therapy protocols for novel entrance are standard for this market today. HCPs have to attest to the fact that patients have been on lower agents, yet their condition persists and are considered to be inadequately managed.\n",
      " \n",
      "We consider these access challenges to be addressable on the basis of four key considerations. One, the patient need for IBSRELA for a condition with limited treatment options; two, HCP demand for IBSRELA and willingness to support the prior authorization requirements. Three, the HCP familiarity and experience in addressing these requirements implicit in the space; and four, the comprehensive customer service support we will have in place to support physician offices. In parallel, we will work with payers to secure access and minimize step therapy requirements. \n",
      " \n",
      "Market penetration with IBSRELA will be enabled by the existing pool of IBS-C patients that are in need of a novel mechanism therapy and considered good candidates for treatment with IBSRELA. counterbalanced by access ramp up challenges and the need for HCPs to work through the expected payer hurdles as I noted earlier. With a targeted specialty Salesforce, full company engagement and innovative omnichannel peer-to-peer and digital initiative, we will bring IBSRELA to the patients being actively managed today, who are in need of additional treatment options.\n",
      " \n",
      "IBSRELA will have a strong commercial and clinical presence at the largest annual GI conference, Digestive Disease Week taking place May 21st to the 24th in San Diego. We plan to leverage this conference as a major launch initiative.\n",
      " \n",
      "Our commercial initiatives and market receptivity are proceeding as anticipated. Gastroenterologists are responding favorably to the IBSRELA mechanism and clinical profile. They are enthusiastic to have a new addition to their treatment armamentarium and have patients in mind that can benefit from IBSRELA. They anticipate prior authorization requirements and are motivated to utilize the structures and processes they have in place in their offices to work through access hurdles. In many cases, in partnership with specialty pharmacies or through our Ardelyx assist patient services program. Prescriptions are being written and filled. We are thrilled to bring this much needed, highly differentiated therapy to market, and most importantly, to make a difference in the lives of patients who are suffering from IBS-C.\n",
      " \n",
      "I will now turn the call over to Justin to review our Q1, 2022 financials. Justin?\n",
      " \n",
      "Justin Renz\n",
      " \n",
      "Thank you, Susan. At the end of the first quarter 2022, we had total cash, cash equivalents and short-term investments of $89.7 million as compared to total cash, cash equivalents and investments of $116.7 of million as of December 31st, 2021. As we just discussed, we recognized our first commercial product sales from initial IBSRELA free stocking in March of approximately $0.5 million.\n",
      " \n",
      "Research and development expenses were $8.9 million for the quarter ended March 31st, 2022, a decrease of $11.6 million or 57% compared to $20.5 million to the same quarter last year. The decrease in our R&D expenses is primarily the result of lower clinical study costs from the optimized study, lower to abnormal manufacturing expense, as we've begun to capitalize costs associated with the IBSRELA inventory, and lower expenses falling the elimination of our research function in the fourth quarter of 2021.\n",
      " \n",
      "Selling, general and administrative expenses were $19.3 million for the quarter ended March 31st, 2022, an increase of $2.2 million or 13% compared to $17.1 million for the same quarter last year. The increase in SG&A expenses was primarily due to an increase in costs associated with preparation for the commercial launch of IBSRELA.\n",
      " \n",
      "Our net loss for the quarter ended March 31st, 2022 was $28.1 million or $0.21 per share compared to $33.2 million or $0.34 per share for the same quarter last year. It is important for us to bolster our cash position, and we will continue to pursue and evaluate a number of opportunities, including non-dilutive measures, such as commercial sales of IBSRELA, milestone payments from our partners, as well as judicious cash management.\n",
      " \n",
      "Along those lines, during Q1, we prudently took advantage of our ATM raising $6 million of proceeds from equity sales under the program. As Mike mentioned earlier, in April we announced we'd amended our licensed agreement with KKC. In consideration for a reduction in future royalties upon net sales in Japan, KKC agreed to pay our debt consideration of up to an additional $40 million. KKC reported their Q1, 2022 results earlier this week. And they noted that they remain on track to file their NDA for tenapanor for hyperphosphatemia in Japan in the second half of this year, which in addition to the proceeds we would receive under our recent amendment would also trigger a significant regulatory milestone payment to Ardelyx under our original license agreement. We will continue to actively pursue other non-equity solutions to extend our cash runway further into 2023. We have confidence in our ability to continue to fund our operation.\n",
      " \n",
      "I will now turn the call back to Mike for some concluding comments before we take some questions. Mike?\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Thanks Justin. And before I open the call, I want to emphasize a couple points. We look forward to making a case for XPHOZAH to the FDA's advisory committee in the coming months, as we believe it will be an essential treatment for patients on dialysis with hyperphosphatemia. And although, we are just over a month into the launch, we like the positive response we hear from the field for IBSRELA and the role that it can play in treating patients with IBS-C.\n",
      " \n",
      "Susan has built a spectacular commercial team and they're laser focused on successful execution, working to gain meaningful market share. The opportunity for us with IBSRELA is significant, as it provides a clear line of sight to financial breakeven.\n",
      " \n",
      "Finally, this is an exciting and truly transformational time for Ardelyx, and we are becoming an impressive growth story with lots of opportunities ahead. It's really important to note our internally discovered pipeline has fuel diversification and critical optionality and has positioned us well for near-term and long-term future growth. We look forward to keeping apprise of our progress.\n",
      " \n",
      "And with that, I will now open the call to questions. Debbie?\n",
      " \n",
      "Question-and-Answer Session\n",
      " \n",
      "Operator\n",
      " \n",
      "We will now begin the question-and-answer session. [Operator Instructions]\n",
      " \n",
      "The first question is from Chris Howerton with Jeffrey. Please go ahead.\n",
      " \n",
      "Chris Howerton\n",
      " \n",
      "Excellent. Thank you so much. Excellent news on the advisory committee update and thanks for taking the questions team. So, I guess, maybe, what I'll start off by with respect to the advisory committee for XPHOZAH. I think, Mike, you had mentioned that you're expecting within the coming months, be curious to hear, if you could articulate, just give us a little color on your thinking on the timing of that. Also as it relates to the advisory committee, do you anticipate providing any additional information to the FDA prior to that outside of just the standard briefing documents?\n",
      " \n",
      "And if I may, as a third part of that question would be, what is the significance of patient advocacy groups in your argumentation in discussing the clinical meaningfulness of XPHOZAH? Thank you.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Sure. Thanks Chris for the questions. So, we've not yet heard back from Dr. Stein's office and once we do, obviously that's a meaningful bit of news that we would release. So, our anticipation is that it's not going to be months before we hear every week. And we're thinking that we're going to have three plus months to prepare. So, you'd imagine we've already deployed and are working multiple full-time jobs in order to be as prepared as we can for the AdCom.\n",
      " \n",
      "With regard to your second question, there will be no new data submitted. We will provide our briefing book as we'll be, and we can only work with the data that has been submitted part of our NDA, which is all of our clinical work and the entire Phase 3 program. So, there's a lot there to work with that we've talked about since over a year ago, we received a CRL. So, we're confident with the strength of those data as we prepare for the meeting.\n",
      " \n",
      "Patients and KOL advocacy is a critical part of this. And these are patients, as you can probably imagine. And physicians that we've heard from nonstop since the CRL was officially -- it was originally issued just over a year ago. We have been holding back because we wanted to be thoughtful going through the FDR process. But those are folks that are chomping up a bit to be part of having their voice heard of the importance of a drug like XPHOZAH and blocking phosphorus versus having it be absorbed with all the same mechanism drugs that are out there today. So, it will be a critical part of what we do working with the patient and KOL community.\n",
      " \n",
      "Chris Howerton\n",
      " \n",
      "Okay. Well that's -- I mean, like I said, I think that that's excellent that you've been given that opportunity. So, really -- honestly, really looking forward to that. And I don't know if you're allow me, but if I could sneak in one more for you, Susan. With respect to kind of the launch of IBSRELA, what is your position on things like sampling, or other methodologies such as that to increased demand?\n",
      " \n",
      "Susan Rodriguez\n",
      " \n",
      "Thanks for the question, Chris. It's a -- clearly, what we find with the gastroenterologists that we are engaged with today, that the way they practice the treatment of IBS-C is to sample the patient to -- especially particularly when they're starting a new therapy, to see how the patient responds to that therapy early on. And based on that response, proceed with the prescription and with working through the prior off requirements that they anticipate, having to manage for a specialty drug like IBSRELA.\n",
      " \n",
      "So, sampling is clearly a part of our strategy. But we are pragmatic about it in terms of getting the samples into the offices of the high writers to help them get these new patients started. But not sampling to a level where we're going to interfere with the ramp up of the product. The demand in prescriptions is a very important component to our ramp up to demonstrate demand from the gastro -- the high writing gastros to the payers as we work through the process to secure access for IBSRELA.\n",
      " \n",
      "Chris Howerton\n",
      " \n",
      "Okay. Well, that's very clear. Thank you very much. And I appreciate you taking the questions.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Thanks Chris.\n",
      " \n",
      "Susan Rodriguez\n",
      " \n",
      "Thanks Chris.\n",
      " \n",
      "Operator\n",
      " \n",
      "The next question is from Yigal Nochomovitz with Citi. Please go ahead.\n",
      " \n",
      "Carly Kenselaar\n",
      " \n",
      "Hi. This is Carly on for Yigal. Thanks so much for taking our questions. Just a follow-up on some of your prior comments, can you talk in a little bit more detail about what you're doing to prepare for the XPHOZAH AdCom. I guess, are there any additional analyses you're putting together or can put together to help strengthen the argument around the clinical meaningfulness of the data?\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Sure. Thanks Carly. A lot of this -- it is being prepared, like a Broadway show or something like that, to make sure that you are saying all the right things in the limited amount of time that you have. So, you're going to be looking at the science behind that the clinical data, the patient need all of those things with different people in their presentations, as you've seen with other AdCom meetings.\n",
      " \n",
      "So, there are no new -- as I said in previous question, no new data that are going to be submitted. They've had all the data since we filed the NDA. Certainly, we will focus on what we believe are representative of clinical meaningfulness. Just to remind everyone is this is a program that was completely reviewed every single clinical protocol, statistical analysis plan, endpoints, everything was reviewed with the agency in detail, and even their CRL, they recognized the significance of the decrease that we got with XPHOZAH.\n",
      " \n",
      "We hit every single primary and key secondary endpoint with highly statistically significant results. And we will clearly emphasize that and the need that the patients have for something that's different, taking handfuls of pills every single day, doesn't work because they are unable to take as much as they should. And physician should be given the opportunity with the data that we have generated to make the decision based upon those results on which of their patients are candidates or not for XPHOZAH.\n",
      " \n",
      "Carly Kenselaar\n",
      " \n",
      "Okay. Great. That's really helpful. And then, we just had one question for Justin. Can you comment on how far the additional $40 million expected from KHK, might extend the cash runway? \n",
      " \n",
      "Justin Renz\n",
      " \n",
      "Sure, Carly. So, we are hopeful, as we mentioned for KKC to file in the second half of this year, and then seek approval from the agency in the second half of 2023 in Japan. We haven't disclosed the breakdown of the $40 million. It's going to be in two tranches between this fall and next fall, but $40 million would clearly impact our runway upon receipt, certainly, targeting second half of this year and next year. So, our burn will be going down as we grow our sales for IBSRELA. So, I can't give you specific how long the $40 million add, but it's clearly a material impact in extending our runway into 2023.\n",
      " \n",
      "Carly Kenselaar\n",
      " \n",
      "Okay. Got it. Thanks so much for taking our questions.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Thanks Carly.\n",
      " \n",
      "Operator\n",
      " \n",
      "The next question is from Joseph Thome with Cowen and Company. Please go ahead.\n",
      " \n",
      "Joseph Thome\n",
      " \n",
      "Hello. Good afternoon. Congrats in the progress and thank you for taking our questions. Maybe the first one just on the advisory committee, are you able to sort of suggest a label? So, maybe if they don't feel comfortable giving a broad label for serum phosphorous production in patients, can you say, only use it on top of binders or, patients that can't tolerate binders? Or are you able to kind of suggest anything that might make it a little bit easier, and palatable for the FDA to approve there?\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Yeah. Remember the audience for the AdCom are the members of the advisory panel, not the FDA as much, right? So the AdCom, we're going to be speaking to the established AdCom that's there as well as these additional participants that Dr. Stein referenced in his letter to us. And what we will say to them is, the treatment of hyperphosphatemia is something that's considered at a minimum monthly, as it relates to the serum phosphorus levels that are taken of every single dialysis patients at least once a month and often weekly or three times a week when they're in a dialysis session, and a dietician social worker, the staff there continue to remind them to watch their phosphorus, which is standard there.\n",
      " \n",
      "So the FDA will hear the panel. Importantly, we'll hear that understanding which patients are going to respond to, which drug is something that's a very straightforward thing that they're accustomed to doing today. And that the data that we have generated represent powerful information for those physicians and caregivers that are part of the dialysis process to identify those patients that are going to respond and those who aren't or those who tolerate. And those that don't just as is the case today with binders. And right now, the only thing that they can do is switch to another binder or add a binder, which is nonsensical because they're not different from each other meaningfully in terms of the efficacy that they produce. So that's really the way that we'll approach it. I don't think we would go in and say, this is a proposed label. That's not really the purpose of the presentation to the AdCom.\n",
      " \n",
      "Joseph Thome\n",
      " \n",
      "Got it. And then, for IBSRELA, I mean, you mentioned some stocking, I guess, how should we think about revenues on a quarterly basis? Are they going to be reflective of kind of true patient demand, or is there going to be any pattern to stock the channel or anything like that? Any help…\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Yeah. I mean, we're five weeks into this. So, everything that we know thus far is anecdotal. It's exciting. It's really -- it's a wonderful experience to be at AdCom. The receiving end of those anecdotes, given the over decade work that we've been doing at IBSRELA to get this drug to the market. So, we're not in a position right now to be projecting what -- or providing guidance as to what revenue's going to look like. Please be patient with us as we learn. And you will learn too, as we look at the reliability of scripts that come from IQVIA or Symphony.\n",
      " \n",
      "As Susan mentioned, there's a lot of specialty pharmacy that's in that, that we need to wrap our arms around and all of you do too, as well as we look and see where those data are best reported. So, this is a -- as I said, a period of anecdotal evidence that is exciting, positive, and all in the right direction. But premature to be giving any specifics as to what guidance might look like.\n",
      " \n",
      "Joseph Thome\n",
      " \n",
      "Okay. And maybe one more quick one, if I can just for Justin. R&D came down a lot, which is great to see from an expense standpoint. Is this now kind of the new steady state, or is there still room to come down in the rest of the quarters? Thanks.\n",
      " \n",
      "Justin Renz\n",
      " \n",
      "Sure. That's fair. For Q1 and the rest of this year, I think that's a fair number. One thing we did call out in the press release is the stock compensation expense, the non-cash charge that is obviously highly variable, so that could have an impact, but again, that won't affect our runway. But the overall size of the research and development expenditure for the reminder of this year should be pretty consistent or slightly lower the rest of this year.\n",
      " \n",
      "Joseph Thome\n",
      " \n",
      "Great. Thank you so much.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Thanks John.\n",
      " \n",
      "Operator\n",
      " \n",
      "The next question is from Laura Chico with Wedbush. Please go ahead.\n",
      " \n",
      "Sam Brandeis\n",
      " \n",
      "Good afternoon. This is Sam on for Laura Chico. Thanks for taking our question. So, we have one on the tenapanor advisory committee meeting. Just wondering if you could frame for us the range of outcomes, that might come out of this meeting. Thank you very much.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "So, it can be a unanimous vote. Yes. Unanimous vote, no. And everything in between. And all of us have observed the peculiarities of what have happened at AdCom over the last year plus. So, this is a fight that we're continuing to fight. We believe strongly in our data. We believe the voice of the KOLs have been part of this and those who have read about it since most all of our clinical programs have now been published. So, it's well known and well recognized out in the field as to what it is that XPHOZAH can provide their patients.\n",
      " \n",
      "So, getting to those physicians and patients who understand that and communicating that effectively to the AdCom. We believe will help us be on the right side of that boat versus on the negative side. And as we all know, the agency is not required to take the advice of their own committees. So that continues to be something that we will all watch mostly and feel that the strength of argument will be one that carries the day.\n",
      " \n",
      "Sam Brandeis\n",
      " \n",
      "Makes sense. Thank you.\n",
      " \n",
      "Operator\n",
      " \n",
      "[Operator Instructions]\n",
      " \n",
      "The next question is from Matt Kaplan with Ladenburg Thalmann. Please go ahead.\n",
      " \n",
      "Matthew Kaplan\n",
      " \n",
      "Hey, guys. Thanks for taking the questions and congrats on the AdCom. Just a follow-up to the last question in terms of, assuming you have a positive result from the AdCom, what's the timing after that for potential FDA action on?\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Sure. Yeah. So, since we don't have an active NDA in place, let me actually ask Rob Blanks, our Chief Regulatory Affairs and Quality Assurance Officer, to address the outcomes of what type of NDA we could potentially submit.\n",
      " \n",
      "Robert Blanks\n",
      " \n",
      "Yeah. Thank you, Mike. Just to let you know, obviously this is -- this AdCom is a response to our appeal to OND. So what we do know is that, 30 days after we get -- the AdCom is held, we will get a response from OND as to the final outcome of our appeal.\n",
      " \n",
      "From there, we would provide a -- we prevail then we would likely have a complete response and be a two month review of our NDA. And -- which would mostly be label negotiations at that point, or the alternative is a six month review.\n",
      " \n",
      "Matthew Kaplan\n",
      " \n",
      "Got it. Okay. That's very helpful. Thank you. And then, shifting to the IBSRELA launch. Can you give us a sense in terms of the rollout of payer coverage and patient access corresponding to that in terms of commercial plans and Medicare, Medicaid plans, Part D? How we should think about that kind of in the coming year.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Sure. Susan?\n",
      " \n",
      "Susan Rodriguez\n",
      " \n",
      "Yeah. Thank you Matt for the question. So, first and foremost, it's really important to call out in this early launch phase that there is access to IBSRELA for the physicians who are willing to go through the exception process. And what we're finding in these early stages, because of the way the novel mechanism of the drug, the way we are positioning it, the focus on using this drug in patients that they believe really need a different approach to their treatment. They're motivated to go through that exception process, and we are seeing them clear through that process.\n",
      " \n",
      "And as I mentioned in my narrative, and as Mike had alluded to, we're finding that these high writing gastro groups all are quite linked to -- in many cases to specialty pharmacies who help them with clearing these medic, these exception hurdles. Remember that the world of the gastroenterologist they're involved in writing a lot of specialty products in spaces with costly therapies, ulcerative colitis, Crohn's, HCV. So, we're finding that they have processes in place. \n",
      " \n",
      "So, this early launch phase is really very much about creating that demand and really leveraging that motivation on the part of the gastroenterology groups to work through the exceptions and get these prescriptions through. As we do that, we interface with payers to try to break down some of those hurdles and make it easier for these physicians to secure IBSRELA for the patients that they believe really need it.\n",
      " \n",
      "We -- overall, we anticipate that the access and the commercial side will probably come first just in terms of starting to secure that position. And this is something that we're going to work on. We see throughout this launch sub here in 2022, followed by Medicare and Medicaid, is always the more challenging one from a timeline perspective in terms of trying to knock down some of those barriers.\n",
      " \n",
      "Matthew Kaplan\n",
      " \n",
      "Okay. Okay. Thank you. And then, in terms of pricing and gross to net, any comments on that.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Yeah. Susan?\n",
      " \n",
      "Susan Rodriguez\n",
      " \n",
      "Yeah. Overall, well, we have announced the price for IBSRELA at $1,500 a month. So, the rationale around that pricing is linked to the clinical value proposition. Again, that it's -- IBSRELA on a pose in the market today for the patients who are not adequately managed, there are no other options. And within the range of IBS treatments, we see it ranges from around $500 to a high end of $1,800 or $2,000 for the IBS diarrhea products. This is within the range of the IBS pricing landscape.\n",
      " \n",
      "So that's our price point. And it's priced to a link to the value proposition and the targeted approach and our objective that we had laid out there and belief that we could achieve a high single digit share within this marketplace.\n",
      " \n",
      "And in terms of the cost side of it, we -- as I mentioned will not be rebating to match positions of Linzess and Trulance. This market is cooked, it's established. Those products are locked in. It's -- some plants prefer Linzess, some drive preference to Trulance. We're not competing with that because we are -- where we are focus is on the patients who are in need of a different approach and physicians are motivated to work through those exceptions.\n",
      " \n",
      "So, from a gross to net standpoint, we're not going to be heavily regetting the product, but we will be working with payers to try to minimize those hurdles. And -- yeah -- and then beyond that, it's really just our distribution network. And then, we need to contemplate as well. It's important to consider the affordability side of the access equation. And for commercial patients, we will have our commercial copay program to be able to offset their out-of-pocket expense for their IBSRELA script. Those are the key considerations.\n",
      " \n",
      "Matthew Kaplan\n",
      " \n",
      "Great. Thank you, Susan, for the added detail. Thanks. Thanks for the questions.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Thanks Matt.\n",
      " \n",
      "Operator\n",
      " \n",
      "This concludes our question-and-answer session. I would now like to turn the conference back over to Mike Raab for any closing remarks.\n",
      " \n",
      "Mike Raab\n",
      " \n",
      "Thanks for transformational progress as we launch IBSRELA for patients with IBS-C and continue to navigate the regulatory process with XPHOZAH. We look forward to keeping you apprise of our progress in the coming months. Debbie, you may now end the call.\n",
      " \n",
      "Operator\n",
      " \n",
      "Okay. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# sanity check\n",
    "total_string =\"\"\n",
    "for tag in earning_call_transcipt:\n",
    "    total_string += tag.get_text() + \"\\n\"\n",
    "print(total_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "5e0d0f66",
   "metadata": {},
   "outputs": [],
   "source": [
    "# save text in a file\n",
    "# not working yet\n",
    "with open('data/text_article_4507624.txt', 'w') as f:\n",
    "    f.write(total_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a8af1000",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
